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Hepatocytes can capture dead cells. This phenomenon is called efferocytosis. Furthermore, 
our lab previously observed live CD4+ T cells captured by hepatocytes. This was reminiscent 
of entosis. This project aimed to further the understanding of the mechanisms and 
consequences of these processes. In vitro experimentation showed that efferocytosis could 
be modulated through cytokine treatment and using macropinocytosis inhibitors. Captured 
cells were also shown to associate with the uncharacterised receptor, SCARF2. Furthermore, 
efferocytosis was shown to cause multinucleation in hepatocytes. This was demonstrated in 
vitro, in vivo using mouse models of acute injury, and ex vivo with cauterised donor human 
tissue. Increased multinucleation was also associated with hepatocellular carcinoma and 
vascular invasion. Live CD4+ T cell capture occurred at a lower frequency than efferocytosis 
and required alternative membrane rearrangements. This process also did not share defining 
characteristics of entosis, such as E-cadherin association or susceptibility to Rho-kinase 
inhibitors. Furthermore, anti-inflammatory T-regulatory cells were more likely to enter acidic 
compartments within their captors in vitro. This project has unearthed novel aspects 
regarding the regulation and molecular processes of hepatocyte cell-in-cell structure 
formation. Further understanding into the mechanisms of these processes may provide 
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Chapter 1: Introduction  
1.1 The functions and immunology of the liver 
Note that many of the themes mentioned in this introduction have been described in a 
review published in ‘Frontiers in Immunology’ (1) . 
1.1.1 The structure and functions of the liver 
The liver is the largest internal organ and a multitasking powerhouse, performing over 500 
bodily processes. It sets itself aside from other organs through its unique blood supply (2). 
The portal vein supplies 75% of the livers blood content, delivering partially-deoxygenated 
blood received from the spleen and gastrointestinal tract. The hepatic artery provides 
oxygenated blood from the heart and the remaining blood supply. The liver is then tasked 
with absorption, metabolism and storage of the remaining nutrients found within the blood, 
as well as the detoxication of harmful, possibly xenobiotic products. This includes the 
conversion of ammonia, a by-product of protein metabolism, to urea for its later removal by 
the kidneys. The detoxification of alcohol is conducted through its conversion to acetate by 
alcohol dehydrogenase and aldehyde dehydrogenase (3). The liver is also the producer and 
transporter of bile. This is an alkali substance which is essential for the emulsification, and 
the subsequent absorption and digestion of fats. Bile is also responsible for the excretion of 






The liver is organised into hexagon lobules, the vertices of which are composed of portal 
triads – branches of the bile ducts, the hepatic artery, and the portal vein (Fig. 1Ai). Blood 
perfuses centrally across these lobules through capillary-like structures called sinusoids. 
Blood then collects into the central vein and eventually leaves the liver, en-route to the 
heart. Several immune cells travel through the sinusoids, some of which constitutively 
inhabit the sinusoidal spaces (Fig. 1Aii). Immune cells wishing to enter the parenchyma of 
the liver can extravasate from the sinusoids in a similar manner to how they would leave the 
blood stream across vessel walls. The molecular mechanisms behind this recruitment have 
been well described by members of the Centre for Liver and Gastrointestinal Research in 
Birmingham (4-7). Immune cells tether to sinusoidal endothelial cells through an array of 
adhesion molecules which include selectins, integrins and immunoglobulin members such as 
Intercellular Adhesion Molecule 1 (ICAM-1) (7). Following firm adhesion to the sinusoidal 
endothelia, immune cells can travel paracellularly or transcellularly across the endothelial 
layer using mechanisms which have been reported to involve Common lymphatic 
endothelial and vascular endothelial receptor-1 (CLEVER-1)/stabilin-1 (8). Immune cells can 







Figure 1A: Cellular architecture of the liver. (i) Diagram featuring haematoxylin and eosin stained 
tissue showing the zonation of the liver. Hepatocytes in zone 1 are situated close to the portal 
triad (periportal), which are formed of branches of the portal vein, hepatic artery, and bile duct. 
These hepatocytes have first access to incoming blood and thus have a high oxygen and nutrient 
supply. Zone 3 hepatocytes proximal to the central vein (pericentral) receive less nutrients and are 
thus less metabolically active than those in zones 1 or 2. Scale bar = 50 µm. (ii) Cellular 
organisation of sinusoids. Hepatocytes are organised into two-cell thick cords in between 
sinusoidal spaces, which are lined with liver sinusoidal endothelial cells (LSEC). The sinusoids are 
patrolled by a resident macrophage population called Kupffer cells, as well as circulating dendritic 
cells (DCs) and neutrophils. Stellate cells inhabit spaces between hepatocytes and LSECs, and are 
frequent contributors to liver fibrosis. Adapted from (1). 
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1.1.2 Liver immunotolerance  
Most of the livers bloody supply is delivered by the hepatic portal vein, which is received 
from the gastrointestinal tract. As a result, the liver is perpetually exposed to antigens from 
commensal bacteria and food. Should the immune system recognise these bacterial and 
‘self’ antigens, this could potentially result in prolonged immune activation and 
inflammation. To prevent this, the liver possesses a unique, immunotolerant environment 
which has been established through its cellular composition and structural arrangement (9, 
10). These cells include myeloid cells, such as dendritic cells (DCs) and resident macrophages 
called Kupffer cells. Several studies suggest that DCs in the liver are skewed to invoke anti-
inflammatory responses (10, 11). Plasmacytoid DCs (pDCs), which mature in the bone and 
are normally associated with high type-1 interferon (IFN) secretion, were shown to 
upregulate their surface expression of programmed death ligand 1 (PD-L1) in the liver via 
autocrine stimulation with interleukin 27 (IL-27) (12). This in turn prolongs the survival of 
regulatory CD4+ T cells (Tregs) which promote anti-inflammatory signals. Furthermore, 
myeloid DCs (mDCs) which originate from bone marrow progenitor cells or monocytes, were 
also shown to upregulate their expression of PD-L1 in the liver and increase classic Treg 
survival (13). Finally, Kupffer cells are prominent agents of immunosuppression in the liver. 
Kupffer cells can also express PD-L1 and this is augmented in response to stimulation with 
the anti-inflammatory cytokine, IL-10, allowing these cells to perpetuate initial anti-
inflammatory signals (14). In addition, Kupffer cells are themselves producers of anti-
inflammatory cytokines – both IL-10 and tumour growth factor-beta (TGF-β) – which they 
secret upon capturing apoptotic cells (15). Finally, both Kupffer cells and DCs have been 
reported to secrete an enzyme called indoleamine 2,3-dioxygenase (IDO), which catalyses 
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the metabolism of tryptophan to kynurenine (16-18). This in turn binds to aryl hydrocarbon 
receptor on naïve T cells, promoting the development of Tregs (19). 
A second method by which immune responsiveness in the liver is decreased is through 
lowered recruitment of immune cells associated with the adaptive immune response. This is 
achieved by instead promoting local activation of these cells in the liver parenchyma. Many 
hepatic cell types are capable of presenting antigens in complex with major 
histocompatibility complex molecules (MHCs) to cells of the adaptive immune response, 
namely T lymphocytes (20). However, many of these cells lack appropriate co-stimulatory 
molecules to infer long-term activation and survival of these cells. Furthermore, the 
potential for local activation of CD4+ and CD8+ lymphocytes reduces the requirement of such 
cells to drain into lymph nodes for activation and cross presentation. Therefore, T cells 
become activated rapidly in the liver, but are then quickly turned over, minimising the 
duration of the immune response (10, 20, 21). This turnover is augmented by the high level 
of Fas-ligand (FasL) expressed by hepatic immune cells, including DCs and Kupffer cells (22). 
This allows the liver to mount a direct and efficient immune response but with a minimal 
duration, swiftly returning to a steady immunotolerant state.  
1.1.3 The “graveyard theory” 
It is well known that the liver is a major site for the removal of defective erythrocytes (4, 23). 
In relation to its status as an ‘immunotolerant’ organ, several studies have described how 
many immune cells, including lymphocytes, become apoptotic more readily upon entering 
the liver, and are subsequently removed (24-28). These studies identified how intrahepatic T 
lymphocytes were susceptible to programmed cell death, partially through increased 
expression of Fas (26, 29). The authors suggested that these T cells were already destined for 
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death and succumbed in the liver. These observations gave rise to the “graveyard theory”, 
coined by Crispe and colleagues, which proposes that lymphocytes are prone to cell death 
upon entering the liver. This, in part, contributes to immune tolerance as it prevents the 
propagation of an unnecessary response from the adaptive immune system. Contrarily, the 
increased tendency of immune cells to die in the liver would create a burden for the 
clearance of apoptotic corpses which, if left uncleared, could further promote the risk of an 
immune response (discussed further in section 1.3). Still, the liver houses several cell types 
which can remove these dead cells (1). A largely unknown member of this group is the major 
cell type of the liver, the hepatocyte.  
1.2 Hepatocytes 
1.2.1 Physiological functions of hepatocytes 
Approximately 80% of the liver is comprised of a parenchymal cell type called the 
hepatocyte (3). These cells form 2-cell thick cords in between the sinusoids (Fig. 1Aii) and 
they perform many of the functions of the liver. These include the storage and metabolism 
of nutrients (sugars, fats, proteins, etc.), bile secretion and detoxification of xenobiotics (3, 
30). Hepatocytes are also responsible for converting heme, a residual compound generated 
from the haemoglobin of exhausted erythrocytes, to the waste product, bilirubin. They are 
also the main source of blood proteins including albumin, transferrin, lipoproteins, and 
various coagulation factors like prothrombin and fibrinogen (30). Hepatocytes also possess a 
wide variety of other characteristics, unseen for other parenchymal cells, which bestow the 
liver with its unique properties.  
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1.2.2 Hepatocytes zonation and liver regeneration 
The liver is fascinating in being the only internal organ capable of regeneration. This ability is 
evolutionarily conserved and has been made evident using rodent models of partial 
hepatectomy, where up to 66% of the liver can be surgically removed whilst still allowing for 
complete restoration (31-33). Under normal physiological conditions, this quality is endowed 
from the hepatocytes, which have been shown to begin DNA synthesis and cell division in 
response to hepatectomy (34). This response is not homogeneous throughout the liver. 
Hepatocytes can be separated into 3 zones in relation to their proximity to central veins or 
portal triads (Fig. 1Ai). These populations differ greatly in their metabolic activity and 
molecular signalling rates. This is thought to be, in part, established through Wnt/β-catenin 
signalling (35, 36). Hepatocytes close to portal regions (periportal) are exposed to more 
nutrient-rich blood. As such, periportal hepatocytes are generally more metabolically active 
than those that are pericentral or in an intermediate zone. They are also more likely to 
express genes associated with the onset of regeneration, including those encoding growth 
factors and their regulatory proteins, such as insulin-like growth factor binding protein 1 
(IGFBP1) (37). The regenerative response of hepatocytes is spatiotemporally organised in 
accordance with this liver lobule zonation; periportal hepatocytes are the first to proliferate, 
with waves of division travelling pericentrally (38). Hepatocytes closer to central vein 
branches divide later, relying on different targets of Wnt/β-catenin signalling to those of 
periportal hepatocytes, instead relying on the activity of Leucine-rich repeat-containing G-
protein coupled receptor 5 (LGR5) and Ring Finger Protein 43 (RNF43) (39, 40).  
Hepatocyte damage is often incurred in response to inflammation and immune infiltration. It 
is, therefore, intuitive that hepatocytes can be induced to divide in response to cytokine 
signalling. Historically, it has been known that tumour necrosis factor alpha (TNFα) could 
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augment the effects of growth factors for hepatocyte proliferation (41, 42). Several 
publications have reported the requirement of signals from Kupffer cells for the induction of 
hepatocyte regeneration via NFκB signalling (43, 44). More recently it was reported that 
STAT3 signalling in macrophages, downstream of anti-inflammatory IL-10 signalling, was 
concomitant with liver repair (45). These studies and others show how hepatocytes are able 
respond to a large variety of stimuli to proliferate, whilst allowing the liver to continue to 
function (46, 47). It is of note and admiration that the liver continues to provide its many 
homeostatic functions whilst simultaneously regenerating as necessary.  
1.2.3 Hepatocytes as immune cells 
As well as conducting a lot of the major functions of the liver, hepatocytes have many 
reported functions which directly contribute to immunity and the general immunotolerance 
of the liver (48, 49). In the acute phase of an immunological response, where initial 
inflammatory stimuli are detected by innate immune cells, hepatocytes are capable of 
responding to the inflammatory cytokines secreted by these cells, including TNFα, 
interferons alpha and gamma (IFNα/γ), as well as IL-6 and IL-1β (49-52). Stimulation with 
these cytokines results in subsequent secretion of additional cytokines by hepatocytes, as 
well other proteins which contribute to immunity, such as serum amyloid A protein, which 
augments bile secretion and recruitment of immune cells to the liver (48, 53, 54). Once 
enlisted into the immune response, hepatocytes downregulate their more-housekeeping 
functions such as albumin secretion (51). Hepatocytes can also recognise the same signals as 
innate immune cells, namely pathogen-associated molecular patterns (PAMPs) through Toll-
like receptors (TLRs). Hepatocytes have been shown to respond to bacterial proteins via 
TLR2 (55), which can in-turn induce inflammasome secretions. Hepatocytes are also known 
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to bind to heat-shock protein 72 (Hsp72) via TLRs 2 and 4, which upregulates secretions of 
macrophage inflammatory protein 2 (MIP-2) (56). 
Hepatocytes have developed intrinsic responses to viruses which commonly infect them, 
including hepatitis B and C viruses (HBV/HCV). Intracellular signalling receptors, retinoic acid 
inducible gene-1 (RIG-1) and TLR3, can bind viral RNA and dsDNA, respectively (57). Upon 
engagement, these receptors trigger signalling events which ultimately activate interferon 
regulatory factor 3 (IRF3), a transcription factor which induces type 1 interferon expression 
in response. Hepatocytes also express stimulator of interferon genes (STING), a signalling 
molecule through which many DNA-sensing proteins converge on and is thought to mediate 
RIG-1 signalling (58, 59). STING has recently been hypothesised to reduce HBV replication in 
hepatocytes (59). However, both HCV and HBV are known to have evolved various 
mechanism to dampen STING and IFN-related responses, which systemically reduce innate 
immune activity by hepatocytes (60-63).  
As well as directly responding to inflammatory stimuli, some evidence exists showing that 
hepatocytes can perpetuate immune responses by acting as APCs. Under inflammatory 
conditions, hepatocytes can express major histocompatibility complex, class 2 (MHC-II), 
granting them the ability to activate naïve CD4+ T cells (64). Hepatocytes have also been 
reported to express MHC class I (65). Additionally, investigations by Bertalino and colleagues 
suggest that hepatocytes are, thus, capable of priming CD8+ T cells (66, 67). Hepatocytes 
were shown to activate and induce proliferation of naïve CD8+ T cells. Of note, in both 
investigations, T cells survived for a shorter time, compared to when activated by more-
dedicated APCs such as dendritic cells. This is likely due to the lack of co-stimulatory 
molecules, such as CD80 and CD86. Furthermore, hepatocytes have been shown to 
upregulate PD-L1, which can then induce programmed-cell death in pro-inflammatory T cells 
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(68). Overall, hepatocytes are equally dedicated to liver immunotolerance as they are 
perpetuating immune responses.  
1.2.4 Difficulties with hepatocyte culture and alternatives 
Hepatocytes present multiple problems when it comes to their study; although they possess 
an intrinsic ability to divide and regenerate the liver, this is not retained following their 
isolation from the liver for in vitro cell culture. Furthermore, cryopreservation of primary 
human hepatocytes (PHHs) is difficult to achieve. Several conditions have been published for 
the maintenance and temporary passage of PHH (69), although this is not efficacious for long 
term investigations. This drastic behavioural transformation also disparages the results 
obtained from in vitro PHH for representing their true behaviour in vivo. This is evidenced in 
how PHH respond to only a limited number of growth factors, despite expressing receptors 
for many more (31, 70). Due to this, alternative procedures and models are frequently 
exploited prior to, or instead of, experimentation with PHH. A multitude of transformed 
hepatocyte or hepatoma cell lines are available for in vitro experimentation (30). These cells 
retain a varying degree of physiological and genetic features of PHHs, although often have 
irregularities in cellular signalling and normal hepatocyte functionality (71). Examples of 
these include Huh-7, HepG2 and Hep3B hepatocyte cancer cells. Each of these cell lines 
retain a distinct level of differentiation and p53 expression from their normal counterparts 
(72). HepG2 cells maintain normal p53 status and polarity, forming organoid-like structures 
in vitro (73). Hep3B cells are p53-null and are highly undifferentiated cells, sustaining little 
activity of PHHs. Huh-7 cells possess a point mutation in the TP53 gene (A220G) and are 
frequently used for studies involving viral infection due to their expression of viral entry 
receptors (74). These cell lines have also been further modified to suit specific investigations, 
such as alterations in viral permissiveness and propagation (75, 76). Cell lines, however, do 
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not represent the actions of PHH within the liver. Not only is this due to their tumour status, 
but also because of many varying conditions found in the liver which are absent from 2D 
cultures, such as tissue stiffness and signalling factors. Often, to obtain somewhat more 
physiologically relevant results, many investigations will utilise mouse models to study how 
hepatocytes function in the complete liver, in the presence of other hepatic cells. Overall, 
there are multiple methods to study the activity of hepatocytes, despite the challenges of 





1.3.1 The purpose of Efferocytosis 
Throughout their natural lifecycle, cells eventually become exhausted and undergo regulated 
cell death. These cells must be removed to alleviate space and resources for their 
replacements. The removal of dead or dying cells is also a necessary process for the 
resolution of inflammation and for tissue repair (77). Without the clearance of dead cells, 
corpses gradually decay, and their internal components leak into the surrounding tissues. 
This can have many detrimental consequences. Unregulated activity of digestive enzymes, 
particularly those found in lysosomes like cathepsins, can result in unwanted external 
enzymatic activity and tissue digestion. This activity, coupled with the degeneration of 
cellular components, also generates a large pool of ‘self-antigens’. Of note, these include the 
membranal components of internal organelles, whose membranes have been reported to 
replace portions of the cell membrane during cell death (78). Many of these self-antigens 
can be recognised by one’s own immune cells, which can promote further immune cell 
recruitment, inflammation, and can increase the risk of autoimmune disease. Several cell 
types have therefore evolved to remove dead and dying cells which prevents this premature 
activation of the immune response (77). This process of clearing the dead by specialised 




1.3.2 Mechanisms of apoptotic and necrotic cell clearance 
1.3.2.1 Detection of dying cells 
Several mechanisms have evolved in efferocytes for the detection and engulfment of dying 
cells (79, 80). These are generally associated with the actions of ‘find-me’ signals and ‘eat-
me’ signals (81, 82). ‘Find-me’ signals are generally soluble factors which direct efferocytes 
to the location of dying cells (82). The best example of these include free nucleotides 
released from dying cells as a result of nuclear breakdown (83). Binding of these to nuclear 
receptors, P2X1 and P2Y2, was shown to promote the recruitment of monocytes and 
macrophages. Chemotactic factors including sphingosine-1-phosphate (S1P) and CX3CL1 
(fractalkine) have also been shown to recruit phagocytes to the areas of dying cells (84, 85). 
Upon encountering a dead or dying cell, ‘eat-me’ signals assist efferocytes to identify them 
through direct contact. Probably the most ubiquitous of these is the phospholipid, 
phosphatidylserine (PS) (86). Normally only present on the inner leaf of the cell membrane, 
PS is flipped to the outer leaf by scramblases when a cell undergoes programmed cell-death. 
PS can then be recognised directly through a multitude of transmembrane receptors, 
triggering the internalisation of the dying cell (87). Other ‘eat-me’ signals include various 
opsonising molecules which can bind PS. These include oxidised low-density lipoproteins 
(oxLDLs) which can be recognised by scavenger receptors and have themselves been 
reported to induce apoptosis (88, 89). Intercellular adhesion molecule 3 (ICAM-3) can also 
act as a separate ‘eat-me’ signal; it is recognised by macrophages through its interactions 
with CD14.  (90). Finally, loose nucleotides have also been shown to have dual-modality and 
can act as both ‘find-me’ and ‘eat-me’ signals (91).  
Conversely, other molecules are tasked with preventing the engulfment of cells. These 
proteins, appropriately-named ‘don’t-eat-me’ signals, include the transmembrane protein 
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CD47 (92). This molecule binds to the receptor, signal-regulator protein-alpha (SIRPα) on the 
surface of macrophages, which initiates signalling pathways that prevent the cytoskeletal 
contractility required for efferocytosis (93).  
Efferocytes are required to make direct contact with their ‘prey’. This allows for the 
activation of internal machinery, largely through the GTPase, Rac1, which drives the 
cytoskeletal rearrangements necessary for dead cell engulfment (87). How an efferocyte 
makes direct contact with a dying cell is normally determined by the process through which 
cell has died (Fig. 1B). Throughout steady states, cells may undergo a form of programmed 
cell death known as apoptosis. This is an active process, through which the dying cell induces 
its own death. This can occur in response to external signals received from other cells or 
through intracellular sensing pathways, known as the extrinsic and intrinsic apoptotic 
pathways respectively (94). Both pathways culminate in the activation of caspase enzymes, 
which proceed to digest the internal components of the cell. Although the nucleus, 
cytoplasm and organelles are broken down, resulting in constriction of the apoptotic cell, the 
cell membrane remains intact. As such, this form of cell death is generally considered to be 
immunologically silent, as cells are cleared without invoking an immune response. This is 
facilitated through the presentation of PS on the external leaf of the cell membrane at early 
stages in the cells death. This is recognised by efferocytes through many possible receptors 





Another frequent form of cell death is a passive process called necrosis. In contrast with 
apoptosis, necrosis is unprogrammed and there is no uniform molecular process for its 
induction. It is generally defined by the loss of integrity of the cell membrane, which can be 
caused by numerous methods including physical rupturing, pH alterations or biochemical 
toxicity (96). Necrosis can also be induced by the depletion of ATP within a cell. This often 
occurs in apoptotic cells that are unable to continue with the programmed pathway of cell 
death, instead undergoing ‘secondary necrosis’. Unlike with apoptotic cell recognition, no 
dedicated receptors exist for the detection of necrotic cells. Although some reports have 
suggested that necrotic cells can also be identified through PS-recognition (97-99), it is 
generally accepted that their recognition by efferocytes is improvisational; many receptors 
used are normally tasked with immune response activation and bacterial sensing (80, 95). 
These include receptors for components of the complement system and for Fc regions of 
Figure 1B: Differences in recognition and consequences between apoptotic and necrotic cell 
capture by macrophages. Apoptotic cells are mostly recognised through phosphatidylserine 
(PS) receptors or by scavenger receptors. They can also be internalised through interactions 
between macrophage CD14 and ICAM3 on the dying cell. Capture of apoptotic cells endows a 
more anti-inflammatory phenotype, involving increased expression of TGF-β, and decreases in 
TNF, IL-1β and IL-8. The opposite phenotype is induced following necrotic cell capture, which is 
conducted using receptors that ordinarily are used to initiate an inflammatory response, such 
as those which recognise Fc regions of antibodies and members of the complement pathway. 
TGF-β – tumour growth factor-β; TNF – Tumour necrosis factor; IL – interleukin. Taken, with 
permission, from (95). 
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antibodies, respectively. This is due to the level of degradation associated with necrotic cells, 
whereas apoptotic cells constrict but remain intact. As such, apoptotic and necrotic cell 
capture can be distinguished by the receptors that are used for their recognition.  
1.3.2.2 Molecular mechanisms of efferocytosis and cargo processing 
Several components of internal molecular machinery have been identified which are 
required for the intracellular processing of corpses engulfed by phagocytes. Homologs of 
these genes were initially identified in Caenorhabditis elegans (100, 101). It was shown how 
mutations in genes encoded CED-1/2/5/6/7/8/10 and NUC-1 prevented efficient clearance 
of dying cells within these nematode worms. The roles of human homologs for some of 
these genes, in the context of phagocytosis, were later elucidated (102, 103). CED-2, CED-5 
and CED-10 was shown to resemble the adaptor protein, CrkII, the guanine exchange factor 
(GEF), DOCK180 and the Rho GTPase, Rac1, respectively. A later investigation by 
Ravichandran and colleagues also confirmed the activity CED-12 and its mammalian 
homolog, Engulfment and cell motility 1 (ELMO-1), in macrophage phagocytosis (104). These 
investigations lead to further understanding of the downstream events that incurred once a 
phagocyte recognises a dying cell. Downstream of PS-receptors, such as brain-specific 
angiogenesis inhibitor 1 (BAI1) (105), adaptor proteins, CrkII and ELMO1 are recruited to the 
site of dead cell-recognition. These protein further recruit Dock180. The GEF activity of this 
protein activates Rac1, which drives the actin cytoskeleton arrangements required for dead 
cell engulfment.  
Other early investigations implicated Phosphoinositide 3-kinase (PI3K) in the completion of 
efferocytosis (106). Although normally concerned with growth factor signalling, early reports 
showed that macrophages treated with the broad, potent PI3K inhibitor, wortmannin, 
showed inhibition of FcR-mediated phagocytosis, due to failure to close the phagosome 
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(107). Vieira and colleagues later confirmed that specifically type I PI3Ks, responsible for the 
creation of phosphatidylinositol 3, 4, 5-phosphate [PI(3,4,5)P] were necessary for the actin 
remodelling required for phagosome formation (108). More recently, it was shown that 
PI(3,4,5)P formation was required to recruit Rho GTPase activating proteins (GAPs) capable 
of inhibiting GEFs involved in actin assembly, including cdc42 and Rac1 (109). This permitted 
actin disassembly required for phagosome completion. Conversely, PI(3)P-forming type III 
PI3Ks such as autophagy-related kinase, VPS34, were shown to be involved in phagosome 
maturation and lysosomal fusion. The activity of these kinases were thought to involve the 
recruitment of endosomal trafficking proteins, including Rab GTPases (110). Relating to this 
function, many reports now imply the role of non-canonical autophagy within the ultimate 
processing steps for internalised dying cells. It has been observed that LC3, one of the major 
directing components of the autophagy pathway, would become lipidated to single-
membrane intracellular structures containing engulfed apoptotic corpses (111, 112). This so-
called LC3-associated phagocytosis (LAP), requires the activity of VPS34 and is thought to 
assist the fusion of these structures with lysosomes, allowing for the breakdown of its 
contents (113).  
1.3.3 Non-professional phagocytes 
Cells which have been reported to clear dead cells are commonly divided into 2 distinct 
categories; professional and non-professional phagocytes (114). Much of the studies 
regarding efferocytosis focus on circulatory cells which are recruited to sites of dying cells, 
whose primary function is efferocytosis. These include macrophages and monocytes, as well 
as DCs and neutrophils. However, a large number of non-circulatory, tissue-forming cells are 
capable of engulfing dying cells (97, 114). These cells are critical for relinquishing the burden 
of dead cell clearance when professional phagocytes are unavailable (97, 115).  Best 
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characterised of these are the epithelial cells which line the airway (116, 117). As the first 
responders to airborne toxins and pathogens, these cells have a high rate of turnover. This is 
augmented by the subsequent recruitment of immune cells, including lymphocytes, and 
allergy-related cells such as basophils, eosinophils, and mast cells. Dying epithelial and 
immune cells must be speedily removed to prevent persisting inflammation which could 
disrupt the airway. Efferocytic alveolar and bronchial epithelial cells can clear these cells, 
reducing the time required for professional phagocyte recruitment. However, their ability to 
clear dead cells is still ultimately regulated by airway macrophages activities (118).  
Another class of non-professional phagocytes are retinal pigment cells (RPCs). During the 
development of the retina, these cells engulf neighbouring cells of the same lineage that 
undergo autophagy-related death (119-121). Of note, both airway and retinal cells have 
been shown to recognise dying cells using receptors that are also expressed by professional 
phagocytes, including CD36, αvβ5 integrins and TAM receptors such as MerTK (119, 122-
124). Similar preservation of macrophage efferocytic machinery was also observed in colonic 
epithelial cells; they possess the PS-receptor, BAI1, but also the same downstream 
intracellular machinery used by macrophages to induce the Rac1-driven cytoskeletal 
rearrangements required for efferocytosis (125).  
As with the activity of retinal pigment cells, other non-professional phagocytes have evolved 
the ability to clear dead cells for developmental reasons. Mesenchymal cells have been 
shown to clear apoptotic cells generated in foot limb development in macrophage-depleted 
mice (115). Similarly, neuronal progenitor cells engulf their apoptotic neighbours, which aids 
the process of developing neural networks (126). This exemplifies the evolutionary 
conservation of this activity due to its necessity in early stages of development. This is the 
likely origin of many non-professional phagocytes. This behaviour was subsequently 
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preserved for the prevention of premature inflammatory responses and to supplement the 
activity of professional phagocytes.  
1.3.4 Efferocytosis in health and disease 
Although the clearance of dying cells is often integral to the resolution of disease, 
efferocytosis is in some cases related to actual disease pathogenesis. As explained earlier, 
this discrepancy is inferred from whether apoptotic cells or necrotic cells are captured. The 
clearance of apoptotic cells is generally associated with the resolution of inflammation and 
disease; efficient and early clearance of dying cells reduces the risk of inducing inflammation 
and generally infers anti-inflammatory phenotypes to efferocytes (127). The prevention of 
apoptotic cell clearance is often implicated with inflammatory disease, especially for 
autoimmune disorders (128). The loss of scavenger receptors associated with efferocytosis, 
including axl and scavenger receptor family F member 1 (SCARF1), have been linked to 
autoimmune diseases, such as autoimmune encephalitis and lupus (129, 130). Similarly, mice 
which lacked the scavenger receptor, Mer, and its ligand, Gas6, showed exasperated 
inflammation which was associated with an increase of tumorigenesis (131). More recently, 
mice whose macrophages lacked the PS-receptor, CD300f, were also shown to express a 
lupus-like phenotype (132). Of interest, an upregulation of CD300f on DCs, instead of 
macrophages, resulted in a similar outcome (133). This was also the result of reduced 
efferocytosis in these mice, showing certain PS-receptors can have alternative functions in 
different cells.    
The importance of efferocytosis in the airway, by both professional and non-professional 
efferocytes, has been made evident in numerous investigations into lung and bronchial-
related diseases. Reduced activity of airway macrophages has been linked to the 
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pathogenesis of pulmonary obstruction disease, cystic fibrosis and bronchiectasis (134, 135). 
Furthermore, the promotion of efferocytosis by anti-inflammatory cytokine stimulation was 
shown to reduce inflammation associated with asthma (117). 
 A common cause of pathogenesis associated with reduced efferocytosis is the activity of the 
‘don’t-eat-me’ signal, CD47. The ability of this molecule to promote the longevity of cells has 
been exploited by many varieties of tumour (92, 136, 137). Its expression has also been 
attributed to the aberrant clearance of apoptotic cells that normally comprise the 
vasculature, which can increase in the risk of atherosclerosis (138). In each of these studies, 
blockade of CD47 showed therapeutic potential by restoring efferocytosis.  
Although efferocytosis is generally a pro-resolution process, it can also cause the opposite 
effect under certain circumstances. This is mostly associated with the clearance of necrotic 
cells. As these cells are detected using receptors normally associated with initiating the 
immune response, the downstream consequences are normally pro-inflammatory (79, 139). 
As such, engagement of these receptors by necrotic cell fragments can cause efferocytes to 
enhance localised inflammation. This effect can be synergistically enhanced by increased 
immune cell influx which are recruited by dying cells. In support of such possibilities, the 
removal of scavenger receptor, TIM4, was shown to reduce immune cell infiltration to the 
liver in a model of ischaemia reperfusion injury (IRI) (140). As this mouse model commonly 
presents with localised areas of necrosis, it is likely the efferocytosis of these cells which 
contributes to inflammation. The inflammatory consequences of such incidents may, 
however, be lessened if necrotic cells can be recognised through PS recognition as some 
investigations would suggest (98, 99). Non-professional phagocytes have been shown not to 
develop such a pro-inflammatory phenotype in response to engulfing necrotic cells, 
potentially for this reason (97). Taken together, although efferocytosis is generally necessary 
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for preventing disease pathogenesis, it must still be regulated to reduce the risk of indirect 
inflammatory fallout.  
1.3.5 Hepatic Efferocytosis 
The burden of dying cell removal is particularly palpable in the liver. Frequent cell turnover is 
required in the liver, both of apoptotic immune cells and of dying cells resulting from 
frequent exposure to xenobiotic substances. In relation to its requirement for maintaining an 
immunotolerant environment, the liver possesses many cell types which are capable of 
efferocytosis (1). Many of these are commonly described circulatory cells, including DCs, 
monocytes, and neutrophils. Most investigations concerning this, however, focus on the 
resident macrophage population of the liver, the Kupffer cell (141). Although these cells 
frequently patrol the sinusoidal endothelium, they are also capable of clearing corpses which 
form within the parenchyma. As with most phagocytes, Kupffer cells can respond to ‘find-
me’ signals and clear dying cells from the parenchyma.  
As a further distinctive feature which separates it from other internal organs, most tissue-
forming cells in the liver are non-professional phagocytes (1). Stellate cells, which ordinarily 
contribute to liver fibrosis, have been reported to engulf apoptotic hepatocytes (142). Cells 
which line the bile ducts, biliary epithelial cells (BECs) are also capable of internalising blebs 
exuded from apoptotic cells (143). Liver sinusoidal endothelial cells (LSECs) are also capable 
of apoptotic cell clearance, through the expression of scavenger receptors, SCARF1 and 
stabilin-1/2 (144, 145). Of importance, the major cell type which comprises the liver, the 
hepatocyte, is also capable of efferocytosis. This was originally described in 1944 by Dini and 
colleagues, where erythrocytes were observed within cytoplasmic spaces of rat hepatocytes 
(23). However, further elaborations on this observation were not made until almost 50 years 
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later (146). Hepatocytes are known to express a carbohydrate scavenger receptor called 
asialoglycoprotein receptor (ASGPR). This has been shown to facilitate the capture of 
apoptotic lymphocytes by other efferocytes by sequestering them in the parenchyma (147).  
This potentially crucial aspect of liver biology has been largely confined to history. With 
hepatocytes providing 80% of the livers mass and with the importance of efferocytosis in 
other organs in preventing premature inflammation, it is imperative that this process should 
be further elucidated and understood.  
The occurrence of efferocytosis for the prevention of unwarranted inflammatory responses 
is likely a contributor to liver immunotolerance. In support of this, the activity of MerTK-
expressing professional phagocytes was recently shown to promote resolution in mouse 
models of acute liver injury (148). Mice which lacked MerTK displayed more persistent 
fibrosis and a reduced number of Kupffer cells. Similarly, the PS-opsonising protein, milk fat 
globule-EGF factor 8 (MFG-E8), was shown to be downregulated in liver macrophages that 
were exposed to alcohol (149). In relation to this, expression levels of ASGPR1 were also 
decreased in response to ethanol (150). This is likely to reduce the efficiency of apoptotic cell 
clearance in the liver parenchyma. Overall, it appears that alcohol damage in the liver is 
partially induced by preventing the removal of dying cells.  
The overall contribution of efferocytosis reduction to different forms of liver disease is likely 
to be under-represented in the literature. Several autoimmune disorders are known for the 
liver, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC) (151, 152). Although the exact mechanisms of pathogenesis for 
these diseases are uncertain, they are synonymous with an upregulation of apoptosis, 
particularly for BECs and hepatocytes (153). As mentioned before, failure to clear apoptotic 
cells, allowing their progression to secondary necrosis, can increase the risk of immune 
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system overactivation and autoantibody development (154, 155). It is therefore likely that 
efferocytosis is defective in these diseases. In support of this, PBC patients possess 
autoantibodies raised against pyruvate dehydrogenase complex (PDC-E2), which is 
preserved and exposed in blebs derived from apoptotic BECs (156). Autoantibodies targeting 
ASGPR are also thought to be raised in AIH patients, which are likely to be derived from 
dying hepatocytes (157). This is also likely to contribute further to disease progression by 
disrupting later efforts to clear dying cells. Further understanding into the pathogenesis of 
these diseases is needed to identify a possible reduction in efferocytosis, as well as to which 
efferocytic cell this deficiency is attributed to.  
1.4 CD4+ T-lymphocytes and their interactions 
1.4.1 CD4+ T cell functions and subtypes 
T helper lymphocytes, identified by the surface expression of CD4, denote a major 
component of the adaptive immune system. In cooperation with T cytotoxic cells (CD8+ 
cells), they perpetuate signals derived from innate immune cells and antigen presenting cells 
(APCs), allowing for swifter, more targeted and long-lived responses (158, 159). CD4+ T cells 
invoke different and sometimes contrasting responses, depending on their predominately 
active transcription factors (Fig. 1C). Pro-inflammatory cells can be broadly grouped in to 
TH1, TH2 and TH17 cells, based on their expression of transcription factors Tbet, GATA3 and 
RORγ, respectively (158). TH1 cells are frequently found in the liver during inflammation and 
are the major sources of pro-inflammatory cytokines, including IFN-γ and TNF-α. These cells 
are generally recruited and activated in response to bacterial antigens. TH2 cells are more 
associated with responses to helminth infections and allergy, together with IL-4 secretions. 
Such cells are less frequently found in the liver. TH17 cells, characterised by IL-17 secretions, 
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are variable and versatile in immunity, behaving either pro-inflammatory or anti-
inflammatory. Their activity is determined by their stimulation with cytokines of the same 
overall function (IL-6 and TGF-β, respectively) (160).  
CD4+ T cells can also respond to inflammatory signals and act to dampen immune responses. 
The major cells responsible for this are called T-regulatory cells (Tregs). These cells can be 
identified in mice by their expression of the transcription factor, FOXP3, which is necessary 
for their development and immunosuppressive activity (161). However, in humans, FOXP3 
can also be transiently expressed by non-Treg subtypes (162). Consequently, normal human 
Tregs are instead identified by high expression of CD25 and CD11a, and low expression of 
CD127. Tregs secrete anti-inflammatory cytokines like IL-10 and TGF-β which promotes 
resolution of inflammation. As such, some clinical trials have endeavoured to expand Tregs 
isolated from patients and then re-introduce them as a form of therapeutic intervention 
(163). Although these trials have experienced some success, they run the risk of 
immunocompromising the patient by preventing de novo inflammatory responses. 
Additionally, reports suggest that Tregs can be influenced by pro-inflammatory cytokines to 
acquire more pro-inflammatory characteristics, such as through Tbet expression for example 
(164). Bearing this in mind, it should be noted that CD4+ subsets, although possessing 
identifiable markers, are versatile cells and often do not have terminal functionality. As such, 
controlling the population of CD4+ T cell subtypes within a tissue represents a delicate 








Figure 1C: Development and activities of CD4+ T cells. Naïve CD4+ T cells are committed 
towards a specific subset lineage after activation by T-cell receptor (TCR) engagement with an 
antigen presenting cell (APC). Specific extracellular signals dictate the expression of 
transcription factors which determine the subset which the cell will become. Each subset 
produces a distinct (although not fixed) set of effector mediators which are associated with 
their specific mode of action. CD – cluster of differentiation; TGF-β – tumour growth factor-β; 
TNF – Tumour necrosis factor; IL – interleukin; IFN-γ – interferon-γ; FOXP3 – forkhead box P3; 
RORγt - retinoic acid receptor-related orphan receptors gamma-t; Treg – T regulatory cell. 
Information adapted from (165). 
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1.4.2 How epithelial cells alter CD4+ T cell behaviour 
Although largely determined by other members of the immune system, mostly including 
APCs like DCs, T cell activity can also be altered through interactions with epithelial cells, 
especially in the lung and gut (166). This is mostly achieved through inflammatory signalling; 
several epithelial cell types are capable of cytokine secretion. Airway epithelial cells are 
integral to TH2 cell functionality associated with allergic responses. This is done through the 
production of cytokines such as interleukins 1, 25 and 33, which in-turn alter the behaviours 
of DCs and CD4+ T cells (167). In addition, these barrier epithelial cells are capable of 
producing TH2-related active molecules which are thought to contribute to asthma, including 
periostin and serpinB2 (168).  
Some epithelial cells are capable of influencing T cell behaviour through direct cell-cell 
interactions. Kidney epithelial cells have been shown to upregulate MHC-II molecules in 
response to pro-inflammatory cytokine stimulation, allowing for them to activate CD4+ T 
cells. However, this was shown not to promote their proliferation; a similar situation to T cell 
stimulation in the liver (169). RPCs also express and interact with CD4+ T cells using MHC-II, 
although this was also shown to induce a state of anergy within these cells (170). Similar 
outcomes have been described for colonic epithelial cells, which were hypothesised to 
prevent inappropriate T cell activation (171).  Intestinal epithelial cells (IECs) were 
additionally reported to activate CD4+ T cells in the gut, skewing them to more TH17-like 
lineages (172). This was induced through direct interactions with T cells via the MHC-I-like 
molecule, thymus leukaemia antigen. IECs can also promote TH17 activity in response to 
sensing bacterial DNA, although this is altered to more anti-inflammatory responses when 
sensing DNA from commensal strains (173). Of note, retinal, airway and intestinal epithelial 
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cells are capable of phagocytosing apoptotic cells (as mentioned earlier in section 1.3.3), 
which in turn promotes anti-inflammatory response and Treg activity (116, 120, 174).  
1.4.3 Live T cell capture by other cells 
As the initiators of the immune response, T cells represent key targets in controlling the 
overall activity of the immune system. Although many soluble factors and cytokines have 
been described to alter their activity, some investigations have reported certain situations 
when other cells capture live T cells, providing a mechanism of disease and immunity 
modulation. Under certain circumstances, it has been described how macrophages can 
capture live T cells, a process known as haemophagocytosis (175). This is commonly 
observed in cases of chronic inflammation and hyperactivation of the immune system, such 
as in autoimmunity. In xenograft mouse models of graft vs host disease, both CD8+ and CD4+ 
T cells from donated tissues have been reported to be engulfed by recipient macrophages 
and DCs (176). Additionally, haemophagocytosis is often concurrent with macrophage-
activation syndrome (MAS) (177). In the liver, MAS has been shown to coincide with a large 
influx of inflammatory T cells, both CD4+ and CD8+ varieties, as well as haemophagocytic 
macrophages (178, 179). This results in a large local increase in pro-inflammatory cytokine 
secretion, as well as the inability of engulfed cells to target and eliminate possibly infected 
cells. Under these conditions, despite the outnumbering of CD4+ helper T lymphocytes by 
CD8+ cytotoxic T cells, macrophages can still be observed engulfing CD4+ T cells (178). Aside 
from situations of chronic inflammation, macrophages have also been reported to engulf live 
CD4+ T cells infected with HIV-1, which was shown to be a method of viral transfection of the 
engulfing macrophages (180). 
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Although several situations of live T cell capture have been described, most of these involved 
macrophages as the predatory cell. Minimal examples have been described for other, non-
circulatory cells, especially for live CD4+ T cells specifically. However, it was reported that 
hepatocytes were able to engulf and remove live, autoreactive CD8+ T cells (181). This was 
proposed as another method in which hepatocytes contribute to maintaining a steady 
immune state by removing autoreactive cells from the environment. Additionally, metastatic 
melanoma cells have also been reported to capture CD8+ T cells, as a likely mechanism of 




1.5 Cell-in-cell structures 
1.5.1 The mechanisms of cell-in-cell structures 
In recent years, a new and ever-expanding field of research has emerged concerning cell-in-
cell structures (CICSs). This literally concerns the presence of whole, undamaged live cells 
within other host cells. The mechanisms and consequences of CICSs have proven to be of 
great interest in a growing number of biological systems. Their formation has been most 
efficiently described by Overholtzer and colleagues. They initially observed how primary and 
immortalised breast cancer cells were able to internalise live neighbouring cells of the same 
lineage (183). They named this process as “entosis”. From this, the molecular requisites of 
CICSs and their methods of formation were elucidated (184, 185). They describe how this 
homotypic capture of one cell by another was reliant on Rho GTPase and Rho Kinase (ROCK) 
activity (Fig. 1D). The resulting vesicle containing this live cell would associate strongly with 
E-cadherin and β-catenin, which are well known to interact in the formation of adhesion 
junctions under normal circumstances (185, 186). Some evidence also suggests that entosis 
can be modulated by androgen receptor via the Rho-ROCK pathway in prostate cancer (187). 
Later reports have linked these associations to the establishment of the cell-cell junctions 
following the completion of mitosis (188); “rounder” cells with less-established adherence 
junctions, which is often a state associated with actively dividing cells, were more prone 
internalisation by a neighbouring cell which possessed better-established junctions. This was 
exemplified whereby cells deficient in cdc42, and could therefore not enter the cell cycle, 
were less likely to be engulfed. These collective data thus summarised the molecular 
dynamics of entosis. Although described as form of “non-apoptotic cell death”, the 
internalised cell does not always suffer this fate; investigations have described the 
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proliferation of captured cells, as well as their release from the host cell (183, 184) (Fig. 1D). 
These examples suggest that the purpose and consequences of CICSs are specific to the 
tissue and cells in which they occur. 
1.5.2 Examples and consequences of cell-in-cell structures   
Since the initial definitive markers and mechanisms for entosis were established, other cells 
or tissues which have exhibited similar characteristics have now been described. Historically, 
it has been observed that thymic nurse cells (TNCs) were capable of internalising multiple 
live thymocytes, potentially as process of immature cell elimination (190). It has now been 
shown that the thymocytes take a more active role in the internalisation process than 
initially thought by interacting with cytoskeletal components of the TNC, similar 
circumstances as to those described for entosis (191). Li Y et al, presented a highly 
convincing case for the involvement of entosis in embryo implantation (192). This was a 
paradigm-shifting investigation which demonstrated that blastocyst trophoblasts 
internalised and cleared live uterine epithelial cells. This was an early example of heterotypic 
live-cell capture and showed the absence of apoptosis during blastocyst implantation. Other 
investigations described entosis-like phenomena in keratinocytes, mesenchymal cells, and in 









Figure 1D: The formation and fates of cell-in-cell structures formed via entosis.  A cell invades 
into a neighbouring cell. This required Rho kinase-dependent actomyosin contractile activity and 
cell-cell junction formation involving E-cadherin. A cell-in-cell structure is then created following 
complete internalisation of the captured cell. Reports have shown that cells internalised via 
Entosis can be digested upon lysosomal fusion, which requires the activation of the non-canonical 
autophagy pathway, via VPS34, a class-III phosphatidylinositol-3-kinase. Internalised cells can also 
die via apoptosis, they can persist within the cell and proliferate, or can be released from the 
host. Taken, with permission, from (189).  
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Aside from entosis, other situations and processes which lead to CICS formation have been 
described in the literature, often referred to as ‘emperipolesis’ (184). Many of these are 
heterotypic and frequently involve the capture of immune cells, frequently playing pivotal 
roles in immune responses. It has been widely reported, for example, that live neutrophils 
can be found within megakaryocytes in the bone marrow (184, 196-199). It is thought that 
neutrophils eventually pass through megakaryocytes as a form of transcellular migration and 
enter circulation (199). More recently, some reports have described CICS formation through 
a process known as suicidal emperipolesis (181, 200). This term was used to describe the 
capture and deletion of one live cell by another. As previously mentioned, it was described in 
the liver, whereby autoreactive CD8+ T cells were engulfed and deleted by hepatocytes 
(181), further contributing to liver immunotolerance and homeostasis.  
Each cell type for which entosis has been described has displayed specific requirements for, 
and consequences of this process. Many of these have been related to development and cell 
population control, akin to induced programmed cell death via apoptosis. Additionally, as 
many of these cells have been transformed or are tumour cells, entosis has been suggested 
as a method of intercellular competition (201-203). It was postulated by Sun et al, in 2014 
that during homotypic entosis between cancers, there is ‘winning’ and ‘losing’ cell (203). This 
nomenclature presents a predator-prey-like scenario whereby one cell provides sustenance 
for another, but also relates entosis to a form of Darwinian selection within a tumour that 
maintains more-transformed, oncogenic cells, whilst eliminating less-transformed cells. Sun 
and colleagues evidenced this with experiments whereby transformed cells were observed 
to engulf their normal counterparts (203). The authors also showed that the ability to 
‘entose’ other cells is linked to their oncogenicity and potentially with their capacity for 
metastasis. Cells with higher expression of kras, a well-known oncogene, were shown to 
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engulf their neighbours more frequently. This was concurrent with increased expression of 
Rac1, the Rho GTPase linked to cytoskeletal rearrangement and, by extension, metastasis.  
Aside from providing nutritional support and a mechanism of cell elimination, CICSs were 
shown in early stages of their study to induce genetic alterations to the host cell (185, 204). 
The CICS is an incredibly large internal structure, relative to the size of the host cell, which 
can impose a physical block on the cleavage furrow during cytokinesis. Cells containing CICSs 
were, consequently, more likely to fail cell division, becoming multinucleate and polyploid. 
This can create difficulty in resolving the increased number chromosomes across metaphase 
plates during later cell divisions (205). This leads to further genetic alterations through the 
loss or gain of, so-called “lagging chromosomes”. As such, CICSs can also force cells to 
become aneuploid, as well as polyploid. The increased likelihood of genetic instability 
represents another advantage of Entosis for cancers, as it promotes the accumulation of 
potentially transformative and proliferative mutations. These investigations show that CICSs 
can be a method of controlling cell populations, but are also linked with genetic 
manipulation, particularly in transformed, oncogenic cells.  
1.5.3 Similarities and differences between cell-in-cell structures and efferosomes 
The induction of CICSs and their cellular organisation have obtained their own distinct field 
of research in recent years. Many key techniques utilised to investigate CICSs have been 
modified from those used to study the capture of dead cells and efferosomes. As such, the 
capture of live and dead cells shares several molecular and consequential parallels. The 
clearest molecular link described is through the sharing of molecular machinery associated 
with autophagy (206). Reports have shown how both entotic vesicles and efferosomes 
initially associate with the lipidated version of autophagy initiating protein, Light chain 3 
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(LC3-II) and that their internal processing is regulated by the starvation-sensing protein, 
mTOR (111, 207). This was shown, in breast cancer cells, to be initialised by vacuolar-type 
ATPase (V-ATPase) in response to osmotic alterations in endolysosomal compartments that 
were induced following live or dead cell engulfment (208). Efferosomes were also reported 
to associate with the autophagic molecularly machinery which assists in the lysosomal fusion 
(121, 209). As this is not evident in all phagocytes, this process has received its own 
nomenclature, called LC3-II-associated phagocytosis (LAP) (112, 210). Entotic vesicle 
membranes were shown to be transiently enriched with LC3-II (111). Consequently, these 
cells are engaged by the autophagy pathway, but do not necessarily perish because of this. 
Overall, efferosomes (or at least so-called LAPosomes) share the same association with LC3-
II as entotic vesicles, but not necessarily for the same length of time. This similarity thus may 





The mechanisms and consequences of dead cell capture and live CD4+ T cell capture by 
hepatocytes are poorly understood. I hypothesise that they are phenotypically and 
molecularly distinct processes. To investigate this, the work conducted in this thesis 
endeavoured to accomplish the following aims. 
1. To understand the molecular processes behind hepatocyte efferocytosis.  
2. To outline the consequences of efferocytosis for the engulfing hepatocyte. 





Figure 1E: Problems to be addressed in this PhD project. Previous data in the Stamataki lab has 
demonstrated that hepatocytes (brown) can engulf live CD4+ T cells (blue). Previous reports 
have shown that hepatocytes can also capture apoptotic (red) and necrotic (green) cells. 
Question marks represent the lacking details behind the receptors of cell-cell interactions 
involved in each of these processes, for the molecular processes involved with intracellular 




Chapter 2: Materials and Methods 
2.1 Antibodies 
Table 1, below, details all antibodies used throughout the duration of this project, as well as 
their source, purpose, and their working concentrations.  
 















































































































Primary Immunohistochemistry (1/100) 
Anti- LOX1 Goat IgG 


































































































































































2.2 Reagents and buffers 
Table 2 and table 3, below, details all reagents and buffers, respectively, used throughout 
the duration of this project, as well as their source, purpose, and their working 
concentrations if available. The components, and their concentrations, of all buffers are 
listed. 
 













FITC Annexin V 
Apoptosis 




Detection of apoptotic 
and necrotic cells 


























Culture of suspension 
cells 
N/A 





adherent cells for 
passage 
N/A 





10% in media 
Cell culture 
 Non-essential 















antibiotic for culture 
medium 
1% in media 






























































factor alpha (TNFα) 
PeproTech (300-
01A) 








factor beta (TGF-β) 
PeproTech (100-
21) 





































Dexamethasone Sigma (D2915) 




































staining of cells 
3.7% (w/v) 
Immunofluorescence Hoechst 33342 
Life Technologies™ 
(H3570) 




































Used at 2X 
diluted in TBST 
Immunohistochemistry StayGreen/AP Plus Abcam (ab156428) 
Immunohistochemistry 
(secondary detection) 


























































peroxidase activity of 
tissues 
N/A 









EnVision FLEX wash 
buffer (Tris-
buffered saline with 
Tween - TBST)  




mounting medium  
Life Technologies™ 
(P36930) 
Mounting medium for 
fluorescently stained 








inhibitor used for 
blocking efferocytosis 
and live T cell capture 
Experiment-
specific 
Inhibitor H-1152 Tocris (2414) 
Inhibitor of Rho Kinase 
(ROCK) 
10 µM 
Inhibitor Blebbistatin Sigma (B0560 ) 
Macropinocytosis 
inhibitor used for 
blocking efferocytosis 
and live T cell capture 
50 µM 
T cell isolation Lympholyte 
Cedarlane Labs 
(CL5020) 
Gradient solution for 
isolating live human 
lymphocytes 
N/A 
T cell isolation 
EasySep™ Human 
CD4+ T Cell 
Enrichment kit 
Stem cell (19058) 
Negative selection kit 




Clarity ECL blotting 
substrate 
Biorad (17050) 
ECL substrate for 
western blotting 
exposure 
Used as per 
manufacturers 
instructions 








































Buffer Compenents Component Concentrations 
Isolation Buffer 
PBS Diluent 
FBS 2% (w/v) 
EDTA 1 mM 
FACS Buffer 
PBS Diluent 
FBS 1% (w/v) 
EDTA 2 mM 
SDS Running Buffer 
(10x) 
ddH20 Diluent 
Tris-base 248 mM 
SDS 1% (w/v) 
Glycine 1.92 M 
Transfer Buffer 10x 
stock 
ddH20 Diluent 
Tris-base 250 mM 
Glycine 1.92 M 







TBS (pH 7.6) X10 
ddH20 Diluent 
Tris-base 200 mM 
NaCl 1.37 M 
TBST 
TBS Diluent 
Tween20 0.01% (v/v) 
Staining buffer 
PBS Diluent 
BSA 1% (w/v) 
FBS 1% (w/v) 
Laemelli Buffer 
Tris-base 120mM 
SDS 4% (w/v) 






Table 3: List of buffers used throughout this project and their ingredients. 
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2.3. Cell culture 
Huh-7, HepG2 and Hep3B cells were used for models of primary hepatocytes and were kind 
gifts from Prof. Jane McKeating. All hepatic cell types were cultured in DMEM containing 
sodium pyruvate. For continued passage and for seeding, adherent cells were washed with 
PBS and treated with 0.25% trypsin-EDTA for 3 min, 37°C. Cultures were agitated to ensure 
that all cells were dislodged. Trypsin-EDTA was then quenched with an equal volume - 
minimum – of serum-containing media. Cells were then centrifuged for 5 min, g at room 
temperature. Supernatants were discarded and then cells were used for seeding. Part of the 
culture was retained and replaced into new flasks for continued passage.  
Primary T cells and Jurkat T cell lymphomas were cultured in RPMI. All media was 
supplemented 1% PenStrep, 1% NEAA, 1% L-Glutamine and 10% FBS (hereon known as 
‘complete media’). Media of primary T cells was supplemented with 500 IU Interleukin 2 (IL-
2). All cells were cultured in incubators at 37°C, 5% CO2. 
2.4 Primary T cell isolation and Regulatory T cell separation 
All primary lymphocytes were isolated from blood samples of fully consented 
haemochromatosis patients at the Queen Elizabeth Hospital. Blood was layered was on top 
of Lympholyte cell separation media at a blood:Lymphocyte ratio of 8:3 (commonly 35 ml 
blood was layered on top of 15 ml lympholyte) in 50 ml centrifuge tubes. Tubes were then 
centrifuged for 20 min, 423 g at room temperature, with no brake. Peripheral blood 
mononuclear cells (PBMCs) were then extracted from the subsequent buffy coat. PMBCs 
were then washed in PBS and diluted to a concentration of 5x107 in isolation media (see 
table 2). Primary CD4+ T-cells were then isolated using a STEMCELL negative selection kit, 
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according to manufacturer’s instructions (Cat. 17952). Isolated cells were then cultured in 
media supplemented with 500 IU IL-2. CD127lo CD25+ Treg cells were separated from total 
CD4+ T cells using a different STEMCELL negative selection kit (Cat.18063). Non-Tregs were 
salvaged from these isolations and allowed time for the magnetic beads to detach prior to 
their use within experiments.  
2.5 Induction of apoptosis in primary CD4+ T cells and Annexin V/7AAD 
labelling 
Isolated primary CD4+ T cells were briefly washed in PBS before resuspending in serum-free 
RPMI containing 1 µM staurosporine (STS) or volume-matched vehicle control of DMSO. 
Cells were resuspended at a concentration of 4x106/ml and incubated for a varying period at 
37°C (4 hr was eventually selected). Incubation times were staggered to ensure each were 
completed at the same time. Cells were then washed in PBS and staining using a Biolegend 
FITC-Annexin V Apoptosis Detection Kit with 7-AAD according to manufacturer’s instructions. 
Cells were then analysed by flow cytometry using a Beckman Coulter Cyan ADP9.  
2.6 Cell Tracker labelling 
For most in vitro experiments with an output of fluorescence microscopy, cells were initially 
fluorescently labelled with CellTracker dyes (CMFDA green, CMTPX red or BMQV violet). 
Cells were initially washed with PBS and then incubated with each label, 5 µM in serum-free 
media for 45 min, 37°C. Cells were then washed again in PBS and then rested in serum-
containing media for 1 hr, prior to experimentation, to avoid leaching and cross-labelling.  
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2.7 T-cell and Jurkat lymphoma preparation for co-culture assays  
Co-culture experiments were conducted between hepatoma cell lines and primary CD4+ T 
cells or Jurkat lymphomas. The latter cells were either live, apoptotic or heat-killed cells. For 
live cell co-cultures, the lymphocytes or lymphomas were layered on Lympholyte separation 
medium and centrifuged according manufacturers to instructions. This step was required to 
remove dead cells from the culture, which was later confirmed by trypan blue staining. 
Apoptotic cells were compared through treatments with 1 µM STS, with cells at a 
concentration of 4x106/ml. The development of this protocol and its variations is discussed 
in section 3.2. For heat-killing, cells were placed in a heat block at 60°C for 30 min.  
2.8 Co-culture assays 
For all co-culture assays, hepatocyte cell lines were seeded in polypropylene plates (24 or 96 
wells) for 80% confluence the following day. 13 mm glass coverslips were placed into wells 
prior to seeding for all confocal experiments. Cells were allowed 24 hr to adhere prior to 
experimentation. Cells were then labelled and pre-treated as necessary. All pre-treatments 
were conducted for 1 hr, unless stated otherwise, in 250 ul complete DMEM. Following this, 
the appropriate concentration of either primary CD4+ T cells or Jurkat lymphomas were 
added on top of the Huh-7 cells, dropwise in complete RPMI. Unless stated otherwise, 5x105 
cells were added to each well, giving a rough Huh-7:lymphocyte/lymphoma ratio of 1:2 for 
most experiments, and co-cultured for 3 hr. These suspension cells were either live, 
apoptotic or heat-killed. For most experiments, cells were fixed in -20°C, 100% methanol 
(MeOH) for 5 min and then washed with PBS. Glass coverslips, if used, were then mounted 
onto microscope slides using Prolong Gold antifade mountant. These coverslips were then 
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imaged using a Zeiss 780 or 880 confocal microscope. 5 fields of view were taken for each 
coverslip. Total Huh-7s were determined using Bitplane IMARIS cell rendering tools. 
Internalised cells were determined by eye and assisted using the ‘cell counting’ plugin for 
ImageJ. 
2.9 In vitro multinucleation experiments 
For in vitro induction of multinucleation through efferocytosis, Huh-7 hepatomas were 
seeded as described in section 2.3, but at a density of 2.5x105 in 24-well plates. Huh-7s were 
then incubated with heat-killed Jurkat T cell lymphomas at a ratio of 1:1. Excess Jurkat cells 
were removed following 24 hr co-culture. Cells were then washed with PBS and normal 
culture media was replaced. Huh-7s were permitted to conduct efferocytosis until they 
became confluent, indicating that they had completed efferocytosis (they do not divide 
when conducting efferocytosis). Huh-7s were then trypsinised as described in section 2.3 
and divided between 2 wells of separate 24-well plates. Unfed control wells were passaged 
as needed but seeded at the same time and density as the co-cultured cells for analysis. 
Huh-7s from one well were ‘re-fed’ with heat-killed Jurkat cells as described earlier and the 
experiment as repeated. Huh-7s in the other plate were labelled with Hoechst 33342 and 
CellMask Orange. The mean percentage of multinucleate cells was then determined from 
the total population of cells. Manual counting of these was facilitated by the counting tool 
within Image J. Numbers were generated from 5 fields of view (FOV), taken from 3 technical 
replicates. Means were acquired from 3, staggered experimental replicates.   
Experiments which involved single repeats were conducted as above but were instead 
terminated after a single round of co-culture. The Huh-7:heat-killed Jurkat ratio was altered 
for one experiment which assessed the effect of increased efferocytosis for multinucleation. 
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For experiments requiring 5-(N-Ethyl-N-isopropyl-amiloride) (EIPA), Huh-7s were pre-treated 
with 10 µM EIPA for 1 hour. This concentration was maintained following the addition of 
heat-killed Jurkat cells, which were added at a 1:1 ratio.  
2.10 Animal Experiments 
Observations taken from mouse models of ischemia reperfusion injury (IRI) and paracetamol 
overdose (acetaminophen [APAP] alone with no EIPA treatment) were made from 
haematoxylin and eosin (H&E)-stained paraffin-embedded liver tissues. Ischemia reperfusion 
injury was conducted with 8-week old C57BL/6 mice and induced as previously described 
(211). Mice were reperfused for 6 hr or 24 hr. N=5 per condition. Mr. Ricky Bhogal 
conducted these experiments. Paraffin-embedded tissues from these experiments were 
stained or reanalysed for the purposes of this project. APAP-injury was induced in C57BL/6 
mice through intraperitoneal injections (IP) of 300 mg/kg APAP. For all de novo animal 
experimentation, 20 male, 8-week old C57BL/6 mice were used across 2 individual 
experiments. 16 mice received 300 mg/kg acetaminophen (APAP), in 200 ul PBS, via IP. Half 
of these mice received 2.5 mg/kg EIPA via the same method 1 hour later, whereas the others 
received an equal volume of vehicle (0.001% DMSO). 4 mice received EIPA alone. 20 mice 
were used in total. Mice were sacrificed 24 hr later and their livers were removed. The 
largest lobes were prepped for paraffin wax embedment. Other lobes were snap frozen in 
liquid N2 for later experimentation. Cardiac punctures were also performed for blood 
extraction. Blood samples were then analysed for measurements of liver damage at the 
Birmingham Women’s Hospital: aspartate transaminase (AST) alanine transaminase (ALT), 
alkaline phosphatase (ALP) and bile acid.  Mouse handing was performed by post-doctoral 
researcher, Dr. Lozan Sheriff.  
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2.11 Normothermic machine liver perfusion and cauterisation model 
of liver injury 
Livers that underwent normothermic machine perfusion were donor livers, from consented 
patients, which had been rejected for transplantation (n=3, Centre for Liver research 
numbers: CLR1500, CLR1691 and CLR2519). Livers had undergone a 6 hr perfusion with an 
acellular haemoglobin-based oxygen carrier (HBOC), Hemapure™ or blood, using an Organ 
Assist™, Liver Assist perfusion system, prior to my involvement. Physiological oxygen and 
temperature levels were maintained throughout the perfusion. Livers were sat within the 
same perfusate of which they were perfused with and the entire liver was perfused roughly 
every 2 min. The volume of perfusate was lowered to 1.6 L to limit the mass of EIPA required 
and increase the recycling rate of the entire perfusate volume. A concentrated 500 mM 
stock of EIPA was prepared prior to perfusion to limit the volume of DMSO added to the 
perfusate. 160µl DMSO was added to the perfusate and wedge samples were taken after 5 
min as vehicle-treated controls. 160 µl, 500 mM EIPA was then added to the perfusate (final 
concentration 50 µM) and allowed to perfuse around the liver for 30 min. Further wedges 
were then sampled after this period. All wedges were stored in pre-warmed, DMEM 
throughout all incubation and transportation periods. A blunt surgical needle (14 mm) was 
then heated using a Bunsen burner and immediately bored entirely through each tissue 
wedge. The needle was left in the wedge for at least 1 min before removing it. The wedges 
were then replaced into at least 100 ml DMEM in tin foil-covered beakers and incubated 
overnight at 37°C. Wedges were then fixed in Formalin for at least 3 days and underwent 
preparations for Paraffin embedding. For this, fixed liver tissues were cut down the centre of 
the cauterisation wound and both sides were placed face down in tissue cassettes. This was 
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to ensure that both the wound aperture and the surrounding parenchyma could be seen on 
one tissue section.  
2.12 Assessment of hepatocyte multinucleation in mouse and human 
injury models 
Hepatocyte multinucleation was determined on tissues stained either by H&E or for 
hepatocyte nuclear factor 4-alpha (HNF4α) by immunohistochemistry (IHC). For mouse 
tissues, necrotic lesions were outlined and 3 concentric shapes of 2-3 hepatocytes thick were 
also drawn out. Only suitably isolated lesions were only selected, as the counts may be 
influenced by other nearby lesions. At least 3 lesions were assessed per mouse. 5 random 
fields of view (FOVs) from WT, untreated mice containing at least 100 hepatocytes were also 
analysed for controls. For human tissue with cauterisation injury, 5 FOVs were taken at 
random positions along the length of the wound at 10x magnification, using Zen software. 
The boundary between healthy and dying cell was outlined on each FOV and then areas 5 
hepatocytes thick there outlined. Both total and multinucleate hepatocytes were counted in 
outlined areas using the ‘cell counting’ plugin for ImageJ. 
2.13 Paraffin Tissue Sample Preparation 
Primary liver samples from both consented human patients and mice with APAP injury were 
used for paraffin-embedded samples. All human sections were cut from liver tissue, 
obtained from surgical procedures carried out at the Queen Elizabeth Hospital, Birmingham, 
UK. Ethical approval for the study was granted by the Local Research Ethics Committee 
(LREC) (reference number 06/Q702/61).  All tissues were fixed in 100% formalin (4% 
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formaldehyde) for at least 24 hr and placed in tissue cassettes. Tissues were then embedded 
in wax and allowed 24 hr to set. 3 µm-thick sections were then cut using a rotary microtome 
and then floated on 35°C water to remove undesired tissue folding. Tissue sections were 
then mounted onto charged glass slides. Sections were then loaded into metal racks and set 
at 60°C. These sections were then used for IHC.  
2.14 Immunohistochemistry (IHC) 
Paraffin-embedded tissue samples were initially dewaxed and rehydrated using the 
following treatment procedure:  
• 3 x 3 min incubations in xylene 
• 3 x 3 min incubations in 99% industrial denatured alcohol (IDA)  
• 2 x 3 min ddH20 in order to wash off excess alcohol and keep tissue sections 
hydrated.  
1 L, 1% tris-based (high-pH) unmasking solution (2X overall) was prepared and preheated in 
a microwave oven at max. temperature for 10 min. Rehydrated tissue sections were 
submerged in pre-warmed unmasking solution and microwaved for 30 min for antigen 
retrieval. Tissues were cooled for 10 min following microwave proteolysis. Humidified 
chambers were prepared using plastic slide boxes lined with damp paper towels. Broken, 
parallel glass stripettes were placed inside to act as slide racks. Slides were removed from 
the cooled unmasking solution and tissue samples were outlined using an ImmEDGE 
Hydrophobic Barrier PAP pen. Slides were then washed in TBST for 5 min. For chromogen-
based detection stains, tissues were then blocked for 10 min with Dako Peroxidase blocking 
solution or Vectorlabs Bloxall solution to prevent endogenous peroxidase/alkaline 
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phosphatase activity. Slides were then washed again for 5 min and blocked for a further 10 
min with 2X casein solution. All primary antibodies were diluted in TBST, pH 7.6. Working 
concentrations were optimised on a single tissue cases before batch staining of samples 
from multiple patients. After blocking, tissues were incubated with primary antibody for 1 
hr, RT. Tissues were then washed as before in TBST and then incubated with an appropriate 
secondary antigen solution as per manufacturers instructors; HRP, ALP or fluorophore 
conjugated solutions (See table 2). Tissues were then washed twice with TBST. For 
fluorescent staining, tissues were then immediately mounted using Prolong gold antifade 
mounting reagent and glass coverslips. After the mountant had solidified, tissues were then 
imaged using a Zeiss 780 or 880 confocal microscope. For chromogen-based staining, tissues 
were then incubated with an appropriate chromogen, prepared according to manufacturer’s 
instructions (e.g. IMMpact DAB). Chromogens were washed off with dH20 and then 
counterstained with filtered Mayers haematoxylin for 30-40 sec. The counterstain was 
developed with hot water for 30 sec and then tissues underwent the following dehydration 
and clearing procedure: 
• 2 x 3 min ddH20 in order to wash off excess alcohol and keep tissue sections 
hydrated.  
• 3 x 3 min incubations in 99% industrial denatured alcohol (IDA) 
• 3 x 3 min incubations in xylene 
Tissues were then mounted with DPX mountant and glass coverslips. For non-xylene tolerant 
chromogens (e.g. StayGreen), xylene substitutes were used for 2 x 3 min and tissues were 
mounted with XTF in place of DPX. Once mountants had set, slides were imaged using a Zeiss 
AxioScan Z.1 slide scanner and then analysed using Zen and ImageJ software.  
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2.15 Quantification of multinucleation in tissue samples from HCC 
patients 
Assessment of hepatocyte multinucleation was performed for tissues within a cohort of 
tissue samples from 43 consented patients with hepatocellular carcinoma (HCC) at the 
Queen Elizabeth Hospital, Birmingham, as part of the Birmingham, NHS trust. Tumour and 
normal tissues were available for 12 of these patients. Tissue sections from these patients 
were used to assess differences in multinucleation between tumour and non-tumour areas. 
Tissues were stained for hepatocyte nuclear factor 4 alpha (HNF4α) by IHC and were 
scanned using a Zeiss Axio SCAN.Z1 slide scanner. Random fields of view (FOVs) were 
captured at 20x magnification and a minimum of 1000 cells were assessed for 
multinucleation for each tissues section. The mean percentage of multinucleate cells was 
determined for each patient. Analysis and staining was performed by biomedical science 
undergraduate, Rukhsarr Ahmed.  
Out of this same cohort of patients, 16 samples presented with interface hepatitis. This 
information was received from pathology reports. Areas of interface hepatitis were 
identified in HNF4α-stained section. Areas 5-hepatocytes thick were then outlined with 
increasing distance from the margin of the inflammatory infiltrate. The percentage of 
multinucleate hepatocytes was determined for each area. This analysis was performed by 
biomedical science undergraduate, Devinderjit Sangha. 
All studies conducted using primary human liver sections were ethical approved by the Local 
Research Ethics Committee (LREC). 
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2.16 Gel electrophoresis and Western blotting 
For polyacrylamide gel electrophoresis (PAGE), cells were lysed in 1x Lamelli buffer and 
frozen for storage. Acrylamide gels were made using the following 10 ml recipe:  
Resolving (10%) Stacking (5%) 
Reagent Volume (ml) Reagent Volume (ml) 
40% acrylamide 2.43 40% acrylamide 0.61 
2% BIS-acrylamide 1.34 2% BIS-acrylamide 0.33 
1M Tris pH 8.8 3.75 1M Tris pH 8.8 0.63 
10% SDS 0.10 10% SDS 0.05 
Distilled water 2.34 Distilled water 3.35 
TEMED 0.01 TEMED 0.01 
10% w/v APS 0.03 10% w/v APS 0.03 
 
Samples were denatured at 95°C for 5 min and then loaded into the gel. Samples were resolved 
by SDS-PAGE; samples were run at a current of 40 mA and voltage of 100 V for enough time for 
samples to run through the gel (1.5 hr). Proteins were then transferred to (polyvinylidene 
difluoride) PVDF membranes using a Biorad semi-dry transfer system. A constant voltage of 25 V 
and current of 2.5 mA was used for 25 min. Membranes were then blocked in TBST containing 
5% BSA (w/v) for 30 min. Membranes were then incubated with primary antibodies within the 
same blocking buffer. Incubations were contained within a 50 ml tube and placed on tube roller 
overnight at 4°C. Membranes were then washed 3 times with TBST and incubated with HRP-
conjugated rabbit anti-mouse secondary antibody for 90 min at RT. Membranes were then 
treated with Clarity Western enhanced chemiluminescence (ECL) substrate according to 
manufacturer’s guidelines and exposed to autoradiographic film. 
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2.17 Immunofluorescence staining 
All cells were seeded on 13 mm glass cover slips for immunofluorescence staining. 
Preparation of cells was specific to individual antigens to be detected. In most cases, cells 
were labelled live with Celltracker Dyes prior to fixation. In these cases, nuclei were also 
labelled with Hoechst 33342 simultaneously with these cytoplasmic labels, at a 
concentration of 1 µg/ml. Cells were fixed prior to immunostaining in one of the following 
ways; the optimal fixation strategy was determined for each antigen/antibody, based on the 
largest and most representative signal achieved, prior to experimentation: 
• -20°C, 100% MeOH – 5 min 
• RT 3.7% formaldehyde – 10 min 
• RT 1% paraformaldehyde 
Cells were then washed in PBS and blocked for 30 min in staining buffer. Cells that were not 
fixed in MeOH, and therefore not permeabilised, were blocked in staining buffer containing 
0.1% saponin. Primary antibodies were prepared in the same staining buffer at a previously 
optimised concentration (see section 2.1/table 1). Cells were incubated with primary 
antibody for 1 hr at RT, or 24 hr at -20°C. Cells were washed again in staining buffer and then 
incubated with secondary, fluorophore-conjugated antibodies in the same buffer at the 
appropriate dilution. Cells were then washed twice in PBS and mounted on to glass 
microscope slides using Prolong gold antifade mounting reagent. Coverslips were then 
imaged using a Zeiss 780 or 880 confocal microscope. Images requiring greater resolution or 
clarity were imaged using Airyscan technology available on the Zeiss 880 and were 3D 
volume rendered using bitplane IMARIS cell biology software.  
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2.18 Quantification of SCARF2 vesicles and SCARF2 vesicle MFI 
Confocal images of Huh-7 cells, previously stained for SCARF2 by immunofluorescence, 
acquired using a Zeiss 880 confocal microscopy were uploaded into Bitplane IMARIS. The 
‘spots’ tool was then used to analyse the total and nuclear populations of SCARF2 positive 
vesicles and obtain information regarding their number and mean fluorescence intensity 
(MFI). 10 cells were analysed from images taken across three individual experiments.  
2.19 Scanning electron microscopy 
Huh-7 hepatomas were seeded at a density of 5x104 in 24-well plates on 12mm glass 
coverslips and allowed 24 hr to adhere. Huh-7s were then co-cultured with primary CD4+ T 
cells, as described in section 2.8. T cells were either live, apoptotic, or heat-killed and 
prepared as described in section 2.7. Huh-7s received 2.5x105 T cells/well. Cells were co-
cultured for 4 hr to ensure a selection of cells at different stages of internalisation at the 
point for fixation. Cells were washed with PBS to removed excess, uncaptured T cells and 
then fixed in 2.5% glutaraldehyde for 24 hr. Cells were then imaged using a JSM-7000F (JEOL) 
SEM fitted with an Oxford Instruments Inca Energy Dispersive Spectroscopy (EDS) system.  
2.20 Live, apoptotic and heat-kill cell kinetic comparison and long-
term imaging  
Huh-7 hepatomas were seeded at a density of 2.5x105 in 24-well plates and allowed 24 hr to 
adhere. Huh-7 cells and primary CD4+ T cells were labelled as described in section 2.6. All 
medias were replaced with prewarmed Iscove's Modified Dulbecco's Medium (IMDM) 
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containing ordinary media supplements (FBS, LG, NEAA, PS), as well as 25 mM (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). Spaces between wells were filled 
with 500 µl PBS as form of insulation and to maintain a humid environment throughout the 
culture period. 2.5x105 live, apoptotic or heat-killed CD4+ T cells were added on top of Huh-
7s and co-cultured under normal conditions for an initial 1.5 hr. Cells were then transferred 
to a Cell-IQ time-lapse fluorescence imager. Images were taken every 30 min for 18 hr for 5 
FOVs. For each timepoint, the number of internalised cells per 100 Huh-7 cells were 
determined by eye, which was assisted using the ‘cell counting’ plugin for ImageJ. Images 
were also combined to form movies and analysed to observe the activity of co-cultured cells 
over time.  
2.21 Treg vs. Non-Treg experiments and live confocal imaging 
For live confocal imaging of co-cultures, Huh-7 hepatomas were initially seeded at 1x105 
cells/well in glass-bottomed culture plates and allowed to adhere for 24 hr. The following 
day, CD4+ T cells were isolated from HFE patients and separated into Treg and non-Treg cells, 
as described in section 2.4. Cells were then labelled with BMQC as described in section 2.6. A 
minimum of 2.5x105 Tregs or non-Tregs were then added in wells on top of Huh-7s. Cells 
were co-cultured for 24 hr under normal culture conditions, in the presence of 10 µg/ml 
pHrodo red dextran in the media. Prior to imaging, normal culture conditions were 
established in the Zeiss 780/880 confocal microscope’s incubation chamber. Cells were also 
labelled with 5 µM Cell Mask Deep Red as per manufacturer’s instructions prior to imaging. 
Up to 5 z-stacks were taken per well at x63 magnification using the least possible digital 
zoom. The mean number of internalised, acidified T cells/ Huh-7 cell was then determined by 
eye, using the ‘cell counting’ plugin for ImageJ.   
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2.22 Statistics  
All data was statistically analysed using (GraphPad) Prism software. All in vitro phagocytosis 
and live-cell capture assays were analysed using unpaired, two-tailed Students t tests. 
Numbers were obtained from 3 experimental replicates. Assessment of experimental 
parameters associated with NMLP and animal experiments (multinucleation, p21 and Ki67 
stains, etc) were assessed using paired, two-tailed Students t tests. Standard error of the 
mean (SEM) was calculated for most experiments (unless stated otherwise) and expressed as 




Chapter 3: The mechanisms of 
hepatocyte efferocytosis 
3.1 Introduction 
As described previously, many epithelial cell types clear apoptotic and necrotic cells from the 
parenchyma (77, 80, 114). Amongst the studies concerning these non-professional 
phagocytes, historical publications describe the potential capacity for hepatocytes to engulf 
other cells (23, 147). In 1944, Rosin and Doljanski noticed the presence of erythrocytes 
within rat hepatocytes (23). Almost 50 years later, Dini and colleagues further described the 
presence of vesicles containing apoptotic cells in association with a collection of rat liver 
cells, including hepatocytes (147). This association was partially mediated through the 
asialoglycoprotein receptor 1 (ASGPR1), expressed by hepatocytes. The authors postulated 
that these vesicles contained the corpses of dying hepatocytes, which would be later 
consumed by neighbouring cells. The identity of these engulfing cells, however, remained 
elusive. Besides these studies, the primary focus of the literature for efferocytosis in the liver 
has laid with Kupffer cells (77, 212). Although the role of hepatocytes in the regulation of 
efferocytosis by Kupffer cells has been studied in depth (49), including the secretion of 
complement factors (213), their direct engagement of the process has been largely 
overlooked. As such, the molecular mechanisms, and consequences of hepatocyte 
efferocytosis are poorly understood.  
It is likely that the ability of hepatocytes to capture dead cells is regulated by cytokines. In 
most tissues, efferocytosis is an intrinsic, necessary part of immunity. Dead cells must be 
removed from the environment to prevent the activation of an immune response and to 
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maintain the steady state. As such, the capacity of efferocytes to clear dead cells is 
commonly influenced by cytokine stimulation. Apoptotic cell clearance is generally 
augmented by stimulation with anti-inflammatory cytokines such as IL-10 and TGF-β (214, 
215). Furthermore, it is frequently reported that engulfment of apoptotic cells alters the 
behaviour of efferocytosing cells, switching them more anti-inflammatory phenotypes (1, 
216). As they are integral members of liver immunity, the capacity of hepatocytes to clear 
dead cells is likely to be altered by contrasting cytokine cues. 
Another step towards understanding hepatocyte efferocytosis is to determine the receptors 
which are used by them to recognise dying cells. One possibility is ASGPR1, whose 
expression has already been reported on hepatocytes (147). ASPGR1 is a scavenger receptor 
which binds carbohydrates and has been reported to facilitate the trapping of T cells within 
the liver, which allows for their capture by Kupffer cells (147, 217). However, it’s role in 
efferocytosis conducted directly by hepatocytes has not yet been explored. Several other 
scavenger receptors have been reported to bind dead cells and assist with their 
internalisation (87, 130, 218). Many of these receptors are expressed by hepatic cells, 
although their expression is largely limited, confined to Kupffer cells and LSECs, with very 
few of them shared with hepatocytes. A member of these is scavenger receptor family F, 
member 1 (SCARF1). This receptor is mostly composed of EGF and EGF-like domains. SCARF1 
is expressed on HSEC and has also been shown to recognise apoptotic cells (130, 145). 
Although the absence of SCARF1 expression on hepatocytes was shown by Patten et al, 
2017, the same authors described, in supplementary data, that they’re able to express a 
close family member, SCARF2. Overall, the functions of SCARF2 are not fully understood, as 
previous studies regarding this scavenger receptor are limited. SCARF2 has been shown to 
scavenge acetylated low-density lipoproteins (ac-LDLs) and potentially interact directly with 
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SCARF1 (219). Additionally, mutations in scarf2 have been linked to Van Den Ende-Gupta 
syndrome, although the reason for this is unknown (220, 221). No investigations have 
suggested that SCARF2 is a scavenger of dying cells. Work from Ramirez-Ortiz and colleagues 
even suggest that SCARF2 is incapable of recognising dead cells (130). However, these 
conclusions were drawn from cytokine reporter assays and not those directly assessing 
phagocytosis of dead cells. Such findings do not dismiss the possibility that SCARF2 could 
facility efferocytosis.  
In this chapter, I will describe and discuss the investigations I undertook to understand how 
hepatocytes internalise dead cells.  
3.2 Assay development for investigating hepatocyte efferocytosis 
3.2.1 Development of apoptosis induction protocol  
Efferocytosis encompasses all processes which involve the clearance of dying cells by other. 
However, not all cells are recognised and engulfed in the same manner. As previously 
described in section 1.3.2, different receptors on phagocytes are used to recognised 
apoptotic cells than those which recognise necrotic cells (79). The downstream 
consequences of each process are also often contrasting (1, 79, 139). As such, all 
observations made for hepatocyte capture of apoptotic cells cannot be extrapolated to 
necrotic cell engulfment. Therefore, it was necessary to study efferocytosis of both apoptotic 
and necrotic cells, as it would be likely that these would be alternatively regulated 
processes. A strategy was therefore required with which to induce these states in ‘prey’ 
cells. Necrosis is generally defined by a compromised cellular membrane, which can be 
replicated by heat-treatment (222, 223). This also ensures that all cells receive the same 
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level of damage. Various treatments are available with which to induce apoptosis in target 
cells (224). However, as apoptotic cells can progress to secondary necrosis, it was necessary 
to select a treatment which limits this progression. Staurosporine (STS) has been reported to 
be such a treatment (225); although its mode of action is not thoroughly understood, STS is 
known to act as a broad kinase inhibitor which induces apoptosis, whilst also limiting the 
progression of treated cells to secondary necrosis. Furthermore, effective strategies for 
apoptosis induction using STS have been published for T cell lymphomas called Jurkat cells 
(226). As previously mentioned in section 1.1.3, lymphocytes are frequently induced to 
undergo apoptosis upon entering the liver (24). T cells therefore represent a physiologically 
relevant candidate to be used as ‘prey’ cells within these assays. With this, I aimed to verify 






Human primary CD4+ lymphocytes were treated with varying concentrations of STS for 4 hr, 
as previously described (226). The proportion of apoptotic and secondarily necrotic cells 
after treatment was then determined by labelling cells with Fluorescein isothiocyanate 
(FITC)-labelled Annexin V (AV) and 7-Aminoactinomycin D (7-AAD). AV binds to PS on the 
Figure 3A: Optimisation of Staurosporine (STS) treatment of primary CD4+ T cells for 
apoptosis induction. Primary human CD4+ T cells were treated with varying concentrations of 
Staurosporine (STS) for 4 hr. Cells were then labelled using the Biolegend apoptosis detection 
kit; Annexin V-Fluorescein isothiocyanate (FITC) and 7-Aminoactinomycin D (7-AAD). Cells 
were the analysed by flow cytometry using a Beckman Coulter Cyan ADP9 flow cytometer. 
Single positive cells for Annexin V represent apoptotic cells. Double positive cells represent 
secondary necrotic cells. N=1.  
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outer leaf of cell membranes, which is indicative of apoptotic cells. 7AAD is cell-impermeable 
and only labels necrotic cells which have a compromised membrane. It is thus possible to 
identify the stages of cell death amongst a population of cells by combining these two stains. 
All treatments induced comparable levels of apoptotic and secondary-necrotic cells. As such, 
the smallest concentration used, 1 µM, was selected for the induction of apoptosis in later 
experiments.  
3.2.2 Selection of hepatocyte cell line for efferocytosis assays 
To study the mechanisms and outcomes of hepatocyte efferocytosis, it was necessary to first 
select an in vitro assay for both quantification and molecular probing of efferocytosis. To 
select the most appropriate cell to use for future experiments, I observed the ability of 3 
commonly-used hepatic cell lines to engulf dead cells; Huh-7s, HepG2s and Hep3Bs (227-
229) . These were then co-cultured with apoptotic or heat-killed primary human T cells. All 
cell lines were cultured in multi-welled plates and were fluorescently labelled. Cells were 
then imaged using confocal microscopy (Fig. 3B). Complete internalisation of cells was 
confirmed through acquisition of confocal Z-stacks. All cell lines were capable of 
efferocytosis, which further establishes the ubiquitous nature of this phenomenon for 
hepatocytes. Huh-7s and Hep3Bs formed monolayers in culture, which assisted with 
confirming complete internalisation of dead cells. Reports have shown that Hep3Bs divide 
less frequently in culture due to reduced cyclin D1 expression and possess very few response 
pathways for common signalling pathways (230, 231), partially due to overactive NFκB 
activity and downregulated TGFβ-R (232). As such, Huh-7 cells were selected for in vitro 








Figure 3B: Capture of apoptotic and heat-killed cells was conserved in three hepatocyte cancer 
cell lines. Orthographical images of hepatoma cell lines containing apoptotic or heat-killed CD4+ T 
cells. Huh-7, HepG2 and Hep3B hepatomas were seeded in 24-well plates on glass coverslips and 
fluorescently labelled with Cell Tracker Green (CTG)/ Chloromethylfluorescein diacetate (CMFDA). 
Hepatomas were then co-cultured with primary CD4+ T cells, labelled with Cell Tracker Red 
(CTR)/CMTPX, which were either apoptotic via staurosporine (STS) treatment or heat-killed 
(necrotic), for 3 hr. Cells were then fixed with MeOH and then imaged by confocal microscopy using 
a Zeiss LSM Zeiss 880. Z-stacks were acquired to confirm complete internalisation of T cells. Scale 
bars represent 10 µm. 
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3.3 The mechanisms of efferocytosis by hepatocytes 
3.3.1 Hepatocyte efferocytosis was modulated by cytokines 
To investigate the effect of cytokines on hepatocyte efferocytosis, Huh-7 cells were pre-
treated for 1 hr with cytokines known to be relevant in the establishment and resolution of 
liver inflammation. These cells were then co-cultured with apoptotic or heat-killed (necrotic) 
cells (Fig. 3C). Cells were also treated with insulin-like growth factor-1 (IGF-1) which, when 
secreted by actively efferocytosing macrophages, was reported to reduce the capacity of 
neighbouring airway epithelial cells to engulf apoptotic cells (118). Huh-7s were initially 
serum starved to reverse effects induced by FBS-derived cytokines. Cells were then imaged 
using confocal microscopy and the frequency of efferosomes found within hepatomas was 
quantified. Apoptotic cell capture was significantly increased by TGF-β treatment and 
decreased by the pro-inflammatory cytokine, IL-1β. However, contrary to this, IL-10 also 
caused a decrease in apoptotic cell capture. Other cytokines did not alter apoptotic cell 
capture.  Heat-killed cell capture was augmented by cytokines with contrasting 
immunological functions. The pro-inflammatory cytokine, interferon-gamma (IFN-γ) 
increased the capture of heat-killed cells by 50%. Similar increases were not seen in 
response to cytokines with related functions, like tumour necrosis factor-alpha (TNF-α) and 
IL-1β. Contradictory to this, heat-killed cell capture was also augmented by anti-
inflammatory cytokines IL-10 and TGF-β, although not to the same degree as IFN-γ-treated 
Huh-7s. IGF-1 treatment had no effect of hepatocyte efferocytosis. Together, these data 
suggest show that apoptotic cell capture was altered by alternative cytokines compared to 
necrotic cell capture, the exception being TGF-β, which augmented both apoptotic and 






3.3.2 Hepatocyte efferocytosis was reduced by molecular inhibitors of actin 
polymerisation and macropinocytosis 
The molecular mechanisms regarding the cytoskeletal rearrangements associated with 
efferocytosis have been well characterised for professional phagocytes (233). Such details 
are not known for efferocytosis conducted by hepatocytes. To gain an initial understanding 
as to how hepatocytes perform efferocytosis, Huh-7 hepatoma cells were treated with 
commonly-used inhibitors of similar forms of endocytosis (Fig. 3D). These included verified 
inhibitors of macropinocytosis (234, 235), blebbistatin (234, 236, 237) and 5-(N-Ethyl-N-
Isopropyl) amiloride (EIPA) (234, 236, 238, 239). Huh-7 cells were also treated with the 
Phosphoinositide 3-kinase (PI3K) inhibitor, Wortmannin, as well as an inhibitor of Rho-
associated protein kinase (ROCK), H-1152, which have both been reported to inhibit Fc-
receptor (FcR) mediated phagocytosis by preventing phagosome sealing in macrophages 
(240, 241). These inhibitors were only given to Huh-7s receiving heat-killed cells, as 
apoptotic cells are not normally detected using FcRs (see section 1.3). Cytochalasin D was 
used as a positive control as it is a known global inhibitor of de novo actin polymerisation 
Figure 3C: Capture of apoptotic and heat-killed CD4+ T cells by hepatomas was modulated by 
cytokines. Huh-7 hepatomas seeded in 24-well plates on glass coverslips were fluorescently 
labelled with Cell Tracker Green (CTG)(CMFDA. Huh-7s were then serum starved and treated with 
100 ng/ml cytokines for 1 hr. Huh-7s were then co-cultured with Celltracker Red (CTR)/CMTPX-
labelled primary human CD4+ T cells. T cells were either made apoptotic, via staurosporine (STS) 
treatment, or were heat-killed (necrotic) prior to co-culture. Cells were cultured in the presence of 
cytokines, for 3 hr, fixed with MeOH, and then imaged by confocal microscopy using a Zeiss LSM 
880 microscope. (i) Confocal micrographs of untreated and IFN-γ-treated Huh-7s conducting 
efferocytosis. (ii) Quantification of the number of phagosomes per 100 Huh-7 cells for each 
cytokine treatment. Numbers were obtained using 5 fields of view (FOV), taken from three 
independent experiments (N=3). Statistics were derived from a two-tailed, unpaired Student’s t-
test when comparing other treatments to the control. * - ≤0.05, *** - p≤0.001, **** - p≤0.0001. 
Scale bars represent 50 µm. Error bars represent the standard error of the mean (SEM). IFN-γ – 
interferon-gamma; IL – interleukin; TGF-β – tumour growth factor-beta. Data set was partially 
acquired from work conducted by intercalating medical student, Nick Weight, and Nuffield 




and cytoskeletal movement (242). As expected, capture of apoptotic and heat-killed cells 
was significantly reduced in response to cytochalasin D treatment (Fig. 3Dii). Wortmannin 
and H-1152 induced no significant alteration to heat-killed cell efferocytosis. In contrast, 
macropinocytosis inhibitors caused significant reductions to both heat-killed and apoptotic 
cell capture by Huh-7s. EIPA was particularly effective in blocking heat-killed cell capture, 
ablating efferocytosis more efficiently that cytochalasin D treatment. Together, these data 







3.4 Recognition of dead cells by hepatocytes 
3.4.1 Screening of possible receptors for dead cells 
The number of candidate receptors which may be responsible for recognition of dead cells 
by hepatocytes is limited. Several receptors with varying primary functions can often 
recognise dead cells as a secondary function (87). These include adhesion molecules, which 
are normally concerned with leukocyte recruitment, as well as scavenger receptors that 
often bind dead cells via PS opsonising molecules (243). I hypothesised that molecules within 
these categories that are expressed by hepatocytes could play roles in efferocytosis. To test 
this, immunofluorescence staining of efferocytosing Huh-7 cells was performed for adhesion 
molecules or scavenger receptors whose expression had previously been reported for 
hepatocytes (Fig. 3E-F). These included ICAM-1 (28, 244, 245) and ASGPR1 (147, 217). Cells 
were fixed with the permeabilising fixative, MeOH, and imaged by confocal microscopy, 
using Z-stacks to confirm complete internalisation of dead cell. Images were also 3D volume 
rendered to show to distribution of the molecule that was stained for, in relation to 
internalised cells. ICAM-1 staining was enriched around the base of adhered apoptotic cells 
Figure 3D: Capture of apoptotic and heat-killed CD4+ T cells by hepatomas was modulated 
molecular inhibitors. Huh-7 hepatomas seeded in 24-well plates on glass coverslips were 
fluorescently labelled with Cell Tracker Green (CTG)/ CMFDA. Huh-7s were then serum starved 
and treated with molecular inhibitors, at concentrations indicated, for 1 hr. Huh-7s were then co-
cultured with Celltracker Red (CTR)/CMTPX-labelled primary human CD4+ T cells. T cells were 
either made apoptotic, via staurosporine (STS) treatment, or were heat-killed (necrotic) prior to 
co-culture. Cells were cultured in the presence of cytokines, for 3 hr, fixed with MeOH, and then 
imaged by confocal microscopy using a Zeiss LSM 880 microscope. (i) Confocal micrographs of 
untreated and cytochalasin D-treated Huh-7s conducting efferocytosis. (ii) Quantification of the 
number of phagosomes per 100 Huh-7 cells for each cytokine treatment. Numbers were obtained 
using 5 fields of view (FOV), taken from three independent experiments (N=3). Statistics were 
derived from a two-tailed, unpaired Student’s t-test when comparing other treatments to the 
control. * - ≤0.05, *** - p≤0.001, **** - p≤0.0001 i) confocal micrographs of untreated and IFN-γ-
treated Huh-7s undergoing efferocytosis. Scale bars represent 50 µm. Error bars represent the 




forming a cup-like structure (Fig. 3Eiii). However, vesicles containing fully internalised 
apoptotic cells were not enriched for ICAM-1 (Fig. 3Ei-iii). Necrotic cells showed no 
enrichment with ICAM-1(Fig. 3Eiv-vi). Similar localisation observed for ICAM-1 was also 
observed for ASGPR1 in relation to captured heat-killed cells (Fig. 3F). Partially engulfed 
heat-killed Jurkat cells possessed halos/cup-like structures which stained positively for 
ASGPR1. This highlights a potential role of ICAM-1 and ASPGR1 in the initial adhesion step of 













Figure 3E: Apoptotic and heat-killed CD4+ T cells captured by Huh-7 hepatomas did not 
associate with ICAM-1. Huh-7 hepatomas seeded in 24-well plates on glass coverslips were 
fluorescently labelled with Cell Tracker Green (CTG)/CMFDA. Huh-7s were then co-cultured with 
primary human CD4+ T cells, labelled with Cell Tracker Violet (CTV)/ bromomethyl derivative of 
coumarin (BMQC). T cells were either apoptotic (i-iii) via staurosporine (STS) treatment, or heat-
killed (necrotic) (iv-vi). Cells were co-cultured for 3 hr, fixed with MeOH and stained for 
intercellular adhesion molecule 1 (ICAM-1) via immunofluorescence (shown in red). Cells were 
then imaged by confocal microscopy using a Zeiss LSM 880 microscope. Z-stacks were acquired to 
confirm complete internalisation of T cells. (i+iv) Confocal micrographs of Huh-7 hepatomas 
(green) efferocytosing dead T cells (blue). Orthographical image (right) shows complete 
internalisation of cells. White arrows show fully internalised cells. Yellow arrows show adhered 
cells. (ii+v) 3D renderings, generated with Bitplane IMARIS, of selected regions shown in previous 
images (indicated by pink box in i/iv). (iii+vi) Cross-section of 3D-rendered image made using a 
plane which cuts through internalised T cells, indicated by yellow box in middle panels. Images 
are representative of 3 independent experiments. All scale bars represent 10 µm. Stains using 







Figure 3F: – Adhered heat-killed CD4+ T cells associated with ASGPR1 on Huh-7 hepatomas. Huh-7 
hepatomas seeded in 24-well plates on glass coverslips were fluorescently labelled with Cell 
Tracker Green (CTG)/ Chloromethylfluorescein diacetate (CMFDA). Huh-7s were then co-cultured 
with heat-killed (necrotic) Jurkat T cell lymphomas, labelled with Cell Tracker Violet (CTV)/ 
bromomethyl derivative of coumarin (BMQC). Cells were co-cultured for 3 hr, fixed with MeOH and 
stained for asialoglycoprotein receptor 1 (ASGPR1) via immunofluorescence (shown in red). Cells 
were then imaged by confocal microscopy using a Zeiss LSM 880 microscope. Z-stacks were 
acquired to confirm complete internalisation of T cells. (i) Confocal micrographs of Huh-7 
hepatomas (green) efferocytosing dead T cells (blue), stained using anti- ASGPR1 antibody or a 
Rabbit IgG isotype-matched control (IMC). (ii+v) 3D renderings, generated with Bitplane IMARIS, of 
selected regions shown in previous images (indicated by pink box in i/iv). (iii+vi) Cross-section of 
3D-rendered image made using a plane which cuts through internalised T cells, indicated by yellow 
box in middle panels. Images are representative of 3 independent experiments. All scale bars 
represent 10 µm. Non-rendered images were contributed by intercalated medical student, Ratnam 
Gandhi.  
 
i) Adhered dead cells associated with α-sialoglycoprotein receptor 1 (ASGPR1). Huh-7 hepatomas 
were seeded in 24-well plates on glass coverslips and labelled with Cell Tracker Green (CTG). Huh-
7s were then co-cultured with heat-killed Jurkat T cell lymphomas, labelled with Cell Tracker Violet 
(CTV), 3 hr. Cells were then fixed with MeOH and stained ASGPR1. Cells were then imaged by 
confocal microscopy, in which Z-stacks were acquired. Orthographical image (right) shows 
complete internalisation of cells. White arrows show fully internalised cells. Yellow arrows show 
adhered cells. ii) Hepatocytes do not express lectin-type oxidized LDL receptor 1 (LOX1). Donor liver 
tissue was stained by immunohistochemistry for LOX1 or an isotype-matched control (IMC)   Scale 




3.4.2 Scavenger receptor family F, member 2 (SCARF2) associates with engulfed dead 
cells in hepatocytes 
Previous reports have suggested that hepatocytes express the scavenger receptor, SCARF2 
(145). Details in this report regarding its distribution were limited. Additionally, the function 
of SCARF2 in hepatocytes has never been investigated. As such, I set out to examine the 
localisation of SCARF2 on hepatocytes and hepatomas alike. Immunohistochemistry staining 
of donor liver tissue revealed consistent expression of SCARF2 across hepatocytes (Fig. 3G). 
Its expression was often enriched at junctions between hepatocytes. Furthermore, several 
hepatocytes possessed large SCARF2-positive intracellular structures adjacent to their 




Figure 3G: Hepatocytes expressed SCARF2 in vivo in donor liver tissue. Immunohistochemistry 
(IHC) staining of paraffin-embedded donor liver tissue scavenger receptor family f, member 2 
(SCARF2), shown in in brown. Tissues were also stained using a Rabbit IgG, isotype-matched 
control (IMC). Tissues were counterstained with Mayers haematoxylin nuclear stain (blue). Black 
arrows indicate SCARF2-positive structures within hepatocytes that also possess SCARF2-negative 




Figure 3H: Huh-7 hepatomas expressed SCARF2 in vesicles within the nucleus and perinuclear 
spaces. Huh-7 hepatomas seeded in 24-well plates on glass coverslips were fluorescently labelled 
with Cell Tracker Green (CTG)/ CMDFAand Hoechst 33342 (blue). Cells were then fixed with 
MeOH and stained for scavenger receptor family f, member 2 (SCARF2) or a Rabbit IgG isotype-
matched control (IMC) via immunofluorescence (shown in red). Cells were then imaged by 
confocal microscopy using a Zeiss LSM 880 microscope. Scale bars represent 10 µm.    
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To confirm whether the expression and distribution of SCARF2 was conserved in hepatocyte 
cell lines, immunofluorescence staining was performed of labelled Huh-7 hepatomas (Fig. 
3H). Positive staining was seen mostly in the nucleus and perinuclear compartments. 
Vesicular-like staining was also seen in cytoplasmic spaces. The vesicles ranged from 0.2-1.3 
µm2 in area, which was consistent both within and outside of the nucleus. I next stained 
Huh-7 hepatomas which had been previously co-cultured with heat-killed or apoptotic 
primary T cells, which had been fluorescently labelled (Fig. 3I). These cells were then imaged 
by confocal microscopy, whilst acquiring Z-stacks. It was frequently observed that SCARF2 
expression was enriched at areas surrounding both internalised heat-killed and apoptotic 
cells (Fig. 3Ii). 3D volume rendering of immunofluorescence stains further revealed that 
internalised apoptotic and necrotic CD4+ T cells within hepatomas were fully enclosed in 
SCARF2-positive vesicles (Fig. 3Ii). Non-internalised T cells were not positively stained for 
SCARF2. Aggregation of SCARF2 around the phagosome was also seen in apoptotic cells 
adhered to HepG2 cells (Fig. 3Iii), which shows the conservation of this interaction across 
different hepatocyte cell lines. Together, these observations suggest that SCARF2 may play a 








Figure 3I: Phagosomes containing apoptotic or heat-killed CD4+ T cells associated with 
SCARF2 in Huh-7 and HepG2 cells. Huh-7 (i) or HepG2 cells (ii) seeded in 24-well plates on glass 
coverslips were fluorescently labelled with Cell Tracker Green (CTG)/ Chloromethylfluorescein 
diacetate (CMFDA). Huh-7s were then co-cultured with primary human CD4+ T cells, labelled 
with Cell Tracker Violet (CTV)/ bromomethyl derivative of coumarin (BMQC). T cells were either 
apoptotic via staurosporine (STS) treatment, or heat-killed (necrotic). Cells were co-cultured for 
3 hr. Cells were then fixed with MeOH and stained for scavenger receptor family f, member 2 
(SCARF2) via immunofluorescence (shown in red). Cells were then imaged by confocal 
microscopy using a Zeiss LSM 880, in which Z-stacks were acquired. Images were also 3D 
volume rendered using Bitplane IMARIS software. (i) Top: orthographical image showing 
SCARF2-stained Huh-7 cells (green) possessing fully internalised apoptotic or heat-killed T cells 
(blue). Bottom: cross-sections made using a plane which cuts through the internalised T cell, 
indicated by yellow line on top panels. (ii) Orthographical and 3D-rendered images of SCARF2-
stained HepG2 cells cultured with apoptotic T cells. Images are representative of 3 
independent experiments. All scale bars represent 10 µm. 
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3.4.3 The cellular distribution of SCARF2 was altered in hepatomas in response to 
cytokine stimulation  
Immunofluorescence staining of actively efferocytosing hepatomas revealed that SCARF2 
relocates to the perimeter of efferosomes. This suggests an active role for SCARF2 in 
hepatocyte efferocytosis. To investigate the regulation of this vesicular relocation, 
immunofluorescence staining was performed of Huh-7 cells following a 1 hr treatment with 
cytokines that were used in previous sections to study their effect on the frequency of 
efferocytosis (Fig. 3J). Huh-7s were also treated with EIPA, as this was previously shown to 
significantly inhibit efferocytosis in hepatomas. Cells were stained for SCARF2 and imaged 
using confocal microscopy. The proportion of SCARF2-positive vesicles found in cytoplasmic 
regions appeared to increase in response to treatments, aside from TNF-α. To confirm this, 
the distribution of SCARF2-positive vesicles was then analysed using Bitplane IMARIS 
software (Fig. 3Jii). The percentage of non-nuclear SCARF2 vesicles was significantly 
increased by IFN-γ and IL-10 treatments. The latter cells also displayed increased expression 
of SCARF2 at the perimeter of their membranes. These results showed that SCARF2 
localisation could be influenced by certain cytokines expression and can be altered through 
cytokine stimulation. 
To determine if this shift in the distribution of SCARF2 vesicles was concurrent with an 
alteration in expression, the mean fluorescent intensities (MFI) of vesicles within previously-
treated Huh-7 cells were acquired using Bitplane IMARIS software (Fig. 3K). These values 
were used to approximate SCARF2 expression. Highly significant increases in SCARF2 vesicles 
MFIs were observed in EIPA-treated cells (Fig. 3Ki). A more modest increase was also 
induced in response to IFN-γ. Other treatments did not affect SCARF2 vesicle MFI. Further, 







Figure 3J: The distribution of SCARF2-positive vesicles in hepatomas was altered in response to 
cytokine treatment. Huh-7 hepatomas seeded in 24-well plates on glass coverslips were 
fluorescently labelled with Cell Tracker Green (CTG)/ CMDFA and Hoechst 33342 (blue). Huh-7s 
were then serum starved and treated with 100 ng/ml cytokines or 5-(N-Ethyl-N-Isopropyl) 
amiloride (EIPA) for 1 hr. Cells were then fixed with MeOH and stained for scavenger receptor 
family f, member 2 (SCARF2) via immunofluorescence (shown in red). Cells were then imaged by 
confocal microscopy. (i) Confocal micrographs of labelled Huh-7 cells (green), stained for SCARF2 
(red) following cytokine/EIPA treatments. Scale bars represent 10 µm. Images are representative 
of 3 independent experiments. (ii) Percentage of SCARF2-positive vesicles found within the 
nucleus (grey bar) or outside of it (white bar) in cytokine-treated hepatomas. Numbers were 
obtained from 10 cells imaged across 3 independent experiments (N=3), using Bitplane IMARIS for 
cell biologists software. Statistics were derived from a two-tailed, unpaired Student’s t-test when 
comparing cytoplasmic values of treatments to the control. Data points represent mean value 
obtained for individual cells. Error bars represent the SEM. * - ≤0.05, ** - p≤0.01. TNF-α – Tumour 










Figure 3K: Effect of cytokine stimulation of hepatomas on mean fluorescent intensity (MFI) of 
SCARF2-postive vesicles. Huh-7 hepatomas seeded in 24-well plates on glass coverslips were 
fluorescently labelled with Cell Tracker Green (CTG)/ CMDFA and Hoechst 33342 (as shown in Fig. 
3J). Huh-7s were then serum starved and treated with 100 ng/ml cytokines or 5-(N-Ethyl-N-
Isopropyl) amiloride (EIPA) for 1 hr. Cells were then fixed with MeOH and stained for scavenger 
receptor family f, member 2 (SCARF2) via immunofluorescence. Cells were then imaged by 
confocal microscopy. The mean fluorescent intensity (MFI) of SCARF2-positive vesicles found 
within each cell were then obtained from images using Bitplane IMARIS software. Numbers were 
obtained from 10 cells imaged across 3 independent experiments. (i) MFI values for the total 
population of SCARF2 vesicles. (ii) MFI ratio of cytoplasmic vesicles to nuclear vesicles. Statistics 
were derived from a two-tailed, unpaired Student’s t-test when comparing other treatments to 
the control. * - ≤0.05, **** - p≤0.0001. Data points represent mean value obtained for individual 
cells. Middle line represents mean and error bars represent the SEM. TNF-α – Tumour necrosis 





3.4.4 The distribution of SCARF2 is altered under inflammatory conditions in vivo 
Cells do not necessarily attain the same polarity in 2D cultures that they would in the setting 
of a tissue. As such, the expression and distribution of SCARF2 may differ in vivo to what was 
seen in cell lines. Further, its activity may be altered under inflammatory conditions 
associated with disease that are difficult to simulate in vitro. To investigate whether the 
behaviour of SCARF2 in the liver is comparable to observations made in vitro, IHC staining 
was performed on tissues from patients with a variety of liver diseases (Fig. 3L). Tissues from 
donor livers which were rejected for transplantation were used as ‘normal’ (fatty) controls. 
In these livers, SCARF2 was largely located at nuclear membranes as previously seen in IF 
stains of cell lines. This provides some validation for the antibody used to accurately 
represent SCARF2, as well as for Huh-7 cells to authentically represent its activity. Again, 
large, round structures with positive staining were frequently observed within hepatocytes. 
In contrast, nuclear expression of SCARF2 was reduced in hepatocytes within diseased livers. 
Furthermore, hepatocyte cytoplasm was largely occupied with irregularly sized intracellular 
vesicles with strong positive staining. Taken together, it appears that SCARF2 expression and 






Figure 3L: The distribution of SCARF2 was altered under inflammatory conditions in vivo. 
Immunohistochemistry (IHC) staining of explanted liver tissue from patients with different 
chronic disease for Scavenger receptor family F, member 2 (SCARF2 - brown). Tissues were 
counterstained with Mayers haematoxylin nuclear stain (blue). Inset boxes highlight positive 
structures within hepatocytes which are likely to represent efferosomes. Red scale cars 
represent 100 µm. Black scale bars represent 10 µm. AIH – Autoimmune hepatitis; PBC – 
primary biliary cholangitis; PSC – primary sclerosing cholangitis; ALD – Alcoholic liver disease; 
NASH – Non-alcoholic steatohepatitis; HBV – hepatitis B virus; HCV – hepatitis C virus. Images 






1. Hepatocytes and hepatocyte tumour cell lines are adept at the engulfment of 
apoptotic and heat-killed cells.  
2. Necrotic cell capture by hepatocytes was augmented by both pro-inflammatory 
cytokine, IFN-γ and anti-inflammatory cytokines, TGF-β and IL-10.  
3. Apoptotic cell capture was augmented by TGF-β, as described for other efferocytes, 
but was reduced by IL-10. 
4. Hepatocyte efferocytosis was susceptible to inhibitors of macropinocytosis, 
blebbistatin and EIPA, and actin-remodelling inhibitor, cytochalasin D. 
5. Sites of adhered dead cells were enriched with ICAM-1 and ASGPR1. This association 
was lost upon complete internalisation.   
6. SCARF2 associated with vesicles containing apoptotic and heat-killed cells in 
hepatomas and hepatocellular carcinoma cells in vitro and hepatocytes in vivo.  
7. The distribution of SCARF2-positive vesicles significantly shifted to the cytoplasm in 
hepatomas following stimulation with IL-10 and IFN-γ in vitro and in hepatocytes in 
chronically diseased livers in vivo.  




3.6.1 Hepatocytes as non-professional phagocytes  
3.6.1.1 Hepatomas as in vitro models of hepatocyte efferocytosis 
Hepatocyte efferocytosis was originally described in 1944, where their capacity to engulf 
erythrocytes was described (23). Since then, this novel ability of hepatocytes has been 
largely ignored. The work described here begins to decipher some of the regulatory and 




mechanistic attributes of this process. This was initially achieved using an in vitro model of 
hepatocyte efferocytosis. Combining the in vitro culture of these cells with fluorescent-
labelling, together with confocal microscopy, allowed for the complete internalisation of 
apoptotic or dying cells to be confirmed following the acquisition of Z-stacks. Similar 
techniques have been used to monitor and enumerate efferocytosis in other non-
professional phagocytes (97). Other groups have supplemented these analyses with reporter 
assays which measure the downstream genetic alterations in the predatory phagocyte (130). 
However, this was not possible for hepatomas as these details regarding the downstream 
consequences of efferocytosis were lacking.  
Using this system, it was confirmed that the capacity for efferocytosis was conserved within 
3 different hepatocyte cancer cell lines (Fig. 3B). This would suggest that efferocytosis is still 
a necessary part of the hepatocyte biology, even upon oncogenic transformation and 
isolation from the setting of a complete liver. Furthermore, this model allowed for the 
enumeration of efferocytosis in response cytokine and molecular inhibitors. The validity of 
such findings may be limited by how representative Huh-7 cells are of PHH activity. Huh-7 
cells were selected for the studies presented here, as efferosomes were easily identified in 
the monolayers that they form, following immunofluorescence labelling. However, as with 
other dedifferentiated hepatomas, they lack certain responses to cytokines and growth 
factors (30). Despite this, their capacity for efferocytosis and their expression of SCARF2 was 
notably altered by cytokines in experiments described this chapter. As the latter was also 
confirmed for hepatocytes in diseased human tissues, Huh-7 cells appear to accurately 
represent hepatocytes in the context of efferocytosis.  
There are consistent limitations in the conclusions drawn from 2D in vitro culture systems. 
These predominantly arise from differences in polarity and stiffness between these cells 
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cultured on plastic and those found in tissues. They also eliminate the effects exerted by 
other cells found in tissues, as well as the influences of extracellular matrices (246). As such, 
the molecular activity, as well as the distribution and surface availability of receptors of 
hepatocytes in vivo may differ from these aspects in 2D-cultured cells. This is evident from 
the inability to grow PHHs in vitro and their loss of polarisation following their isolation from 
the liver (69). For these reasons, the capacity for efferocytosis by hepatomas may be 
misrepresented in 2D cultures. 3D in vitro culture models may represent a more 
representative method for culturing hepatocytes and their related cell lines. PHHs grow in 
3D cultures were reported to retain APAP-sensitivity that was lost in 2D cultures (247). 
Notably, Huh-7 cells grown in 3D cultures were shown to obtain a more differentiated 
phenotype and were more permissive to HCV infection (248). As the latter characteristic is 
likely related to availability of HCV entry receptors, including scavenger receptor class B type 
1, Huh-7 cells grown in 3D cultures may also provide more accurate model in studying 
efferocytosis.  
3.6.1.2 Heat-killing as method for creating necrotic cells 
Throughout these experiments, heat-killed cells were used as a representation of necrotic 
cells. Although this is accepted as general method for inducing necrosis in cells (223), results 
obtained whilst using them are not always consistent with those acquired when using 
necrotic cells formed using an alternative method. Hirt and Leist showed that secondary 
necrotic (ATP-depleted) cells induced anti-inflammatory responses in macrophages when 
engulfed (99). This was not recapitulated in macrophages that engulfed heat-killed cells. This 
discrepancy is possibly due to the differences in molecules released from heat-killed cells 
following heat-treatment, compared with alternatively-induced necrotic cells. Levels of heat-
shock protein 72 (HSP-72) have been shown to increase in heat-treated cells (56). Of note, 
HSP-72 has been reported to induce pro-inflammatory phenotypes in hepatocytes (56). 
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Furthermore, heat treatment is likely to denature certain ligands of dead cell-receptors on 
their surfaces which might be preserved in necrotic cells produce by alternative means. 
Overall, observations made using heat-killed cells to assess necrotic cell capture require 
confirmation using different methods for inducing necrosis, such as ATP depletion and H202 
treatment (249). 
3.6.1.3 The mechanisms and regulation of hepatocyte efferocytosis; differences between 
apoptotic and necrotic cell capture 
Different cytokine treatments elicited varied effects on apoptotic and heat-killed cell capture 
by hepatomas (Fig. 3C). These results provided potential similarities and differences to 
efferocytosis conducted by other cells. In general, efferocytosis of apoptotic cells is inhibited 
by pro-inflammatory stimulation and promoted by anti-inflammatory stimulation (1, 127, 
139). The opposite is normally true for the uptake of necrotic cells (95). In hepatomas, anti-
inflammatory cytokine, TGF-β increased apoptotic cell capture. Additionally, pro-
inflammatory cytokines, IFN-γ and IL-1β promoted the capture of heat-killed necrotic cells. 
These observations were consistent with how efferocytosis is regulated in both professional 
and non-professional phagocytes (79). In contrast to these findings, TGF-β and IL-10, another 
anti-inflammatory cytokine that has been reported to promote apoptotic cell capture in 
macrophages (214), also augmented heat-killed cell capture by Huh-7 cells. Surprisingly, IL-
10 significantly reduced apoptotic cell capture in hepatomas. The mechanisms for these 
differences are unclear. Overall, the results displayed here suggest that hepatocyte capture 
of apoptotic cells is alternatively regulated to their capture of necrotic cells, which is akin to 
the behaviour other efferocytes. However, they also suggest that hepatocyte efferocytosis 
bears some situational and regulatory differences to other efferocytes. This is likely due to 
adaptations to the immunotolerant environment of the liver. As such, responses to both 
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pro- and anti-inflammatory stimuli may be skewed towards the clearance of dying cells in 
the liver and promoting resolution. Further elucidation into hepatocyte inflammasome 
beyond the scope of this project may be required in future to explain the effects of cytokines 
on hepatocyte efferocytosis.  
Although the effects of cytokines were varied between apoptotic and heat-killed cell 
capture, the effects of molecular inhibitors were comparable for both processes (Fig. 3D). 
Inhibition of these processes by cytochalasin D was expected as de novo actin polymerisation 
is necessary for all forms of endocytosis (250). Of interest, both processes were susceptible 
to blebbistatin and EIPA. Both molecules inhibit macropinocytosis, albeit through different 
mechanisms. This would suggest that hepatocyte efferocytosis is mechanistically similar to 
macropinocytosis. Taken together, these data suggest apoptotic and necrotic cell capture by 
hepatocytes may be regulated through distinct mechanisms, but their effects may converge 
to regulate similar intracellular contractile machinery.  
3.6.1.4 How do hepatocytes recognise and internalise dying cells? 
Immunofluorescence staining of efferocytosing Huh-7 cells combined with 3D volume 
rendering allowed for visualising the distribution of candidate dead cell-receptors in relation 
to fully and partially internalised cell corpses. These combined technologies revealed 
possible roles for ICAM-1 and ASGPR1 in hepatocyte efferocytosis. ICAM-1 associated with 
apoptotic cells that were adhered to the surface of hepatomas (Fig. 3Ei-iii). This association 
was lost on vesicles containing fully internalised apoptotic cells. Heat-killed cells did not 
associate with ICAM-1 during any stage of their capture by hepatomas. The denaturation of 
its ligands, like CD11a, by heat treatment may have contributed to this. Such ligands are 
more likely to be retained on early apoptotic cells. As such, ICAM-1 may provide similar 
assistance to efferocytosis as they do for lymphocyte recruitment (251), by binding apoptotic 
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cells to allow for other receptors to interact with their ligands, initiating internalisation of 
the dying cells. In contrast to this, ICAM-1 expression was shown to be inversely proportional 
to efferocytosis by M2 macrophages (252). This presents another difference between 
efferocytosis by hepatocytes and professional phagocytes. However, immunofluorescence 
staining does not distinguish the ownership of the specific antigen that has been probed. 
ICAM-1 expression has also been reported for CD4+ T cells that were used in these assays 
(253). Furthermore, this association may only be present with apoptotic cells that previously 
expressed ICAM-1 ligands. Overall, it is uncertain as to whether ICAM-1 is necessary for the 
hepatocyte efferocytosis.  
ASGPR1 was shown to associate with partially engulfed necrotic cells (Fig 3F). This 
carbohydrate scavenger receptor was already reported to be expressed by hepatocytes and 
to bind apoptotic T cells in the liver (147). The data shown in this chapter mark the first 
report of its capacity to bind necrotic cells. As with ICAM-1 however, not all adhered necrotic 
cells were enriched for ASGPR1. As such, ASGPR1 may facilitate efferocytosis but not be 
required. It is likely that the molecules investigated in this chapter do not act in isolation; 
there are likely other receptors that facilitate hepatocyte efferocytosis that were not 
investigated in this project, as well as redundancy in between them; macrophages express 
multiple receptors which recognise dying cells (87, 254). Treating actively efferocytosing 
hepatomas with functionally blocking antibodies to these molecules or performing siRNA-
mediated knockdowns would be needed to determine their specific functions and necessity 
for hepatocyte efferocytosis. 
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3.6.2 An important new role for SCARF2 in the liver? 
3.6.2.1 Evidence supporting SCARF2 as a hepatocyte dead cell receptor  
Although the molecular mechanism of hepatocyte efferocytosis still remains uncertain, these 
investigations have unearthed a potential novel role for SCARF2 in this process. Little is 
known regarding the functions of this scavenger receptor. Mutations in its gene have been 
attributed to the development of the rare autosomal-recessive development disorder called 
Van Den Ende-Gupta syndrome (220, 221). The contribution of mutated SCARF2 to the 
pathogenesis of this disease is still unknown. Interest in the activity of SCARF2 has largely 
stayed in relation to this disorder, or in comparison with SCARF1 activity (145). With regards 
to the latter, one report disregarded SCARF2 for an involvement with efferocytosis when 
comparing its activity to SCARF1 (130). However, observations described in this chapter have 
shown that SCARF2 associated with efferosomes containing both apoptotic and necrotic cells 
(Fig. 3I). Furthermore, the percentage of SCARF2-postive vesicles found outside of the 
nucleus was increased in Huh-7 cells in response to treatment with cytokines that were also 
shown to increase efferocytosis these cells (Fig. 3J). This redistribution of vesicular SCARF2 
was also recapitulated in vivo (Fig. 3L) in hepatocytes within livers plagued with chronic liver 
disease. These hepatocytes would be frequently exposed to cytokines (49). The latter 
observation suggests that the activity of SCARF2 in hepatomas is representative of its in vivo 
activity in hepatocytes. These data collectively suggest that SCARF2 may form part of the 
molecular machinery associated within hepatocyte efferocytosis. This represents the first 
candidate receptor involved in how hepatocytes recognise dying cells since ASGPR1.  
In support of its potential role in hepatocyte efferocytosis, the distribution of SCARF2-
positive vesicles was altered in response to cytokine treatment, with significant differences 
observed in response to IFN-γ and IL-10 (Fig. 3J). These cytokines were also shown to 
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augment heat-killed cell capture (Fig. 3C). This increase may therefore be linked with the 
observed alteration in SCARF2 vesicle localisation. The exact mechanism as to how this 
occurs is unclear. The MFI of SCARF2 vesicles in Huh-7 cells was used as a proxy to 
investigate if these cytokines increase the expression of SCARF2 in the cytoplasm (Fig. 3K). 
Although IFN-γ increased SCARF2 vesicle MFI, this was not seen with other cytokine 
treatments. Furthermore, IFN-γ, nor IL-10 altered the MFI of cytoplasmic SCARF2 vesicles 
relative to nuclear population. Therefore, it is more likely that SCARF2 is mobilised towards 
the cytoplasm in response to cytokines. In support of this, the activity of vesicle trafficking 
proteins, Rho GTPases, have been shown to influenced but NFκB activation by various 
cytokines (255).  In further support of this, EIPA treatment caused the most significant 
increase in SCARF2 vesicle MFI, despite significantly inhibiting hepatocyte efferocytosis. This 
increase in MFI may be the result of SCARF2-postivie vesicles arresting in the hepatocyte, 
preventing its trafficking to the cell membrane, which in turn would reduce the cells capacity 
to capture dead cells. This observation may also provide insight into the exact mode of 
action for how EIPA inhibits hepatocyte efferocytosis. More accurate methods to assess 
protein expression, such as western blotting, as well as live tracking of SCARF2 vesicles will 
be required to validate these theories.  
3.6.2.2 How does SCARF2 function? 
Exactly what SCARF2 binds to remains uncertain, as does the modality through which it acts; 
whether it is involved in dead cell binding, internalisation, or intracellular trafficking. As 
SCARF2 associated with both necrotic and apoptotic cells, it is likely to recognise a 
component shared between both forms of dead cell. It is likely to be an opsonising molecule 
that may bind PS. One possibility is that the SCARF2 can recognise dead cells through 
modified low-density lipoproteins (LDLs). Similar activity has been reported for the receptor 
Lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1), and SCARF2 has been 
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reported to bind to acetylated and oxidised LDLs (ac-LDLs/ox-LDLs) (219, 256). However, 
SCARF2 expression was shown not to increase LDL internalisation. As such, this protein may 
instead act as an adhesion molecule to initiate the internalisation of dead cells. We also saw 
that SCARF2 could be found at intercellular junctions between hepatocytes (Fig. 3G). 
Coupled with its likelihood to denote efferosomes, this appears to be reminiscent of the dual 
modality of certain integrins. Certain combinations like αvβ3/β5 can recognise PS but also 
form a part of adhesion junctions (257). Despite its difference in structure, SCARF2 may also 
act in a similar manner. Its expression has been linked to increased clumping of cells through 
homophilic interactions (219). This further exemplifies its role as an adhesion molecule, 
rather than a scavenger receptor, and illustrates its likely importance in the liver. Further 
experimentation is necessary to further understand the functionality of SCARF2 in the liver.  
The observations made in this study do possess the drawbacks of relying on antibody 
staining. Only a single antibody which recognises SCARF2 is commercially available. Although 
the use of this rabbit polyclonal antibody has been described before in the literature (145), it 
has not undergone extensive validation. Furthermore, polyclonal antibodies possess 
drawbacks of recognising multiple epitopes, creating batch variability. As such, it is not 
entirely certain if it specifically and correctly recognises SCARF2. This casts doubt on its 
distribution observed in hepatocytes and related cell lines within the experiments described 
here. As such, further verification of this antibody would be required to validate these 
findings. This could be achieved by using the antibody to stain cells which have been 
confirmed not to express SCARF2. Furthermore, the Fc region of the antibody could be 
tagged in a way to allow its use within pull-down assays or purification columns. The 
proteins which are pulled out from hepatocyte lysates by the antibody could then be 
identified by mass spectrometry to confirm the presence of SCARF2 amongst them.  
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The activity of SCARF2 could also be tested in future experiments by performing 
efferocytosis assays in the presence of molecules which mask its candidate ligands. 
Efferocytosis by both professional and non-professional phagocytes is frequently inhibited 
experimentally by masking PS with soluble Annexin V (AV) (97, 258, 259). In addition, 
modified LDLs have also been used to inhibit the activity of scavenger receptors which assist 
the capture of dead cells, such as LOX-1 (89, 260) and kidney injury molecule-1 (KIM-1) 
(261). Similar treatments have been previously shown to interrupt SCARF2 interactions with 
SCARF1 (219). Treatment of hepatocytes or hepatomas with modified LDLs may therefore 
reduce efferocytosis. Contrastingly, coating of dying cells with LDLs may increase 
efferocytosis by providing more targets for SCARF2. Such experiments would provide some 
information as to the ligands of SCARF2 and its role in hepatocyte efferocytosis. Genetic 
silencing of SCARF2 would also shed further light on its global role both in the liver. This will 
highlight the importance of SCARF2 in the future.  
3.6.3 Do hepatocytes control liver immunotolerance? 
Several aspects of the biological activity of hepatocytes can be attributed to the general 
immune-unresponsiveness in the liver (48). They’re able to prematurely activate 
lymphocytes under inflammatory circumstances, thus reducing their longevity (21). The work 
discussed here now exemplifies a further role for hepatocytes in promoting 
immunotolerance in the liver by clearing dying cells. Efferocytosis is generally considered an 
anti-inflammatory process, as preventing the accumulation of dying cells in the parenchyma 
is vital for avoiding further tissue damage and leukocyte recruitment (77, 127). As the liver 
frequently accumulates apoptotic cells, both tissue-forming and circulating, hepatocytes 
now possess another primary immune function with removing these cells. What’s more, 
hepatocytes can also clear necrotic cells as well as apoptotic cells. Although necrotic cell 
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capture can impose a pro-inflammatory phenotype on phagocytes, this is not thought to 
happen with non-professional phagocytes (97). Furthermore, capture of necrotic cells by 
hepatomas was augmented by anti-inflammatory cytokines, suggesting that hepatocyte 
efferocytosis may not incur the same inflammatory consequences as other phagocytes. As 
such, efferocytosis conducted by hepatocytes may reduce the likelihood of further immune 
activation in the liver.  
The ability of the major liver cell type to clear dying cells gives a greater protection from 
premature immune responses than if professional phagocytes were working alone. Although 
Kupffer cells (212) and infiltrating phagocytes (262) effectively contribute to clearing dying 
cells in the liver , it may not be advantageous to increase the number of these cells in the 
parenchyma as they have the potential to acquire pro-inflammatory phenotypes in a disease 
setting. It is therefore more efficient for hepatocytes to largely control the burden of 
removing dead cells, as they are less likely to contribute to liver inflammation and fibrosis. 
They are also most likely to be the cell to first encounter a dead cell within the liver, which 
limits the time between cell death and its clearance. A similar hierarchy is established in the 
airways, another series of tissues with frequent exposure to potentially toxic substances 
(116, 117, 263). In these tissues, epithelial cells can efferocytose which alleviates the burden 
of this for macrophages and prevents further inflammatory cell recruitment. It would now 




Chapter 4: The consequences of 
efferocytosis by hepatocytes 
4.1 Introduction 
4.1.1 Cell-in-cell structures can cause multinucleation in the host 
As a field that is generally in it’s infancy, multiple aspects of CICSs are available for further 
study. Although a lot of pioneering work has focussed on the molecular mechanisms and 
signalling pathways which are involved in live cell capture, other investigations have 
focussed on the impact for the predatory cell (185, 204, 264). The original authors who 
described entosis observed that breast cancer cells who engulfed their live neighbours were 
prone to failing cytokinesis (204); the large internal vesicle containing the “prey cell” served 
as a physical impediment to the cytokinetic cleavage furrow (Fig. 4Ai). As such, the host cell 
would fail cytokinesis and become multinucleate. This has been hypothesised to increase the 
accumulation of genetic abnormalities in these cancers, potentially incurring greater levels 
of survival for the tumour (202, 204). In support of this, cytokinesis failure and binucleate 
cell formation in tumours has been previously linked to tumorigenesis (265). Furthermore, 
breast cancers with higher ploidy levels have been associated with poor prognosis (266). 
CICS formation can therefore bestow profound genetic changes to the predatory cell.  
Similar mechanisms have been reported whereby an intracellular physical impediment can 
result in the failure of cytokinesis. Macrophages infected with Chlamydia trachomatis have 
been reported to have their cleavage furrows perturbed by the infections inclusion bodies, 
resulting in multinucleation (267). The same authors recapitulated this same cytokinetic 
failure using latex beads, a common tool used to model phagocytosis in macrophages (268). 
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This would suggest that phagocytosis also has the potential to induce cytokinetic failure, as a 
similar physical impediment is created by a phagosome.  
4.1.2 Hepatocyte ploidy  
Alterations in ploidy are more frequently associated with pathological and oncogenic 
transformations and are often the result of cell cycle dysregulation (269-272). Physiologically 
normal cases of polyploidy, however, have been described and are often the result of cell 
fusion. These phenomena are generally associated which terminal stages of cell 
differentiation, including the development of muscle fibres and the formation of osteoclasts 
in the bone (273, 274). They can also occur under chronic inflammatory conditions, as seen 
with the formation of multinucleate giant macrophages (274). Hepatocytes, however, are 
unique in that a percentage of these cells have a propensity to be multinucleate and 
polyploid under homeostasis (205). Approximately 50% of human hepatocytes are polyploid 
and this percentage is higher in mice (205). Marcus Grompe and colleagues have reported 
several observations regarding the potential of hepatocytes to gain multiple chromosome 
sets. They have described how polyploidy in mouse hepatocytes was increased with age 
(275, 276). This change was predominantly the result of cytokinetic failure. The authors also 
reported that hepatocytes in mice could also lose whole sets of chromosomes through 
reductive cell divisions, a process known as ‘ploidy reversal’. However, this process was less 
frequent than cytokinesis failure. These observations lead to the creation of their “ploidy 
conveyor” model, which describes the gradual increase in hepatocyte polyploidy over time 





Figure 4A: Sources of multinucleation and ploidy increases through cell-in-cell structures and 
cytokinesis failure in the liver. (i) Mechanism of cytokinesis failure induced by cell-in-cell 
structures. The large vesicle formed through the engulfment of a live or dead cell imposes a 
physical block on the cytokinetic cleavage furrow. This causes the cell to abandon cell division, 
despite having replicated its genome. Two nuclei form, resulting in binucleation of the host cell. 
Modified, with permission, from (204). (ii) The ploidy conveyor model of hepatocyte 
polyploidisation established by Marcus Grompe and colleagues. During liver regeneration, 
increases in ploidy are frequent in the liver (depicted by larger number of red arrows) caused by 
failed cytokinesis. During the same periods, the less frequent event of multipolar mitotic spindle 
formation (depicted by fewer red arrows) results in the loss of chromosome sets, a process 
known as ‘ploidy reversal’. Hepatocytes thus cycle through increases and decreases in ploidy, 
skewing more to the gain of whole chromosome sets. The origin of initial diploid cells within the 
cycle is not known. Taken, with permission, from (205) 
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How hepatocytes polyploidisation is induced is not thoroughly understood. Cytokinesis 
failure was originally observed to be the major source of polyploidisation in the liver, which 
is concurrent with multinucleation. This is not always the case in patients with Non-alcoholic 
Fatty Liver Disease (NAFLD) or Non-alcoholic Steatohepatitis (NASH). It was shown that 
polyploidy was induced by cell cycle arrest in phases prior to cytokinesis due to oxidative 
stress (277). This would result in polyploid, mononucleate cells in contrast to the binucleate 
cells generated from cytokinesis failure. The exact reasons or mechanisms for cytokinesis 
failure in hepatocytes are, to this point, uncertain. Recent evidence in mice has suggested 
that the microRNA, miRNA-122, regulates polyploidisation by antagonising the expression of 
cytokinetic machinery (276). Mice possessing no miRNA-122 exhibited significantly reduced 
binucleation, yet some binucleate hepatocytes were still recorded. Although it has been 
reported that hepatocytes conduct efferocytosis, the consequences of this for hepatocyte 
ploidy have not been examined. I therefore set out to interrogate the effects of efferocytosis 
on hepatocyte multinucleation using in vitro, in vivo and ex vivo models. 
4.2 Efferocytosis increased multinucleation in hepatomas in vitro. 
When CICSs are created via entosis, they create a large internal structure which has the 
potential to prevent cytokinesis and induce multinucleation in the host cell. During 
efferocytosis, dying cells are also compartmentalised into large intracellular vesicles. I 
hypothesised that efferosomes could induce multinucleation via cytokinetic failure in 
hepatomas, as they readily divide when cultured in vitro. To test this, Huh-7 hepatomas 
were labelled with Hoechst 33342 following co-culture with heat-killed Jurkat lymphoma 
cells (Fig.  4B). Huh-7 cells that underwent consecutive feeds exhibited cumulative increases 
in multinucleation with each round of efferocytosis (Fig. 4Bi). Large hepatocytes possessing 
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up to 8 nuclei were observed in cultures at the end of this experiment (Fig. 4Bii). 
Furthermore, a dose-dependent increase in hepatocyte multinucleation was observed with 
increasing ratios of Huh-7:Jurkats after only 24 hours of co-culture (Fig. 4Biii). To ensure that 
increases in multinucleation were not the result of factors exuded from the Jurkat cell 
corpses, Huh-7s were co-cultured with heat-killed Jurkat cells for 24 hours in the presence or 
absence of 10 uM EIPA (Fig. 4Biv). This inhibitor was previously shown to inhibit hepatocyte 
efferocytosis (Fig. 3D). The concentration was lowered compared to previous experiments as 
not to severely perturb macropinocytosis and induce apoptosis. There was no observable 
increase in multinucleation in the presence of EIPA compared to untreated cells (Fig. 4Biv, 
left). The number of Huh-7 cells present at the end of the experiment rose when co-cultured 
with dead cells (Fig. 4Biv, right). This increase was not affected by EIPA treatment. Overall, 





Figure 4B: Efferocytosis increased multinucleation in hepatomas in vitro. (i) cumulative co-cultures 
with dead cells caused cumulative increases in multinucleation in hepatomas. Huh-7 cells were then 
incubated with heat-killed Jurkat T cell lymphomas at a ratio of 1:1. Excess Jurkat cells were 
removed following 24 hr co-culture. Cells were then washed with PBS and normal culture media was 
replaced. Huh-7s were permitted to conduct efferocytosis until they became confluent, indicating 
that they had completed efferocytosis (they do not divide when conducting efferocytosis). Huh-7s 
were then trypsinised and divided between 2 wells of separate 24-well plates. Unfed control wells 
were passaged as needed but seeded at the same time and density as the co-cultured cells for 
analysis. Huh-7s from one well were ‘re-fed’ with heat-killed Jurkat cells and the experiment was 
repeated. The mean percentage of multinucleate cells were determined from cells seeded in the 
other well. These cells were labelled with Hoechst 33342 and CellMask Orange to facilitate the 
counting of nuclei ownership (ii) Phase contrast image of multinucleate Huh-7 following 3 
consecutive feeds with heat-killed cells. Scale bar = 50 µm. (iii) Dose response of increasing Huh-
7:heat-killed cell ratios on Huh-7 multinucleation. Experiment conducted as in part (i) but only for a 
single feed. N=1. *** - p≤0.001. (iv) Effect of 5-(N-Ethyl-N-isopropyl)amiloride (EIPA) treatment on 
Huh-7 multinucleation over a single co-culture at a ratio of 1:1. . Means for all experiments were 
determined from 5 FOVs obtained across 3 technical replicates. N=1. * - p≤0.05. Statistics were 
derived from a two-tailed, unpaired Students t-test. Error bars represent SEM.  
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4.3 Hepatocyte efferocytosis induced multinucleation in mouse 
models of acute liver injury 
To investigate if efferocytosis could cause multinucleation in hepatocytes in vivo, 
Haematoxylin and Eosin (H&E)- stained liver tissues from mice modelling ischemia 
reperfusion injury (IRI) [described in reference (211)] were examined. In this model, the 
portal vein and hepatic artery of the mouse is clamped for the 30 min, causing ischaemia to 
part of the mouse liver (Fig. 4Ci). The clamp is then released, allowing the blood to re-
perfuse. This creates a time-dependent increase in necrotic lesions in the liver. I 
hypothesised that the live hepatocytes surrounding these areas of necrosis would be actively 
efferocytosing. As such, these cells should be more multinucleate than hepatocytes further 
from the necrotic lesions. H&E-stained tissues from mice with 6 hr and 24 hr reperfusion 
injury were examined for discreet, localised areas of necrosis (Fig. 4Cii). Up to three, 2-
hepatocyte thick, concentric zones were outlined from the necrotic lesions (Fig. 4Ciii). The 
level of multinucleation for each concentric layer was then determined (Fig. 4Civ). 
Hepatocytes were significantly more multinucleate when proximal to necrotic lesions, both 







Figure 4C: Efferocytosis induced multinucleation in vivo in a mouse model of ischaemia 
reperfusion injury (IRI). (i) Diagram describing the IRI mouse model. The portal vein and hepatic 
artery in the livers of 8-week old male C57BL/6 mice were clamped for the 0.5 hr, obstructing the 
blood supply to the median and left lateral lobe. The clamp was then released to allow the blood 
to perfuse for 6 or 24 hr, causing a time-dependent increase in necrotic lesions in the liver. 
Adapted, with permission, from (211). (ii) Haematoxylin and eosin stain of IRI mouse liver, 
showing area of necrosis (N) and proximal multinucleate hepatocytes (highlighted in black boxes). 
Scale bare represents 20 µm. (iii) Hepatocyte zonation around necrotic lesions used for assessing 
increased multinucleation. Areas of necrosis (N) were identified by Haematoxylin and Eosin (H&E) 
staining. Concentric zones, 2 hepatocytes-thick were then outlined. (iv) Quantification of 
multinucleate hepatocytes in areas surrounding IRI-induced necrotic lesion. Multinucleate 
hepatocytes were recorded in zones moving proximal to distal from areas of necrosis in IRI mice. 
Lesions were identified and collectively analysed from 4 animals per group (8 total). Hepatocytes 
within random fields of view (FOVs) were also analysed from 4 uninjured mice as controls. 
Numbers were used to determine the multinucleation index (mean no. counted nuclei/no. 
hepatocytes counted per zone). * - p<0.05, ** - p<0.01. Statistics were derived from a two-tailed, 
paired Student t-test when comparing multinucleation values in concentric zones to values 
obtained from uninjured mice.   
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To show that this observation was not specific to this acute injury model, tissues were also 
examined from mice modelling paracetamol overdose [described in reference (278)] (Fig. 
4D). These 8-week old, male C57BL/6 mice had received 300 mg/kg acetaminophen (APAP) 
and were then taken after 24 hr. Similar, discreet areas of necrosis were identified and then 
analysed as previously done for IRI mice (N=4). Again, there was a significant increase in 
multinucleation in live hepatocytes at the circumference of the necrotic lesions (Fig. 4Dii). 
Furthermore, immunohistochemistry staining of these tissues for SCARF2 revealed live 
hepatocytes at the circumference of necrotic legions that contained positively-stained 
intracellular structures resembling phagosomes (Fig. 4Diii). 
It was not clear as to whether the observed increases in hepatocyte multinucleation were 
the result of efferocytosis-induced cytokinesis failure. The ability of EIPA to inhibit Na+-H+ 
exchanger 1 (NHE1) and diminish macropinocytosis is conserved in mice liver (279). 
Therefore, to confirm that multinucleation was induced by efferocytosis, mice who had 
received APAP-induced injury were given a dose of 2.5 mg/kg EIPA, or an equal volume of 
DMSO (vehicle) (Fig. 4E). Four mice were used per experimental group. Although other 
studies have described the use of 25 mg/kg for inhibiting macropinocytosis in mice (279), a 
smaller dose was used to lower the required volume of DMSO for control animals. H&E 
staining was performed for liver tissue from these mice. Discreet areas of necrosis were 
again identified, and the proximal regions were assessed for multinucleation (Fig. 4Eii-iv). 
Hepatocytes in proximity to the necrotic lesion were more multinucleate than hepatocytes 
situated further away as previously observed. In contrast, this increase in multinucleation 
was not seen in mice treated with EIPA. Blood samples from mice were also examined for 
prognostic markers of liver injury (280) (Fig. 4Ev). Increases of detectable alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) and were recorded in APAP 
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treated mice compared to untreated. This damage was not significantly altered by the 
addition of EIPA treatment. These data provide more evidence that efferocytosis may induce 




Figure 4D: Hepatocytes were more multinucleate proximal to areas of acetaminophen (APAP)-
induced injury in mice. Eight-week old male C57BL/6 mice which received 300 mg/kg APAP in 
saline by intraperitoneal injection were then sacrificed after 24 hr. Tissues were harvested, fixed 
and paraffin-embedded for staining. (i) Areas of necrosis (N) and portal triads (P) in mouse livers 
which received an APAP-induced chemical injury, as shown by Haematoxylin and Eosin (H&E) 
staining. Arrows indicate hepatocytes containing small, dark-stained efferosomes. Scale bars 
represent 100 µm. (ii) Quantification of multinucleate hepatocytes in areas surrounding APAP-
induced necrotic lesions in mouse livers. Numbers were derived from tissue analysis and did not 
required new experimentation.  A minimum of 5 lesions were assessed each from 4 animals 
(N=4). ** - p<0.01, *** - p≤0.001. Statistics were derived from a two-tailed, paired Student t-test 
when comparing multinucleation values in concentric zones to values obtained from the most 
distal zone identified. (iii) Immunohistochemistry staining for Scavenger receptor family F, 
member 2 (SCARF2 - brown) of liver tissue from mice treated with APAP alone. Tissues were 
counterstained with Mayers haematoxylin nuclear stain (blue). Black arrows indicate positively-
stained intracellular structures resembling phagosomes. Dotted black line outlines necrotic lesion. 




Figure 4E: Increases in hepatocyte multinucleation in response to injury were abolished 
following treatment with EIPA in mice with APAP-induced injury. (i) Diagram of experiment 
design. 8-week old male C57BL/6 mice received 300 mg/kg APAP in saline by intraperitoneal 
injection. Then they received 2.5 mg/kg 5-(N-Ethyl-N-isopropyl) amiloride (EIPA) through the same 
method. Mice were sacrificed after 24 hr and livers were collected for fixation, paraffin-
embedding and staining. (ii) Example of Haematoxylin and Eosin (H&E) staining used to identify 
necrotic lesions (N), with outlined 2-hepatocyte thick concentric zones, moving proximal to distal. 
(iii) Identification of multinucleate cells (shown within black boxes) in areas surrounding necrotic 
lesions. (iv) Quantification of multinucleate hepatocytes with increased distance from the necrotic 
lesions. A minimum of 5 lesions were assessed per animal. N=8/experimental group. *** - 
p≤0.001. (v) Levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
recorded from mice subjected to each condition. Error bars represent SEM. Statistics were derived 
from a two-tailed, paired Student t-test when comparing multinucleation values in concentric 
zones to values obtained from the most distal zone identified. Mouse handling, culling and liver 
harvesting were performed by Dr. Lozan Sheriff. 
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4.4 Hepatocytes proximal to necrotic lesions were more multinucleate 
than distal hepatocytes in tissues of paracetamol overdose patients. 
Based on previous observations made in vitro and in mice in vivo, I hypothesised that 
efferocytosis could also induce multinucleation in human hepatocytes. To obtain an initial 
indication for the validity of this, I analysed tissues of both explants and biopsies from 
patients who required a transplant due to paracetamol overdose injury (POD) (Fig. 4F). This 
is the form of acute livery injury that is by simulated in mice by direct APAP administration. 
Giant hepatocytes possessing multiple nuclei were observed (Fig. 4Fii) that were reminiscent 
of cumulatively fed Huh-7 cells previously observed in vitro (Fig. 3Bii). However, the 
coverage of blanket necrosis is often much greater in human POD than in APAP-treated 
mice. As such, discreet necrotic lesions with enough viable surrounding tissue with which to 
assess for multinucleation were limited. Nevertheless, in one patient, I was able to assess a 
limited number of lesions were assessed as previously performed for mouse models (Fig. 
4Fiii). Hepatocytes proximal to the necrotic lesions were again more multinucleate than 




4.5 Cauterisation model of injury in ex vivo human livers recapitulated 
consequences of hepatocyte efferocytosis in mouse models 
Several clinical trials are currently underway at the Queen Elizabeth hospital which involve 
using normothermic machine liver perfusion (NMLP) (281, 282). The primary goal of these 
trials is to improve liver viability pre-transplantation by promoting normal metabolic activity 
of the liver, thus increasing the likelihood of successful transplantation. Many livers are 
perfused with blood or substitutes designed to improved oxygen delivery, such as the 
Figure 4F: Hepatocytes were more multinucleate proximal to areas of acetaminophen (APAP)-
induced injury in paracetamol overdose patients. Staining and analysis of liver tissue explanted 
from a patient who suffered with paracetamol overdose (POD). (i) Areas of necrosis (N) and portal 
triads (P) as shown by Haematoxylin and Eosin (H&E) staining. Arrows indicate hepatocytes 
containing small, dark-stained efferosomes. Scale bars represent 100 µm. (ii) H&E stain showing 
larger multinucleate hepatocyte observed in the paracetamol overdose patient. (iii) 
Quantification of multinucleate hepatocytes in areas surrounding APAP-induced necrotic lesions 
in human liver. 5 lesions were assessed. N=1. * - p<0.05. Statistics were derived from a two-tailed, 
paired Student t-test when comparing multinucleation values in concentric zones to values 
obtained from the most distal zone identified. 
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acellular hemoglobin-based oxygen carrier (HBOC), Hemapure (281). Livers which do not 
meet the criteria required for transplantation are available for experimentation. 
NMLP presented a unique opportunity for the delivery of drugs throughout the entirety of a 
human liver, ex vivo. It was reasoned that this setup could be used to assess whether 
efferocytosis specifically induces multinucleation in human hepatocytes under near-normal 
physiological conditions. Henceforth, NMLP was used to deliver 50 µM EIPA to donor livers 
which had previously under long-term perfusion with blood or Hemapure (Fig. 4G) (N=3). 
Livers were perfused for 30 min with EIPA-containing perfusates before wedge samples were 
taken. Livers were also perfused with DMSO and sampled prior to EIPA perfusions for use as 
controls. Wedges then received a cauterisation wound from a heated needle (Fig. 4Gi, right) 
to create a localised injury as a source of dying cells. The wedges were then incubated in 
DMEM for 24 hr to allow hepatocytes to efferocytose. Liver tissues were then fixed and 
paraffin-embedded for staining, whilst preserving the area of cauterisation. I hypothesised 
that these hepatocytes should be more multinucleate than those situated further away from 
the cauterisation wound, in a similar manner to the hepatocytes close to necrotic lesions in 
the previously used mouse models. To show this, H&E staining was performed on these 
tissues, which aided the identification of the “crush-like” cauterisation wound (Fig. 4Gii). 
Possible phagosomes, and multinucleate hepatocytes, were observable in these tissues (Fig. 
4Giii-iv). Five-hepatocyte thick zones radiating from the wound were outlined and assessed 
for multinucleation (Fig. 4Gv). Hepatocytes were more multinucleate when situated closer 
to the cauterisation wound. This increase was abolished in tissues which were sampled post-
perfusion with EIPA. In addition, the percentage of multinucleate hepatocytes was further 
augmented in liver tissue incubated with IFN-γ. This showed that efferocytosis could be both 






Figure 4G: Cauterisation injury in normothermic machine perfused, preserved human livers 
induced multinucleation to injury-proximal hepatocytes. Donor livers which had undergone 6 hr 
perfusion using normothermic machine perfusion (NMP) with blood or blood-substitutes, using a 
Liver Assist perfusion system, were sampled both before and after a 0.5 hr perfusion with 5-(N-
Ethyl-N-isopropyl) amiloride (EIPA). Samples then received a localised cauterisation injury using a 
hot needle and were then incubated in media at 37°C for 24 hr to allow for hepatocyte 
efferocytosis and regeneration. Some samples were also incubated with media containing 
interferon-gamma (IFN-γ). Tissues were then fixed and stained with Haematoxylin and Eosin 
(H&E) and hepatocyte multinucleation was assessed compared to distance from the cauterisation 
wound.  (i) Photographs of a Liver Assist perfusion machine (Left) containing a donor liver 
(middle) attached by the hepatic artery (HA) and portal vein (PV) and containing a bile collection 
(BC) tube, and of a heated syringe needle (right) used to create the cauterisation injury. (ii) H&E 
stained tissue identified the cauterisation would and the layout for analysing hepatocyte 
multinucleation, moving from proximal to distal from the site of necrosis (N). (iii) hepatocyte 
potentially containing an efferosome. (iv) Multinucleate cells present in cauterised tissue, as 
shown by blue arrows. (v) Percentage of multinucleate hepatocytes (shown in black boxes) with 
increased distance from the cauterisation wound. A minimum of 5 fields of view (FOV) were 
assessed per sample. N=3. * - p<0.05, *** - p≤0.001, **** - p≤0.0001. Statistics were derived 
from a two-tailed, paired Student t-test when comparing multinucleation values in concentric 
zones to each other. 
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4.6 Expression of proliferation and cell-cycle arrest markers was 
altered in hepatocytes proximal to sites of necrotic injury 
This section details experiments which assessed the effect of hepatocyte efferocytosis on 
the expression of markers related to the continuity or arrest of the cell cycle.  
4.6.1 Ki67 expression was increased in hepatocytes proximal to injury compared to 
distal hepatocytes in APAP-treated mice in vivo and cauterised human tissue ex vivo.   
 
Previous reports regarding changes in polyploid in hepatocytes, either full sets or single 
chromosomes (aneuploidy), have been linked to the onset of liver regeneration (205, 275, 
276, 283, 284). In addition, a recent report linked increases in macrophage efferocytosis with 
liver tissue repair and hepatocyte division (45). To investigate whether similar mechanisms 
could be incurred from hepatocyte efferocytosis, untreated and EIPA-treated liver tissues 
from APAP-treated mice and previously perfused, cauterised ex vivo human tissue, 
previously assessed for multinucleation at proximal regions to necrosis were stained for the 
proliferation marker, Ki67 (285), using immunohistochemistry (Figs. 4H+I). Ki67 has been 
previously validated as a marker for regenerating hepatocytes (276). An increase in Ki67 
positive cells was observed in hepatocytes proximal to necrotic lesions in mice (Fig. 4Ii). An 
increase in Ki67 expression was also detected in hepatocytes close to the site of injury than 
those situated further away in cauterised human tissue (Fig. 4Iii). No change in Ki67 
expression was seen in EIPA-treated tissues with increasing distance from the site injury. 
These data suggest that hepatocyte proliferation may be promoted in areas where these 







Figure 4H: Immunohistochemistry staining for Ki67 of liver tissues from mouse in vivo model 
and human ex vivo model of acute liver injury Paraffin-embedded tissues from mouse in vivo 
models and human ex vivo of acute liver injury were stained by immunohistochemistry for Ki67 
(brown) or using an appropriate isotype-matched control (IMC; Goat IgG for mice, mouse IgG1 
for human). Tissues were counterstained with Mayers haematoxylin (blue). Black scale bars 
represent 100 µm. Mouse tissues were derived from 8-week old male C57BL/6 mice which had 
received 300 mg/kg APAP in saline by intraperitoneal injection. Mice were sacrificed after 24 hr 
and their livers were collected for fixation and staining. Mouse handling, culling and liver 
harvesting were performed by Dr. Lozan Sheriff. Human tissue was supplied by donor livers which 
had undergone 6 hr perfusion using normothermic machine perfusion (NMP) with blood or 







Figure 4I: Hepatocytes proximal to injury displayed EIPA-sensitive increases in Ki67 expression 
compared to distal hepatocytes in APAP-treated mice in vivo and cauterised human tissue ex vivo.  
Paraffin-embedded tissues from (i) mouse in vivo models and (ii) human ex vivo of acute liver injury 
were stained for Ki67 (brown) by immunohistochemistry and counterstained with Mayers 
haematoxylin (blue) (left panels). The percentage of positive hepatocytes (right panels) were then 
scored in proximal and distal areas relative to areas of necrotic injury (N). White and black scale bars 
represent 50 µm. * - p<0.05, *** - p≤0.001. Statistics were derived from a two-tailed, paired Student 
t-test when comparing multinucleation values in concentric zones to each other. Black boxes 
indicate positively stained hepatocytes. (i) 8-week old male C57BL/6 mice received 300 mg/kg APAP 
in saline by intraperitoneal injection. They then received 2.5 mg/kg 5-(N-Ethyl-N-isopropyl) amiloride 
(EIPA) through the same method. Mice were sacrificed after 24 hr and their livers were collected for 
fixation and staining. A minimum of 5 lesions were assessed per animal. Eight animals were used per 
experimental group (N=8). Mouse handling, culling and liver harvesting were performed by Dr. 
Lozan Sheriff. (ii) Donor livers which had undergone 6 hr perfusion using normothermic machine 
perfusion (NMP) with blood or blood-substitutes were sampled both before and after a 0.5 hr 
perfusion EIPA. Samples then received a localised cauterisation injury using a hot needle and were 
then incubated in media at 37°C for 24 hr. Some samples were also incubated with media containing 
interferon-gamma (IFN-γ). Tissues were then fixed and stained.  A minimum of 5 fields of view (FOV) 




4.6.2 Expression of p21 in hepatocytes proximal to injury increased in APAP-treated 
mice in vivo, compared to distal hepatocytes, but decreased in cauterised human 
tissue ex vivo  
To provide further evidence that efferocytosis by hepatocytes could promote liver 
regeneration, tissues that were previously stained for Ki67 were also stained on serial 
sections for p21, a regulator of the G1-S phase checkpoint and marker of cellular senescence 
(Fig. 4J+Ki) (286, 287). Significant increases in p21 expression were also observed at proximal 
regions compared to distal hepatocytes, in relation to necrotic lesions in APAP-treated mice 
(Fig. 4Ki). However, this increase was also observed in mice also treated with EIPA. Stains 
performed on cauterised human liver tissue showed collectively more p21-positive cells in 
tissues perfused with EIPA than in untreated tissues (Fig. 4Kii). Additionally, the median of 
p21-postive cells in these EIPA-treated human tissues was over double that of their mouse 
counterpart. Finally, a decrease in p21 expression was detected in hepatocytes proximal to 
the cauterisation injury in untreated and IFN-γ-treated tissues which was not observed in 







Figure 4J: Immunohistochemistry staining for p21 of liver tissues from mouse in vivo model and 
human ex vivo model of acute liver injury Paraffin-embedded tissues from mouse in vivo models 
and human ex vivo of acute liver injury were stained by immunohistochemistry for p21 (brown) 
or using a rabbit IgG isotype-matched control (IMC). Tissues were counterstained with Mayers 
haematoxylin (blue). Black scale bars represent 100 µm. Mouse tissues were derived from 8-
week old male C57BL/6 mice which had received 300 mg/kg APAP in saline by intraperitoneal 
injection. Mice were sacrificed after 24 hr and their livers were collected for fixation and staining. 
Mouse handling, culling and liver harvesting were performed by Dr. Lozan Sheriff. Human tissue 
was supplied by donor livers which had undergone 6 hr perfusion using normothermic machine 






Figure 4K: p21 expression in hepatocytes proximal to injury increased in APAP-treated mice in 
vivo, compared to distal hepatocytes, but decreased in an EIPA-sensitve manner in cauterised 
human tissue ex vivo.  Paraffin-embedded tissues from (i) mouse in vivo models and (ii) human 
ex vivo models of acute liver injury were stained for p21 (brown) by immunohistochemistry and 
counterstained with Mayers haematoxylin (blue) (left panels). The percentage of positive 
hepatocytes (right panels) were then scored in proximal and distal areas relative to areas of 
necrotic injury (N). White and black scale bars represent 50 µm. * - p<0.05, ** - p≤0.01, *** - 
p≤0.001. Statistics were derived from a two-tailed, paired Student t-test when comparing 
multinucleation values in concentric zones to each other. Black boxes indicate positively stained 
hepatocytes. (i) 8-week old male C57BL/6 mice received 300 mg/kg APAP in saline by 
intraperitoneal injection. They then received 2.5 mg/kg 5-(N-Ethyl-N-isopropyl) amiloride (EIPA) 
through the same method. Mice were sacrificed after 24 hr and their livers were collected for 
fixation and staining. A minimum of 5 lesions were assessed per animal. Eight animals were used 
per experimental group (N=8). Mouse handling, culling and liver harvesting were performed by 
Dr. Lozan Sheriff. (ii) Donor livers which had undergone 6 hr perfusion using normothermic 
machine perfusion (NMP) with blood or blood-substitutes were sampled both before and after a 
0.5 hr perfusion EIPA. Samples then received a localised cauterisation injury using a hot needle 
and were then incubated in media at 37°C for 24 hr. Some samples were also incubated with 
media containing interferon-gamma (IFN-γ). Tissues were then fixed and stained. A minimum of 5 





4.7 Hepatocyte multinucleation in hepatocellular carcinoma  
Changes in ploidy have been a frequently remarked feature of epithelial tumours (265, 269, 
270, 272). Furthermore, multinucleation is often associated with the most prominent form 
of liver cancer, hepatocellular carcinoma (HCC) (288), and has also been noted to promote 
survival of in HepG2 cells (289). This section will address multinucleation in a cohort of HCC 
patients from the Birmingham NHS trust.  
4.7.1 Hepatocyte nuclear factor 4α (HNF4α) staining facilitated hepatocyte 
multinucleation counts in normal liver and hepatocellular carcinoma 
The relationship between multinucleation/ploidy increases and hepatocellular carcinoma 
(HCC), the most prominent form of liver cancer, has not been fully characterised. Liver 
cancer cells are much smaller and irregularly shaped, whilst often associated with other 
infiltrating cells (Fig. 4Li). This makes the task of attributing nuclei to specific cells difficult in 
these tumours. To overcome this, a method was developed to highlight hepatocyte-specific 
nuclei by staining tissues from HCC patients for hepatocyte nuclear factor 4 alpha (HNF4α) 
by immunohistochemistry (Fig. 4Lii). The antibody that was used has been to reported to 
selectively stain hepatocyte nuclei and exclude those of other hepatocyte cell types such as 
BEC (290). Hepatocyte nuclei could be identified in both normal and tumour tissue using 
HNF4α staining. Furthermore, non-hepatocytes could be identified as cells which were 
haematoxylin stained only, such as BECs, LSECs and lymphocytes. Negative staining of 
lymphocytes allowed them to be identified as CICSs or artefacts of tissue slicing, and thus 
not be included in multinucleation counts. This reduced the likelihood of confusing 
hepatocytes containing internalised cells with binucleates. Overall, HNF4α staining allowed 
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for the identification of hepatocyte-specific nuclei and their allocation to individual 







Figure 4L: Immunohistochemistry staining of HNF4α accurately and specifically identified the 
nuclei of hepatomas in patients with Hepatocellular carcinoma (HCC). (i) Haematoxylin and 
Eosin (H&E) staining of normal liver tissue and HCC. (ii) Normal and HCC tissues stained for 
hepatocyte nuclei factor 4-alpha (HNF4α) by immunohistochemistry (brown) and counterstained 
with Mayers haematoxylin (blue). Normal tissues from the same patient were also stained using a 
mouse IgG2a isotype-matched control (IMC). Black arrows identify HNF4α +ve, binucleate 
hepatocytes. White arrows identify HNF4α -ve cells in hepatocyte cytoplasmic. Scale bars 
represent 50 µm. 
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4.7.2 Hepatocytes were more multinucleate near regions of interface hepatitis 
Several patients with liver disease, particularly those which are autoimmune, often present 
with interface hepatitis, a process of parenchyma erosion is periportal areas, which correlate 
with a large mononuclear lymphocytic infiltration (291-293). Many of these areas are rich in 
dying, apoptotic cells, both of lymphocytic and hepatic origin. I hypothesised that 
hepatocytes in these regions would clearing these apoptotic cells and be more multinucleate 
than those further away from areas of interface hepatitis. To address this, IHC staining for 
HNF4α was performed on liver tissues from HCC patients presenting with interface hepatitis, 
as determined by the resident pathologist (n=16, Fig. 4M). This staining facilitated the 
accurate determination of hepatocyte nuclei in these parenchymal areas with heavy 
inflammatory cell infiltration. Five hepatocyte-thick ‘zones’ were then outlined, radiating 
from the border of the hepatic infiltrate (Fig. 4Mi). The percentage of multinucleate 
hepatocytes within each of these zones was then determined. Significantly more 
hepatocytes were multinucleate in zones proximal to the region of interface hepatitis than 
those situated further away (Fig. 4Mii). Out of 16 patients analysed, 14 displayed a decrease 
in hepatocyte multinucleation when moving proximal to distal from the area of interface 







Figure 4M: Proximity to areas of high efferocytosis linked to inflammation, correlated with 
more multinucleate hepatocytes. Paraffin-embedded liver tissues from patients presenting with 
chronic liver disease, hepatocellular carcinoma and interface hepatitis were stained for 
hepatocyte nuclear factor 4α (HNF4α) and counterstained with Mayers haematoxylin. The mean 
number of nuclei/hepatocyte was then determined in five-hepatocyte-thick areas with increasing 
distance from areas of inflammatory infiltrate. (i) Left: Example area of HNF4α staining (brown) 
and sectioning of parenchymal areas with distance from inflammatory infiltrate (large areas of 
smaller blue cells), moving from proximal (P) to distal (D) areas; Right: corresponding 
quantification of mean no. of nuclei/hepatocyte with increasing distance from inflammatory 
infiltrate. *- p<0.05 as determined by Pearsons correlation coefficient. (ii-iii) Collective 
quantification of mean no. of nuclei/hepatocyte in hepatocyte areas with increasing distance 
from inflammatory infiltrate. Data are plotted both (ii) grouped per hepatocyte areas and (iii) 
linked per patient sample. Each colour represents an individual patient. *** - p<0.001. Middle line 
represents mean and error bars represent the SEM. Statistics were derived from a two-tailed, 
paired Student t-test when comparing multinucleation values in concentric zones to each other. 




4.7.3 Tumours Increased hepatocyte multinucleation was associated with tumours  
To demonstrate whether tumour cells were more multinucleate than their corresponding 
non-neoplastic hepatocytes, HNF4α IHC staining was performed for HCC tissue samples, 
both from liver resections and biopsies, of tumour, distal, and marginal regions within the 
same patient (Fig. 4N). Normal and tumour regions in tissues were easily identifiable in 
HNF4α-stained tissues (Fig. 4Ni). This staining also allowed for the identification of CICSs 
within hepatocyte cancer cells (Fig. 4Nii). The percentages of multinucleation within normal 
hepatocytes and tumours were then assessed (Fig. 4Niii-iv). In all cases analysed, tumour 
cells were more multinucleate than their non-neoplastic counterparts. These observations 






Figure 4N: Hepatomas displayed more frequent multinucleation compared to marginal and 
distal hepatocytes in hepatocellular carcinoma (HCC) explants and resection specimens. 
Paraffin-embedded liver tissues from patients with HCC were stained for hepatocyte nuclear 
factor 4α (HNF4α) by immunohistochemistry and counterstained with Mayers haematoxylin to 
allow for the confident identification of hepatocyte/hepatoma nuclei, as well as neoplastic areas. 
(i) Example tissue stained for HNF4α (brown) with identifiable areas of HCC tumour lesion 
surrounded by a fibrous capsule (T) and adjacent non-cancer liver lobules (N). (ii) Left; Area of 
tissue exhibiting efferocytosis by neoplastic hepatocytes. Arrows show small dark blue nuclei seen 
inside the cytoplasm of hepatic tumour cells. Hepatoma nuclei were large and oval. Right; Red 
box displaying zoomed image of an efferocytosing neoplastic hepatocyte. (iii-iv) Mean values of 
hepatocyte multinucleation for HCC patients, comparing tumour to distal/margin areas where 
available. Each data point represents mean values for an individual patient where over 1,000 
hepatocytes were scored per patient. (iii) Comparison of hepatocyte multinucleation in tumour 
and non-tumour regions in resected tumours. Left; total available tumour and non-tumours. 
Right; matched comparison within the same patient. (iv) Comparison of hepatocyte 
multinucleation in tumour and non-tumour regions in tumours explants. ** - p<0.01, *** - 
p<0.001 based on an unpaired two-tailed Students t-test comparing tumour and non-tumour 
values. These stains and analyses were partially performed by Biomedical Science undergraduate, 




4.7.4 Tumours with vasculature invasion possessed more multinucleate hepatocytes  
Increases in ploidy have been linked to more aggression and an increased risk of metastasis 
in cancers (294). It is likely that increased multinucleation may have similar implications for 
HCC. An unexpected benefit to HNF4α staining of HCC tissues was that it was possible to 
identify tumour cells that were invading into vessels (Fig. 4Oi). With this, the percentage of 
multinucleate hepatocytes (both normal and neoplastic) was compared between samples 
from patients with or without evidence of vascular invasion by cancer cells (Fig. 4Oii). More 
multinucleate hepatocytes were seen in tumours that also presented evidence of tumour 
invasion. This provides evidence that multinucleation may also be associated with increased 





Figure 4O: Patients with evidence of vascular invasion possessed a higher incidence of 
multinucleate hepatocytes. Paraffin-embedded liver tissues from patients with hepatocellular 
carcinoma (HCC) were stained for hepatocyte nuclear factor 4α (HNF4α -brown) by 
immunohistochemistry and counterstained with Mayers haematoxylin (blue) to allow for the 
confident identification of hepatocyte/hepatoma nuclei, as well as neoplastic areas. (i)  Area of 
HCC tumour metastasis. White arrows indicate binucleate cells. Black arrow indicates outlined 
region of vascular invasion. (ii)  Percentages of multinucleate normal and neoplastic hepatocytes 
in tissues with and without evidence of vascular invasion of tumours. Middle line represents 
mean and error bars represent the SEM.* - p<0.05. Statistics were derived from an unpaired, two-





1. Efferocytosis induced cumulative increases in multinucleation in hepatomas in vitro.  
2. Hepatocytes were more multinucleate when proximal to necrotic lesions, both in 
mouse models of acute liver injury and in human livers with APAP-induced injury. 
3. The hepatocyte efferocytosis inhibitor EIPA abolished the increase of multinucleation 
in hepatocytes proximal to sites of injury in mouse and human tissue with acute injury.  
4. Hepatocytes proximal to necrotic lesions in mice expressed Ki67 more frequently than 
distal cells. This was abolished in EIPA-treated mice. 
5. Hepatocytes proximal to necrotic lesions in cauterised ex vivo donor liver tissue from 
NMLP-treated livers expressed p21 less frequently than distal cells. This was not 
observed in EIPA-treated mouse livers. 
6. Hepatocytes proximal to areas of interface hepatitis with high efferocytosis rates 
were consistently more multinucleate than distally situated hepatocytes in patients with 
chronic inflammation.  
7. Tumour cells were more multinucleate than non-neoplastic hepatocytes in patients 
with the hepatocellular carcinoma. 
8. Increased multinucleation was associated with increased vascular invasion in 
hepatocellular carcinoma.  
 
  






4.9.1 Hepatocyte efferocytosis induced multinucleation in three different 
experimental models 
Experimentation using a variety of differently biological models has provided robust 
evidence that efferocytosis can induce multinucleation in hepatocytes. Initial evidence for 
this came from in vitro experiments, whereby the frequency of multinucleate Huh-7 cells 
was increase following their ‘feeding’ with heat-killed Jurkat lymphomas. Heat-killed cells 
were used over apoptotic cells as they create generally larger efferosomes which are more 
likely to impede cytokinesis. In isolation, these experiments did not reflect the likelihood of 
efferocytosis to increase multinucleation in vivo; Huh-7 cells are cancerous cells and may 
have different propensities for efferocytosis. The liver is also occupied by other efferocytes, 
such as Kupffer cells, which would partial relieve the burden of clearing dead cells in the liver 
(1). However, increases in multinucleation were observable in vivo in hepatocytes proximal 
to necrotic lesions in different mouse models of acute liver injury, but also in cauterised ex 
vivo human tissue. Collectively, using in vitro, in vivo and ex vivo provided robust evidence 
that efferocytosis could cause multinucleation in hepatocytes.  
Cytokinesis failure was never observed in actively efferocytosing cells. However, this 
phenomenon was implied by the ubiquitous effect of the previously validated inhibitor of 
hepatocyte efferocytosis, EIPA, to prevent multinucleation in all three experimental models. 
Another explanation for the abolishment of increased hepatocyte multinucleation following 
EIPA-treatment would be if hepatocytes were prevented from proliferating; cells must enter 
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the cell cycle and complete DNA synthesis to become binucleate following failure of 
cytokinesis. However, EIPA treatment did not prevent Huh-7 cells from dividing in vitro (Fig. 
4Biv). Additionally, treatment of mice and ex vivo human tissue with EIPA did not reduce the 
overall expression of Ki67 in hepatocytes in the liver when compared to controls (Fig. 4I). 
These data suggest that efferocytosis is more likely to induce multinucleation by cytokinesis 
failure in similar fashion to CICSs (185, 204). 
4.9.2 Advantages of normothermic machine liver perfusion for research investigations 
The work described in section 4.5 exemplifies, for the first time, a novel use of NMLP as an 
investigative tool for answering a research question. This provided an effective drug delivery 
tool which allowed for the studying the effects of EIPA on hepatocytes in the setting of a 
complete liver. This model of using human ex vivo tissue provides numerous advantages 
over commonly used tools. The foremost of which is the opportunity to work directly with 
human tissue. All findings made using this system can thus be directly applied to human liver 
biology. This removes the requirement for validation or stratification of results produced 
from mouse models. Furthermore, as there are numerous differences in the immune system 
and liver transcriptome, between mice and humans, mouse models do not accurately 
represent human disease pathology (295, 296). As such, NMLP and human ex vivo tissue may 
represent a more biologically relevant model than mice. Adapting the use of NMLP, or 
potentially related, downscaled technologies, for use with diseased liver tissues may 
alleviate the requirement for representative mouse models for each aetiology of chronic 
liver disease.  
Direct experimentation using ex vivo human liver also reduces the complications associated 
with using primary human hepatocytes (PHH) for experimentation. PHH are difficult to 
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isolate and culture in vitro. Furthermore, they do not maintain many of their functions when 
isolated from the liver; many signalling pathways are silenced, their polarity is altered, and 
they fail to proliferate (247). Studying hepatocytes in the context of an intact human liver 
removes the requirement to isolate them and maintains their correct functionality and 
polarity. As such, it is likely that results achieved with this model are more representative of 
authentic hepatocyte behaviour.  
The validity of the results derived from NMLP tissue was made apparent by its ability to 
recapitulate results derived from in vivo mouse models (Fig. 4G). Cauterisation of human 
tissue was able to able to mimic the induction of hepatocyte efferocytosis which was 
achieved by APAP treatment in mice. Equally, the capacity of EIPA to prevent efferocytosis in 
the liver was achieved in both models. Importantly, this would suggest that the ability of 
hepatocytes to clear dead cells, as well as its susceptibility to EIPA, is conserved between 
mice and humans. As such, evolutionary conservation of efferocytosis in hepatocytes is 
made evident by comparing data received from both mouse and human, which 
demonstrates the physiological importance of this process for the liver.  
4.9.3 Ploidy alterations in the liver – a complex system for adaptation 
Changes in the quantity of chromosomes within hepatocytes presents a complex and 
intricate system for intercellular adaptation. It is known that increased genetic diversity 
within the liver grants aspects of increased survival, such as the ability to adapt to more 
detrimental mutations by gaining others which compensate for them (297, 298). 
Additionally, increased multinucleation in normal hepatocytes is thought to decrease the risk 
of tumorigenesis by preserving tumour-suppressing genes (299). Although this was initially 
thought to be caused by cytokinetic failure, based on expression of the cytokinetic 
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machinery (276, 300, 301), the data presented in this chapter now show a new phenomenon 
where hepatocytes can intrinsically promote their own multinucleation. Due to the higher 
degree of potential variation between hepatocytes in ploidy, coupled to the unique role of 
certain hepatocytes caused by lobular positioning, it is conceivable that multiple subtypes of 
hepatocytes may develop over a lifespan. Understanding how and when ploidy alterations 
are generated, and to which of these persist in the liver, may improve our understanding as 
to how the liver changes over time. Furthermore, this may also yield useful insights into risk 
factors of HCC, particularly for patients already suffering with end-stage liver disease with a 
high burden of necrosis.  
4.9.4 Is efferocytosis the primary signal of liver regeneration?  
The ability for hepatocytes to proliferate and regeneration large portions of the liver in 
response to damage has set them aside from other parenchymal cell types. However, 
although signalling events and molecular alterations are involved in liver regeneration, many 
of the signals which stimulate hepatocytes to proliferate are not well understood (31). 
Hepatocytes rarely divide under homeostasis and lose the ability to divide once isolated 
from the liver (69). A greater insight into the initiation mechanisms of hepatocytes would be 
of benefit for both physiological and experimental reasons. A recent publication described 
evidence for infiltrating, efferocytosing macrophages in promoting liver regeneration 
through STAT3 signalling (45). However, in response to parenchymal liver injury, it would be 
hepatocytes who would initially respond and engulf their necrotic or apoptotic brethren. It is 
logical that hepatocytes would proliferate in response to signals from dying cells, as they 
would be required to replace cells which were lost. 
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Using cauterised ex vivo human tissue, it was shown that in parenchymal areas proximal to 
injury, hepatocytes were more likely to express Ki67 and less likely to express p21 (Fig. 
4K+4I). These observations were lost in EIPA-treated tissue, suggesting that these changes in 
expression were consequences of hepatocyte efferocytosis. EIPA-sensitive increases in Ki67 
expression in injury-proximal hepatocytes were also observed in APAP-treated mice (Fig. 
4K). Contradictory to this, p21 expression in hepatocytes was also higher in these areas (Fig. 
4I). However, the same increases were also seen in EIPA-treated animals, suggesting that 
efferocytosis stimulated by injury did not influence p21 expression. This was logical as the 
livers of these mice were otherwise healthy prior to APAP delivery. As such, these mice 
would only possess a minimal quantity of senescent hepatocytes, which may have been in 
acutely increased next to areas of metabolic injury. Collectively, these data suggest that 
hepatocytes can be induced to divide through signals derived from dying cells, or 
hepatocytes which are actively engulfing them. Further understanding as to the identity of 
these signals may prove useful in promoting liver generation in patients. The same 
information may also prove effective in extending the in vitro culture time of PHH isolated 
from the liver, as they do not proliferative under currently used culture conditions.  
The observed decreases in p21 expression in hepatocytes proximal to cauterisation injury 
suggests that efferocytosis may rescue hepatocytes from senescence and become available 
for liver regeneration. Under chronic inflammatory conditions, often associated with fatty 
diets or increased alcohol consumption, hepatocytes can lose the ability to regenerate the 
liver because of decreased intracellular signalling in response to inflammatory stimuli (302, 
303). Coupled to the limited capacity of hepatocytes to regenerate, due to nodular fibrotic 
scarring, liver regeneration is often compromised during end-stage liver disease. As such, 
patients with chronic liver disease have difficulty in recovering damage which occurs to their 
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liver. This may be coupled with a reduced capacity either of hepatocytes to conduct 
efferocytosis or for them to recover from senescence in response to dying cells. With further 
understanding into the exact mechanisms involved with hepatocytes responses to 
internalising dying cells, such mechanisms could be exploited to reduce senescence within 
patients with chronic liver disease.  
4.9.5 Hepatocyte efferocytosis and multinucleation – balance of good and evil? 
Many reports have shown how multinucleation in hepatocytes can be of great benefit to the 
hepatic ‘cellular ecosystem’. As to whether changes in ploidy in hepatocytes are solely 
beneficial or detrimental to the liver is currently in dispute. Duncan et al, 2012, used both 
single and double knockout mouse models for members of the tyrosine metabolism pathway 
to illustrate how genetic instability could promote Darwinian survival of adapted 
hepatocytes (298). The production of a hepatotoxic substance in the single knockouts, 
caused by the incomplete metabolism of tyrosine, created widespread liver damage and 
weight-loss. After these mice recovered, all hepatocytes had the same genotype as the 
double knockout mouse. The hepatocytes which had gained genetic alterations were able to 
adapt to the toxic insult. This demonstrates how the liver is designed to establish genetic 
diversity at the cellular level. The capacity of hepatocytes to engulf apoptotic cells in 
homeostasis may represent a catalyst for this by promoting multinucleation and increasing 
the incidence of aneuploidy by ‘lagging chromosomes’. 
It is often described that end-stage chronic liver disease, regardless of the aetiology, is 
tantamount to onset of HCC (304). This would imply that different chronic liver diseases 
share the same oncogenic process, even if they arise under different circumstances. One 
aspect associated with all liver diseases is the increase of cell corpses in the liver, both of 
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hepatocytes and infiltrating immune cells. Given the capacity of hepatocytes to efferocytose 
dying cells, this would also suggest that all forms of liver disease are concurrent with 
increases in hepatocyte multinucleation. Several large multinucleate cells were previously 
observed in patients with POD (Fig. 4F). 
Though this is a form of acute liver injury, it typifies the possibility of increased 
multinucleation and dysregulated cells in response to necrotic injury. On these grounds, 
despite the inherent advantage of efferocytosis for hepatocytes to improve their survival 
through genetic alteration, unregulated efferocytosis in disease states may increase the risk 




In conclusion, the influence of efferocytosis on hepatocyte ploidy exists a tenuous balance 
(Fig. 4P); in the steady state, ploidy increases which arise from random cytokinetic failure or 
hepatocyte efferocytosis in homeostasis are most likely to be of benefit as they provide 
genetic adaptions at the cellular level. This would ensure that some hepatocytes would be 
adapted to specific inflammatory insults or injuries, as shown by Duncan et al. Initially this 
would provide a source of genetic variation throughout the liver and increase the likelihood 
that a population of hepatocytes could adapt to certain toxic or inflammatory insults. 
However, in liver disease hepatocyte efferocytosis is increased by the larger incidence of cell 
death. Although this is initially still beneficial to the liver by limiting inflammatory responses 
and potentially promoting regeneration, high volumes of efferocytosing cells may eventually 
become detrimental; not only will hepatocytes frequently fail to divide when actively 
efferocytosing, but they will continue to gain whole chromosome sets and genetic 
alterations. Eventually, a ‘point of no return’ may be reached in which efferocytosing 
hepatocytes eventually acquire oncogenic alterations and develop HCC. Cancer cells may 
also continue to efferocytose and gain further genetic abnormalities. Overall, efferocytosis in 
the liver is a process that is necessary to ensure immunotolerance and provide genetic 







Figure 4P: The balance of hepatocyte efferocytosis in the liver. Left: moderate efferocytosis of 
dead cells (green) by hepatocytes (brown) during homeostasis promotes cytokinesis failure in a 
limited number of hepatocytes. These cells may gain adaptations as a consequence of obtaining a 
second nucleus (blue). These could include the ability to survive specific insults to the liver and 
provide potential protection from tumorigenesis. Efferocytosing cells may also promote 
hepatocyte proliferation and regeneration through currently unknown signals. Right: 
uncontrolled efferocytosis, caused by frequent cell death associated with chronic liver disease 
causes many hepatocytes to fail cytokinesis. Continuous failure of cytokinesis could increase the 
risk of asymmetric cell division and further genetic dysregulation. This would further increase the 
risk of developing hepatocellular carcinoma throughout the duration of chronic liver disease.  
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4.9.6 Targeting hepatocyte efferocytosis in hepatocellular carcinoma 
Many types of tumours have been reported to display increased aggressiveness and poorer 
prognosis in association with ploidy increases (265, 270, 272, 294). Data described in this 
chapter now show the potential of a similar aspect for HCC. Tumour cells in HCC patients 
were consistently more multinucleate than their distal or marginal counterparts (Fig. 4N). 
Furthermore, increased multinucleation in tumour cells and hepatocytes in these patients 
correlated with the appearance of tumour invasion (Fig. 40). Although increased ploidy can 
reduce the risk of hepatocellular carcinoma (299), this does not discredit the advantages of 
higher ploidy for cancer cells which maintain the capacity to efferocytose. Such cells would 
also not be in short supply of corpses; many lymphocytes are recruited to tumours and then 
subsequently induced to apoptose (67), which is already a frequent event in normal liver (9). 
Furthermore, HCC shares a trait of many solid tumours in which the high oxygen demand of 
tumours causes the core of the tumour to become necrotic, providing more dying cells in 
which to clear (305, 306). These tumours therefore have multiple opportunities to clear dead 
cells throughout their development, providing a source of both cellular nutrition and a 
pathway for genetic alteration. Therapeutic targeting of tumour efferocytosis may therefore 
be of benefit for reducing tumour progression. This would lower the survivability of tumours 
by removing the nutritional benefit of efferocytosis but also by reducing the potential of 
them obtaining further mutations that promote growth, invasion, or metastasis.  
Candidate treatments for specific targeting of tumour cell efferocytosis are still lacking. 
Although EIPA was shown to be significantly effective in preventing hepatocyte efferocytosis 
in vivo, it may not represent an ideal targeted therapeutic. EIPA specifically inhibits sodium-
proton exchanger 1 (NHE1), but also indirectly inhibits macropinocytosis by lowering the 
submembranous pH. This pH change inhibits the activity of Pak1, thereby preventing 
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downstream signalling associated with macropinocytosis (307). As this pathway is largely 
conserved across different cell types, it would not be possible to specifically inhibit tumour 
efferocytosis. Furthermore, long-term inhibition of macropinocytosis throughout the liver is 
likely to induce undesired cell exhaustion. Further understanding of how hepatocytes 
recognise dying cells may yield receptors that could prove to be more appropriate 
therapeutic targets. Such candidates may include SCARF2 which was previously identified as 
a likely contributor to hepatocyte efferocytosis. As SCARF2 is not expressed on other hepatic 
efferocytes, blocking this receptor specifically would still allow for other efferocytes in the 




Chapter 5: Hepatocytes engulf live CD4+ 
T cells 
5.1 Introduction 
In earlier chapters I have discussed the adept capacity of hepatocytes to engulf dead cells 
and its links to multinucleation and liver regeneration.  These observations also provide 
novel insights into the contribution of hepatocytes to immune regulation in the liver; the 
swift and efficient clearance of dying cells is required to prevent an immune response (148). 
Like with their capacity for efferocytosis efferocytosis, other aspects of hepatocyte 
contribution to liver immunology are poorly understood. One major aspect of this entails 
interactions between hepatocytes and immune cells. The series of events involved in 
immune cell migration from the sinusoids to the liver parenchyma have been efficiently 
elucidated by members of the Centre for Liver and Gastrointestinal Research (CLGR) at the 
University of Birmingham (4, 6-8, 308). Less details are available for the activities of 
lymphocytes in the parenchyma where they come into contact with hepatocytes. 
Previous co-culture experiments in the Stamataki lab have yielded novel findings regarding 
interactions between hepatocytes and different types of lymphocyte. It was found that CD4+ 
T helper cells were frequently, and reproducibly, engulfed by hepatocytes, whilst still alive 
(Fig. 5Ai). The same observations were not seen with CD8+ T cytotoxic cells or B cells. This 
phenomenon bore resemblance to the formation of the  previously described cell-in-cell 
structures (CICSs), whereby a live cell is engulfed by another (184). Several processes have 
been attributed to CICS creation, including entosis and emperipolesis (184). A similar process 
in the liver was previously reported in the literature whereby hepatocytes were shown to 
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selectively engulf and delete autoreactive CD8+ cells, through a process termed as “suicidal 
emperipolesis” (181). However, our lab has shown that CD4+ T cells entry into hepatocytes 
does not require self-reactivity, nor does this always result in the deletion of the T cell (Fig. 
5Aii). It is also not known as to whether this process bears molecular similarities to other 









Figure 5A: Previous work in the Stamataki lab showing the capture of live CD4+ T cells in 
vitro. (i) Confocal micrographs with Z-stacks showing fluorescent-labelled hepatocytes 
(green) co-cultured with lymphocytes (red), separated into CD4+ T cells, CD8+ T cells or B cells. 
CD8+ T cells and B cells travel in between hepatocytes within the monolayer whereas CD4+ T 
cells become completely internalised by them. (ii) Confocal micrograph of a captured and 
uncaptured CD4+ T cell. Hepatocytes were labelled with Cell Tracker green (CTG) and T cells 
were labelled with Cell Tracker Violet (CTV) prior to co-culture. Prior to imaging, cells were 
labelled with CellMask membrane (grey) to show complete T cell internalisation and 





When our lab initially observed that live CD4+ T cells were engulfed by hepatocytes, two 
possible explanations came to the forefront; transcellular migration or efferocytosis. As the 
initial data was acquired from imaging fixed cells from a single timepoint, one possibility was 
that these images represented T cells undergoing transcellular migration. Previous work 
published by the CLGR has exemplified how T cells can enter the liver by travelling through 
the cytoplasm of HSECs (8). However, long-term imaging of T cells co-cultured with 
hepatocytes revealed that internalised cells do not exit hepatocytes over periods of several 
hours. Therefore, it is unlikely that the process witnessed was as a form of transcellular 
migration. 
It is also conceivable that live CD4+ cell capture by hepatocytes is related to their previously 
discussed ability for efferocytosis. Validating this possibility, however, presents several 
challenges. Although much of the molecular machinery used by efferocytosing cells has been 
identified, especially in macrophages (233, 243), it is still uncertain as to whether the same 
molecules are involved in hepatocyte efferocytosis. As such there was no obvious pathway 
with which to target for inhibition to investigate whether live CD4+ T cell capture by 
hepatocytes is molecularly similar or distinct to efferocytosis. 
This final results chapter will aim to describe and discuss the experiments undertaken to 




5.2 Hepatocyte internalisation of CD4+ T cells is not the same process 
as efferocytosis 
5.2.1 Hepatocyte capture of CD4+ T cells was phenotypically different to efferocytosis 
A conceivable explanation for the presence CD4+ T cells within hepatocytes is that they have 
been mistaken for dying cells. Although both processes are poorly understood, it is possible 
to assess them by comparing observable phenotypic differences between these two 
processes. Many distinct membranal structures have been described for different forms of 
endocytosis, including macropinocytosis and phagocytosis (234, 309). To image these 
structures on hepatomas, scanning electron microscopy (SEM) was used because it provided 
a greater resolution than confocal microscopy. Huh-7 hepatomas were co-cultured with live, 
apoptotic or heat-killed (necrotic) primary human CD4+ T cells. Cells were co-cultured for 4 
hr in order to image cells at several stages of capture. The cells were then fixed and imaged 
using SEM to observe the initial tethering of lymphocytes to hepatomas, through to 
complete internalisation of a cell (Fig. 5B). The formation of membrane ruffles was 
frequently observed on hepatocytes which were actively engulfing heat-killed or apoptotic 
cells. This is also characteristic of professional phagocytes, including macrophages (310). In 
contrast, hepatocytes that were in the process of capturing live T cells were frequented with 
membrane blebs. These observations showed that live CD4+ T cell capture employed 






Figure 5B: Hepatomas used different membrane structures to capture live CD4+ T cells compared 
to those used for efferocytosis. Huh-7 hepatomas seeded on glass coverslips were co-cultured 
with primary CD4+ T cells, which were either live, apoptotic via staurosporine (STS) treatment or 
heat-killed (necrotic), for 24 hr. Cells were then fixed in 2.5% glutaraldehyde and imaged by 
scanning electron microscopy (SEM) using a JSM-7000F (JEOL) SEM. i) Pseudocoloured SEM 
micrographs showing the membranal blebs formed by the Huh-7 cells during live CD4+ T cell (blue) 
capture, as well as the membrane ruffles formed when capturing apoptotic (red) or heat-
killed/necrotic (green) cells. ii) SEM micrographs detailing the membranal structures formed 
throughout the capture of live, apoptotic, and heat-killed CD4+ T cells by Huh-7 cells.  
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5.2.2 The kinetic of live CD4+ T cell capture by hepatomas was slower to that of dead 
cells 
Scanning electron microscopy revealed that different membranal structures on the surface 
of the hepatocytes are used for capturing live CD4+ T cells compared to those used for 
efferocytosis. This could imply that these processes also possess contrasting kinetics. To test 
this, fluorescently-labelled Huh-7 cells were co-cultured with alternatively-labelled live, 
apoptotic or heat-killed primary human CD4+ T cells. Cultures were preincubated for 90 min 
and were then imaged overnight at 30 min intervals using time-lapse fluorescence 
microscopy. The number of internalised cells at each time point was then assessed (Fig. 5C). 
At the beginning of the imaging period, more apoptotic and heat-killed cells were 
internalised than live cells; only 20% of Huh-7 cells contained vesicles, whereas twice as 
many cells contained heat-killed cells (Fig. 5Ci). Throughout the experiment, the number of 
vesicles containing apoptotic cells gradually increased (Fig5Cii). The number of internalised 
heat-killed cells within hepatocytes did not alter throughout the duration of the experiment. 
In contrast, the number of Huh-7s containing live cells was fewer than those containing 
apoptotic cells and half the number which contained heat-killed. What’s more, this number 
only increased modestly over the course of the experiment, peaking at 9 hr post-incubation. 
Interestingly, the number of hepatomas containing live cells gradually decreased following 9 
hr incubation. Overall, it appears that the kinetic of live cell capture is a slower than 







5.2.3 Vesicles containing captured live CD4+ T cells did not associate with SCARF2 
It was uncertain as to whether captured live CD4+ T cells were internally trafficked by 
hepatomas through the same processes as apoptotic or heat-killed cells. It was revealed 
earlier (section 3.4.2) that hepatocyte efferosomes frequently associated with the scavenger 
receptor, SCARF2. I hypothesised that if live CD4+ T cells were engulfed and trafficked 
intracellularly through the same processes as dead cells, it would be expected that SCARF2 
would also associate with captured live cells. To investigate this, I co-cultured Huh-7 cells 
with live, primary human CD4+ T cells. These were the fixed, permeabilised and stained for 
SCARF2 by immunofluorescence. Cells were the imaged by confocal microscopy (Fig. 5D). 
Images were also 3D volume rendered to provide more accurate information regarding the 
distribution of SCARF2 in relation to the internalised T cell. Vesicles containing fully 
internalised live CD4+ T cells showed no association with SCARF2. As such, the capture of live 
CD4+ T cells does not share this aspect of intracellular processing that was seen with 
efferosomes.  
  
Figure 5C: The kinetic of live CD4+ T cell capture by Huh-7 hepatomas was slower to that of 
apoptotic and heat-killed cells. Huh-7 hepatomas seeded in 24-well plates (some on glass 
coverslips for confocal microscopy [i]) were labelled with Cell Tracker Green (CTG)/ 
Chloromethylfluorescein diacetate (CMFDA). Huh-7s were then co-cultured with primary CD4+ T 
cells, which were labelled with Cell Tracker Violet (CTV)/bromomethyl derivative of coumarin 
(BMQC and either live, apoptotic via staurosporine (STS) treatment or heat-killed (necrotic), for 1.5 
hr. Plates were then transferred to a Cell-IQ time-lapse, fluorescence imager and imaged for a 
futher 18 hr. (i) Confocal microphaphs of Huh-7 – T cell co-cultures following 1.5 hr co-culture (time 
point zero [T0]). (ii) Quantification of captured CD4+ T cells per 100 Huh-7 cells after the initial 1.5 hr 
co-culture period (Left, T0), and throughout the 18 hr culture period at 3 hr intervals. Numbers 
were derived from 3 technical repeats, using 5 fields of view (FOV) per repeat. * - p≤0.05, ** - 
p≤0.01. Statistics were derived from a two-tailed, unpaired Students t-test when comparing 
capture of each cell condition to each other. Error bars represent the SEM.  
 
 
Huh-7 hepatomas seeded on glass coverslips were co-cultured with primary CD4+ T cells, which 
were either live, apoptotic via staurosporine (STS) treatment or heat-killed for 24 hr. Cells were 
then fixed in 2.5% glutaraldehyde and imaged by scanning electron microscopy (SEM). i) 
Pseudocoloured SEM micrographs showing the membranal blebs formed by the Huh-7 during live 
CD4+ T cell (blue) capture, as well as the membrane ruffles formed when capturing apoptotic (red) 
or heat-killed/necrotic (green) cells. ii) SEM micrographs detailing the membranal structures 






Figure 5D: Captured live CD4+ T cells did not associate with SCARF2 within Huh-7 hepatomas. 
Huh-7 hepatomas were seeded in 24-well plates on glass coverslips were fluorescently labelled 
with Cell Tracker Green (CTG)/ Chloromethylfluorescein diacetate (CMFDA). Huh-7s were then co-
cultured with live, primary human CD4+ T cells, labelled with Cell Tracker Violet (CTV)/ 
bromomethyl derivative of coumarin (BMQC). Cells were co-cultured for 3 hr. Cells were then 
fixed with MeOH and stained for scavenger receptor family f, member 2 (SCARF2), shown in red. 
Cells were then imaged by confocal microscopy using a Zeiss LSM 880, in which Z-stacks were 
acquired. Images were also 3D volume rendered using Bitplane IMARIS software. Bottom panels 
show cross-sections made using a plane which cuts through the internalised T cell, as indicated by 
yellow line on top-right panel. Scale bars represent 10 µm.    
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5.2.4 Live CD4+ capture by hepatocytes was unaffected by cytokine treatment 
Both hepatocytes and lymphocytes can take cues from cytokines in the liver (9, 49, 55). 
Cytokines have also been shown to trigger or influence processes of live cell internalisation, 
including macrophage capture of live T cells (178). It is thus prospective that such 
stimulation may alter the ability of hepatocytes to capture live CD4+ T cells. To test this, Huh-
7 hepatomas were pre-treated with cytokines and then co-cultured with live, primary human 
CD4+ T cells in the presence of both pro- and anti-inflammatory cytokines (Fig. 5E). The 
number of internalised T cells per hepatocytes was determined after 3 hr co-culture. There 
was no significant alteration in the capacity of Huh-7 cells to internalise live cells in response 







Figure 5E: Capture of live CD4+ T cells by hepatomas was unaffected by cytokines. Huh-7 
hepatomas seeded in 24-well plates on glass coverslips were fluorescently labelled with Cell 
Tracker Green (CTG)/ Chloromethylfluorescein diacetate (CMFDA). Huh-7s were then serum 
starved and treated with 100 ng/ml cytokines for 1 hr. Huh-7s were then co-cultured with 
Celltracker Red (CTR)/CMTPX-labelled live, primary human CD4+ T cells. Cells were cultured in the 
presence of cytokines, for 3 hr, fixed with MeOH, and then imaged by confocal microscopy using a 
Zeiss LSM 880 microscope. Graph shows the quantification of the number of captured live CD4+ T 
cells per 100 Huh-7 cells for each cytokine treatment. Numbers were obtained using 5 fields of 
view (FOV), taken from three independent experiments (N=3). Statistics were derived from a two-
tailed, unpaired Student’s t-test when comparing other treatments to the control. Error bars 
represent the SEM. IFN-γ – interferon-gamma; IL – interleukin; TGF-β – tumour growth factor-
beta. Data set was partially acquired from work conducted by Nuffield Foundation work 
experience student, Sophie Rouvray. 
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5.3 Hepatocyte internalisation of CD4+ T cells was distinct to entosis 
Entosis is the homotypic internalisation of a live epithelial cell by another and prominent 
process in CICS formation (183-185). Live capture of CD4+ by hepatocytes may bear some 
similarities to this process. This section will aim to compare the capture of live CD4+ T cells by 
hepatocytes to entosis.  
5.3.1 Capture of live CD4+ T cells was inhibited by macropinocytosis and actin 
remodelling inhibitors but unaffected by an inhibitor of entosis 
Entosis can be identified by its sensitivity to the ROCK inhibitor, H-1152 (183, 311). To 
investigate if the activity of ROCK is associated with live CD4+ T cell capture by hepatocytes, I 
attempted to perturb CD4+ T cell capture using H-1152. To ensure that Huh-7 hepatomas 
were susceptible to H-1152, I assessed its ability to inhibit more frequent activities of ROCK.  
ROCK phosphorylates and activates LIM kinase, which subsequently phosphorylates the 
actin-binding protein (ABP), cofilin, and increases the stability of filamentous actin (312). 
This ultimate phosphorylation of cofilin was shown to be susceptible to H-1152 treatment 
(313). Therefore, Huh-7s and live, primary CD4+ T cells were treated with 10 µM H-1152 for 1 
hr. Cells were also treated with previously used inhibitors; cytochalasin D was again used as 
a positive control, as inhibition of actin polymerisation has been reported to prevent entosis 
(194, 314). Furthermore, as membrane blebs have been reported for cells conducting 
macropinocytosis as well as ruffles, cells were also treated with inhibitors of this process, 
EIPA and blebbistatin. Levels of total and cofilin and phosphorylated cofilin (P-cofilin) in cell 
lysates were then determined by western blotting (Fig. 5Fi). Total cofilin was unaffected by 
inhibitor treatment. However, all cells displayed substantial reductions in P-cofilin in 
response to inhibitors.  
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With the knowledge that Huh-7 cells were susceptible to H-1152 treatment, Huh-7 cells 
were co-cultured with live, primary CD4+ T cells in the presence of H-1152 and the other 
tested inhibitors (Fig. 5Fii). As expected, live CD4+ T cell capture was almost totally ablated 
by cytochalasin D treatment. Contrasting to reports on the mechanism of entosis, inhibition 
of ROCK by H-1152 did not reduce live CD4+ cell capture by Huh-7s. In contrast, significant 
decreases in CD4+ T cell capture by Huh-7s were seen in response to treatment with EIPA 
and blebbistatin. Inhibition by EIPA was comparable to that seen from cytochalasin D 
treatment. As H-1152 failed to inhibit hepatocyte capture of live CD4+ T cells, it would 









5.3.2 Vesicles containing live CD4+ T cells in hepatocytes associated with β-catenin but 
not with E-cadherin.  
An early observation in the developing concept of entosis was the requisite for CICSs created 
in this way to associate with β-catenin and E-cadherin (183). Other studies have used these 
observations to identify entosis in other cell types. To elucidate whether captured live CD4+ 
T cells possessed this characteristic, Huh-7 cells were stained by immunofluorescence for E-
cadherin (Fig. 5G) and β-catenin (Fig. 5Hi) following co-culture with primary CD4+ T cells. 
Cells were then imaged using confocal microscopy. Images were also 3D volume rendered to 
show the distribution of the probed molecules in relation to the internalised CD4+ T cell. 
Huh-7 cells stained positively for both proteins with little positivity present when using an 
isotype matched control (IMC) (Fig. A2). The membranes of vesicles containing live CD4+ 
cells were enriched with β-catenin (Fig. 5Hi). However, these vesicles did not associate with 
E-cadherin (Fig. 5G).  
Figure 5F: Capture of live CD4+ T cells by hepatomas was unaffected by inhibitors of entosis but 
was reduced by those inhibiting macropinocytosis and cytoskeletal rearrangements. (i) Western 
blot showing expression levels of cofilin and phosphorylated cofilin (P-cofilin) in Huh-7 hepatomas 
and primary human CD4+ T cells following treatment with molecular inhibitors. Cells were treated 
with 10 µM H-1152, 1 µM cytochalasin D, 100 µM 5-(N-Ethyl-N-isopropyl) amiloride (EIPA) or 50 
µM blebbistatin for 1 hr. Inhibitors were diluted in serum-free media. Cells were then lysed, and 
their lysates were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Bands were 
then transferred to PVDF membranes via western blotting. Membranes were then blotted for 
cofilin and P-cofilin. Membranes were also blotted for GAPDH as a loading control. (ii) Huh-7 
hepatomas seeded in 24-well plates on glass coverslips were fluorescently labelled and treated 
with inhibitors at concentrations indicated above for 1 hr. Huh-7s were then co-cultured with 
alternatively-labelled, live, primary CD4+ T cells, in the presence of inhibitors, for 3 hr. Cells were 
then fixed with MeOH, and then imaged by confocal microscopy using a Zeiss LSM 880 
microscope. The number of captured CD4+ T cells per 100 Huh-7 cells was then quantified for 
each treatment. Numbers were derived from three experimental repeats (N=3), using 5 fields of 
view (FOV) per repeat. *** - p≤0.001. Statistics were derived from a two-tailed, unpaired 
Student’s t-test when comparing other treatments to the control. Error bars represent the SEM. 




To confirm the presence of β-catenin on vesicles containing live lymphocytes, and to confirm 
the specificity of the antibody used, tissues from ‘normal’ donor livers were stained for β-
catenin by IHC (Fig 5Hii). The expected ‘chicken-wire’ structure of junctional β-catenin was 
visible in between hepatocytes which verifies the accuracy of this antibody. In addition, 
several circular intracytoplasmic structures within hepatocytes document were documented. 
Taken together, thesis data imply that the activity of β-catenin may be involved with the 







Figure 5G: Vesicles containing captured live CD4+ T cells did not associate with E-cadherin 
within Huh-7 hepatomas. Huh-7 seeded in 24-well plates on glass coverslips were 
fluorescently labelled with Cell Tracker Green (CTG/ CMFDA). Huh-7s were then co-cultured 
with primary human CD4+ T cells, labelled with Cell Tracker Violet (CTV/BMQC) for 3 hr. Cells 
were then fixed with 3.7% formaldehyde and stained for E-cadherin via immunofluorescence 
(shown in red). Cells were then imaged by confocal microscopy using a Zeiss LSM 880, in 
which Z-stacks were acquired. Images were also 3D volume rendered using Bitplane IMARIS 
software. (i) Confocal micrograph with orthographical view showing a Huh-7 hepatoma 
(green) containing internalised live CD4+ T cell (blue). (ii) Confocal micrograph together with 
3D-rendered images. Bottom panel shows cross-section made using a plane which cuts 
through the internalised T cell, as indicated by yellow line on the left panel. Images are 
representative of 3 experimental repeats. Scale bars represent 10 µm. Isotype-matched 






5.4 Vesicles containing captured human T-regulatory cells within 
hepatomas acidified more frequently than non-T regulatory cells 
Although Entosis and other processes of live cell capture are often termed as ‘non-apoptotic’ 
forms of cell death, not all CICSs are destined for lysosomal degradation. Some reports 
suggest that cells can survive within their host and sometimes even escape their captors 
(184). In relation, previous data in our lab showed that only 20% of captured CD4+ T cells 
enter acidic compartments in hepatocytes. In addition, in vivo observations made in our lab 
across multiple liver diseases suggested that hepatocytes preferentially engulf cells 
expressing forkhead box P3 (FOXP3), a transcription factor that arbitrarily denotes human T 
regulatory cells (Tregs)(161), compared to other T cell subsets. Hepatocytes may process 
internalised Tregs differently compared to non-regulatory sub-types (non-Tregs). To address 
this, total CD4+ T cells were isolated from PBMCs and then Tregs were separated from non-
Treg cells based on high CD25 and low CD127 expression. Both Tregs and non-Tregs were 
then labelled and co-cultured for with Huh-7 cells 24 hr, in presence of pHrodo red dextran, 
a pH indicator which fluoresces red in acidic cellular compartments. Cells were then labelled 
Figure 5H: Captured live CD4+ T cells associated with β-catenin within Huh-7 hepatomas in vitro 
and possibly in hepatocytes in vivo. Scale bars represent 10 µm. Huh-7 seeded in 24-well plates 
on glass coverslips were fluorescently labelled with Cell Tracker Green (CTG/CMFDA). Huh-7s 
were then co-cultured with primary human CD4+ T cells, labelled with Cell Tracker Violet 
(CTV/BMQC) for 3 hr. Cells were then fixed with 1% paraformaldehyde and stained for β-catenin 
via immunofluorescence (shown in red). Cells were then imaged by confocal microscopy using a 
Zeiss LSM 880, in which Z-stacks were acquired. Images were also 3D volume rendered using 
Bitplane IMARIS software. (i) Confocal micrograph with orthographical view showing a Huh-7 
hepatoma (green) containing internalised live CD4+ T cell (blue). Bottom panel shows cross-
section made using a plane which cuts through the internalised T cell, as indicated by yellow line 
on the right panel. Images are representative of 3 experimental repeats. (ii) 
Immunohistochemistry (IHC) staining of paraffin-embedded normal donor liver tissue for β-
catenin (brown). Tissues were counterstained with Mayers haematoxylin nuclear stain (blue). 
Black arrows indicate hepatocytes containing large, positively stained vesicles. Isotype-matched 




with a membrane dye, CellMask Deep Red and imaged live using confocal microscopy (Fig. 
5I). Fully internalised cells were identified through the absence of CellMask labelling (Fig. 
5Ii). The percentage of internalised cells, both Treg and non-Treg, within acidic 
compartments was then determined (Fig. 5Iii). Almost three-times as many Tregs compared 
to non-Tregs were found within acidic compartments; a mean of 60% internalised Tregs 
were positively stained for pHrodo red compared to around 20% for non-Tregs. This showed 




Figure 5I: Tregs acidified within hepatomas more frequently that non-Tregs in vitro. Huh-7 
hepatomas were seeded in glass-bottomed 24-well plates and allowed to adhere for 24 hr. 
Primary CD25+, CD125lo T regulatory cells (Tregs) were isolated from donor peripheral blood 
mononuclear cells (PBMCs) using a Stemcell™ magnetic negative-selection kit. The separated cells 
were recovered and designated as non-Tregs. These were fluorescently labelled with Cell Tracker 
Violet (CTV)/ bromomethyl derivative of coumarin (BMQC) and then co-cultured in equal numbers 
with Huh-7 cells for 24 hr in presence of the pH sensing reagent, pHrodo red dextran (red in acidic 
conditions). Cell membranes were then labelled with CellMask membrane (grey) and then cells 
were then imaged live using a Zeiss 780 confocal microscope. (i) Representative confocal 
micrographs of CellMask -labelled Huh-7 hepatomas co-cultured with fluorescent-labelled CD4+ T 
cells (violet). ii) Quantification of acidified vesicles in Huh-7s containing Treg or non-Tregs. 
Numbers were derived three experimental repeats (N=3) from 5 fields of view (FOV) per 
experiment. **** - p≤0.0001. Statistics were derived from a two-tailed, unpaired Students t-test. 
Errors represent the SEM. Data in this figure was supplemented by work conducted by visiting 




5.5 Chapter summary 
 
5.6 Discussion  
5.6.1 Live CD4+ T cell capture by hepatocytes is a unique and distinct process 
5.6.1.1 Live CD4+ T cell capture by hepatocytes is not efferocytosis 
Our lab previously described a novel phenomenon whereby CD4+ T lymphocytes are singled-
out and engulfed by hepatocytes. Scanning electron microscopy revealed that this processed 
involved the formation of membrane blebs at the surface of the engulfing hepatocyte (Fig. 
5B). This contrasted with the ruffles that were formed during efferocytosis and implies that 
different cytoskeletal rearrangements are required of hepatocytes for the internalisation of 
live CD4+ T cells to those induced for efferocytosis.  
Time-lapse fluorescence microscopy showed that the capture of live CD4+ T cells was also 
shown to have a slower kinetic than efferocytosis of apoptotic and head-killed cell (Fig. 5C). 
1. Efferocytosis of dead cells by hepatomas involved the formation of membrane 
ruffles. In contrast, live CD4+ T cell capture involved membrane bleb formation and was 
less frequent than efferocytosis. 
2. Live CD4+ T cell capture by hepatomas was unaffected by an inhibitor of entosis or by 
cytokines but was susceptible to macropinocytosis inhibitors. 
3. Hepatoma vesicles containing live CD4+ T cells did not associate with E-cadherin or 
SCARF2 in vitro. 
4.  Vesicles containing live CD4+ T cells associated with β-catenin in hepatomas in vitro 
and in hepatocytes in vivo.  
5. Vesicles containing T regulatory cells acidified more frequently than those containing 
non-Tregs. 




Of note, the number of Huh-7 cells containing live cells steadily decreased after 9 hr 
incubation. The reason for this was unclear, but may be related to several observed fates of 
CICSs (184). One possibility is a portion of captured cells were digested throughout the 
course of the experiment. T cells may also have been released from Huh-7 cells. It was not 
likely that the latter would be captured when imaging the cells every 0.5 hr.  More frequent 
imaging times, as well as beginning the experiment at an earlier point may provide more 
information to the dynamics of Huh-7 interactions with CD4+ T cells. This would also provide 
more information on the dynamics of hepatocyte efferocytosis. The number of heat-killed 
cells found within the Huh-7 cells did not change throughout the experiment. This is likely 
because of heat-killed cell saturation during the pre-incubation period. 
Finally, immunofluorescence staining revealed that vesicles containing these cells did not 
associate with SCARF2 (Fig. 5D) as previously described for hepatocyte efferosomes. This 
implies that CD4+ T cells are recognised or internally processed through distinct to 
mechanism to dead cells. Taken together, these data demonstrate that live CD4+ T cell 
capture is not a case of mistaken identity, and that hepatocytes do not accidentally capture 
live T cells, believing they are dead.  
5.6.1.2 Is live CD4+ T cell capture affected by cytokines? 
Another way in which live capture of CD4+ T cells differed from efferocytosis was its response 
to cytokines. Huh-7 cells co-cultured with live, primary human CD4+ T cells in the presence of 
different cytokines showed no variation in their capacity to conduct this process (Fig. 5E). 
However, this is unlikely to be a true representation of this process. Compared to studying 
efferocytosis, this process has the added complication of involving a live T cell that can also 
respond to cytokines as well as the Huh-7s. CD4+ T cells also encompass a wide variety of 
subtypes with different effector functions [Fig. 1C (165)]. Each subtype of CD4+ T cells 
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displays individual responses to cytokine stimulation and also produce their own repertoire 
of cytokines, based on their role in immunology (315). Therefore, using a mixed population 
of CD4+ T cells was unlikely to provide informative results. Cytokine stimulation may also 
alter T cell permissiveness to internalisation by hepatomas. This is supported by previous 
observations made in our lab in which Tregs were more frequently found within hepatocyte 
cytoplasmic spaces in vivo compared to other subtypes. Specific responses of Huh-7 cells and 
T cells could not be separated with this approach. This experiment could be improved by 
pre-treating either Huh-7 cells or T cells with cytokines prior to their co-culture, ensuring 
that all stimuli are removed prior to this. Isolation of individual subtypes, as performed in 
later experiments concerned with Treg internalisation, may also allow more accurate and 
detailed conclusions to be drawn from this type of experiment. 
5.6.1.3 Live CD4+ T cell capture was distinct to entosis  
This process was also shown not to share all qualities of CICSs formed through entosis; it was 
not perturbed by ROCK inhibition (Fig. 5F) as with entosis  (183) and immunofluorescence 
staining showed that vesicles containing live CD4+ T cells did not associate with E-cadherin 
(Fig. 5G). This was confirmed by 3D volume rendering of these stains. These observations 
suggest that alternative cell-cell interactions may be utilised for this process when compared 
with entosis. This is conceivable as entosis generally involves cells with similar polarities, 
whereby the cell with less-well established adhesion junctions often becomes the 
internalised cell. This has been reported in both epithelial cells (188) and non-adherent 
cancer cells (202, 203). The latter was shown to be dictated by E-cadherin expression. 
Comparatively, CD4+ T cells are circulatory and have different migratory habits to 
hepatocytes. Therefore, they would have alternative capacities for forming cell-cell 
junctions. In conclusion, these results collectively demonstrate that this activity of live CD4+ 
T cell capture by hepatocytes is a novel example of a CICS, which is unique to the liver.  
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5.6.1.4 Similarities of CD4+ T cell capture by hepatocytes to macropinocytosis 
Although it was shown that Huh-7 cells did not require the activity of ROCK to capture live 
CD4+ T cells, this process was susceptible to inhibition by cytochalasin D (Fig. 5F). This 
suggested that cytoskeletal rearrangements within the hepatocyte are necessary for live cell 
capture. It also implies an active role for the hepatocyte to physically engulf the live T cell. 
Alternatively, this process could also have been a form of T cell invasion into the hepatocyte. 
In addition, this process was also susceptible to macropinocytosis inhibitors, EIPA and 
blebbistatin. This is the only similarity which this process has shared with efferocytosis. In 
support of this observation, macropinocytosis has been reported to be identifiable by both 
membrane ruffles and blebs (234). This would suggest that although live cell capture by 
hepatocytes is a distinct process to efferocytosis, some of their intracellular molecular 
machinery may be shared. Further exploration into the molecular processes that regulate 
live CD4+ T cell capture will be required to validate further similarities of this process to 
macropinocytosis.  
5.6.2 What is the purpose of CD4+ T cell capture by hepatocytes? 
An explanation as to why the capture of live CD4+ T cells by hepatocytes has been preserved 
in the liver remains uncertain. Some situations in which lymphocytes are cannibalised are 
conducted to prevent the initiation of an immune response. Melanoma cells have been 
reported to cannibalise CD8+ T cells, which was reported to prolong the survival of these 
tumour cells (182). It is likely that hepatocytes capture T cells to assist with immune 
modulation and maintaining immunotolerance within the liver. As only a small proportion of 
total captured CD4+ T cells acidify, it is unlikely that this process is a form of population 
control. Perhaps hepatocytes can limit the activation of T cells by relocating them within 
their own cytoplasm. They may also be able to change the activity of cells which they engulf. 
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Profiling CD4+  T cell transcriptomes and secretomes before and after their internalisation 
into hepatocytes may provide insights into the requirement of this process for the liver. This 
is assuming that T cells can be activated from within the hepatocytes.  
The internalisation of these T cell by hepatocytes may also act as a somewhat forceful 
method to retain T cell populations within the liver. Certain stimuli may also dictate their 
release from hepatocytes. This is related to the observed gradual decrease in the number of 
hepatocytes that contained live CD4+ T cells after 9 hrs incubation (Fig. 5Cii), which may 
imply that these cells were released. Similar scenarios of leukocyte-based cell-in-cell 
structure release have been reported (184, 190, 196). As to what causes this process in 
hepatocytes is uncertain. Thymocytes internalised by thymic nurse cells were released as a 
result of poor recognition of self-antigens (190). This was a method of ensuring the survival 
of non-autoreactive T cells. It is not certain as to whether a similar internal checkpoint exists 
within hepatocytes, or to what might determine the release of CD4+ T cells. As hepatocytes 
can respond to inflammatory stimulators via TLRs and cytokine receptors (48), similar 
stimulation may dictate the release of T cells. This would allow hepatocytes to respond to 
inflammatory insults by quickly deploying T cells, reducing the time taken for resolution and 
the need for further T cell recruitment. It is also likely that these T cells will have not been 
activated using co-stimulatory molecules and would only remain active for a shorter amount 
of time as previously described for CD8+ T cells (66). Treatments of hepatocytes/hepatomas 
in possession of live CD4+ with inflammatory stimuli would help to validate this theory. 
Although cytokine stimulation did not alter the capacity of the hepatocytes to engulf live 
CD4+ T cells in vitro, (Fig. 5E), it may encourage the release of T cells which have already 
been internalised.   
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5.6.3 How do hepatocytes recognise and internalise CD4+ T cells? 
Insights into the molecular machinery behind CD4+ T cells capture by hepatocytes are still 
lacking. The experiments described in this chapter involving ineffective treatments of Huh-7 
hepatomas with inhibitors of entosis imply that this process is distinct. Previous work in our 
lab showed that hepatocytes can distinguish CD4+ T cells for engulfment from other types of 
lymphocyte (Fig. 5A). This would suggest that hepatocytes can recognise these cells through 
some form of intercellular interaction. This recognition is likely to be reciprocated by the 
CD4+ T cell. This is implied by the slow rate of internalisation (Fig. 5C) and the formation of 
blebs on the surface of actively engulfing hepatomas (Fig. 5B). In contrast to speedy 
efferocytosis, the hepatocyte must negotiate a live, actively moving T cell into its cytoplasm. 
As such, the two cells are likely to directly communicate to allow this. The proteins involved 
in forming this interaction must be present on all subsets of CD4+ T cells but absent on other 
lymphocytes, as other lymphocyte types were not observed to enter hepatocytes. This 
reduces the likelihood that immune response-specific signalling is used. Although 
hepatocytes can express MHC-II, this is not done constitutively (64). It is thus unlikely that an 
immunological synapse is formed between hepatocyte and T cell to facilitate their 
internalisation. Whether this interaction occurs intracellularly instead is still not certain. This 
has been reported in thymic nurse cells, which present self-antigens in MHC complexes to 
immature thymocytes (190). Initial contacts between hepatocytes and T cells are likely to be 
reminiscent of the primary interactions associated with lymphocyte recruitment. Blockade of 
ICAM-1, for example, has been shown to reduce of frequency of phagocytosis of live CD4+ 
and CD8+ T cells, and thymocytes by haemophagocytic macrophages (175). In agreement 
with this, our lab previously found that treatment of hepatomas with ICAM1-blocking 
antibodies reduced T cell capture by hepatocytes following short co-cultures, but not after 
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incubations longer than 60 min. This implies a role for molecules involved with lymphocyte 
tethering in the initial binding of T cells to hepatocytes but not for their complete 
internalisation. How the hepatocyte negotiates the T cell into its cytoplasm following its 
initial binding is still unknown.  
Understanding the process of live T cell capture by hepatocytes is difficult without knowing 
the form of endocytosis through which they are internalised. I observed that blebs formed 
on the surface of hepatomas that were actively engulfing live T cells. As stated earlier, the 
formation of these blebs have been reported for cells conducting macropinocytosis (234) 
and live CD4+ T cells capture was susceptible to inhibitors of this process. This suggests that 
this process may be related to macropinocytosis, although the exact mechanical cascades 
involved are lacking. Certain aspects of these are likely to be shared by hepatocyte 
efferocytosis which was also susceptible to inhibition by EIPA. Similar parallels between 
efferocytosis and live cell capture have been described previously. The universal ‘don’t eat 
me’ signal for apoptotic cell capture, CD47, has been shown to aid both leukemic cell 
survival, as well as donor T cell survival in models of graft vs host disease (92, 136, 176). Both 
pathways may also converge on the autophagy pathways as also described for entosis (206). 
Further dissection of the initiating events for both live and dead cell capture are needed 
before both processes can separated on a molecular level.   
Perhaps related processes involving molecular scavenging are repurposed either for T cell 
capture or retention. One example involves the metabolism of lipids. Hepatocytes possess 
several receptors, including class B receptors CD36 and SR-B1, involved in scavenging lipids 
like LDLs, HDLs and cholesterol (316-318). This helps to control their available levels in the 
liver and potentially convert them to bile acids. A recent publication may suggest that this 
process could be exploited for T cell dissolution and capture. Surls et al, described how 
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membrane levels of cholesterol could alter the activity of CD4+ T cells (319). Increased 
cholesterol was shown to increase the resting population of rest CD4+ T cells, but not CD8+ T 
cells. Furthermore, these T cells were more likely to differentiate into TH1 cells. In agreement 
with these findings, it was also shown that cholesterol starvation of mice caused a decrease 
in T cell proliferation (320). Lipid sensing by hepatocytes through scavenger receptors could 
be an initiating event for engulfing overactive or overpopulating T cells. In relation to this, 
increases in cell membrane cholesterol were reported to act as negative regulator of CICS 
formation (321). Liver-infiltrating T cells are likely to alter their membrane composition in a 
lipid-rich environment like the liver. As such, high lipid content may be a signal for 
hepatocytes to internalise these cells and prevent/reduce their inflammatory activity. In 
relation to this, our lab previously observed that hepatomas infected with HCV could not 
internalise live T cells. This virus infects hepatocytes through interactions with SR-B1 (322). 
This receptor may be downregulated after viral infection to prevent subsequent virion 
particle binding, which would concomitantly reduce their capacity for live CD4+ capture. This 
has been reported for its co-receptor for viral entry, CD81 (323). Increased lipidation of T 
cells before co-culture with hepatocyte cell lines could be used to verify this theory. This still 
does not explain the preference of hepatocytes to engulf Tregs cells, as Surls et al reported 
that FOXP3+ activity was not altered by increased membrane cholesterol. Other, possibly 
synergistic processes which may explain this are discussed below.  
5.6.4 Why do T-regulatory acidify within hepatocytes? 
Tregs are the major cell type responsible for dampening inflammatory responses. This has 
brought them a lot of attention as potential therapeutics for inflammatory disease, including 
those within the liver (163). The immunotolerant environment of the liver, however, 
presents complications in the necessity of Tregs in this organ. Many regulatory mechanisms 
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are already in place in liver to limit the duration of inflammatory responses, such as the 
increased induction of lymphocyte apoptosis and their short-term activation by hepatocytes 
(9, 66). Immunotolerance in the liver is, thus, not achieved by an abundance of Tregs. This 
may provide explanations as why Tregs captured by hepatomas entered acidic 
compartments of their host more frequently than non-Tregs (Fig. 5I). Even so, it would be 
counter-intuitive to delete local Tregs when aiming to maintain an immunotolerant 
environment. Additionally, even though these observations were made using hepatomas, it 
is unlikely that this preference for deleting Tregs is a tumour-specific observation, as Tregs 
are often beneficial for tumours to avoid immune detection (324-326). 
One possible reason for the potential deletion of Tregs would be as an additional process of 
immune control within the liver. Were the ratio of Treg : non-Tregs to skew in the liver, 
potentially through increased preservation of T-regulatory cells, it may become impossible 
for an adequate immune response to be mounted, rendering the liver ‘immunoblind’. This 
may shed light on the role of this observed deletion of Tregs by hepatocytes. Hepatocytes 
may possess an intrinsic capability of limiting the number of available Tregs within 
parenchymal regions. Coupled with the lower tendency of hepatocytes to kill non-Treg cells, 
hepatocytes may control the potential of the liver to mount an immune response. Not only 
do hepatocytes reduce the viability of activated pro-inflammatory cells, but by capturing and 
deleting Tregs, they ensure that the liver can mount an immune response altogether. This 
may also provide some insight into the absence of cytokine sensitivity of live cell capture. 
Although the capacity of hepatocytes to capture live cells was unaffected by cytokine 
stimulation, be it pro-inflammatory or anti-inflammatory, such treatments may skew the 
fates of already internalised cells. This may reduce the frequency of Treg acidification, 
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potentially increasing the livers capacity for raising an anti-inflammatory response, 
presuming that Tregs are released or still able to function from within hepatocytes.  
Preferential acidification of vesicles containing Tregs suggested that Tregs could be 
differentially recognised or processed by hepatocytes. This implies the presence of an 
intracellular decision-making mechanism for the trafficking of certain Tregs to acidic 
compartments.   The molecular mechanisms of how this is conducted remain a mystery. An 
internal mechanism of sensing T cell subsets must be present within the hepatocyte. One 
investigation reported that increased activity and stability of Tregs was associated with 
higher intracellular expression of β-catenin (327). Overexpression of β-catenin in Tregs, even 
in FOXP3- cells, was associated with lower activity of effector T cells. Although this was 
hypothesised to be mostly endowed through overactive Wnt signalling pathway, increased 
total β-catenin expression would also increase the pool available for cell junction formation. 
In vitro immunofluorescence staining revealed that β-catenin associated with internalised 
live CD4+ T cells (Fig. 5Hi). Further, in vivo IHC staining revealed β-catenin-positive 
intracellular structure within hepatocytes which were of a comparable size to lymphocytes 
(Fig. 5Hii). Interactions involving membranal β-catenin may therefore dictate which cells 
become internalised. This may represent yet another aspect of liver biology that contributes 




Chapter 6: General Discussion 
6.1 How hepatocyte cell-in-cell structures effect general hepatocyte 
function 
6.1.1 Efferocytosis and hepatocyte activity 
Hepatocytes form 80% of the human liver and conduct most of it’s functions. Furthermore, 
they are significantly involved with immune responses within the liver and contribute to the 
immunotolerance in the liver (48). In relation to this, I have now shown that hepatocytes 
play further immunological roles in the liver, by engulfing both dying cells and live CD4+ T 
helper cells. How hepatocytes balanced their wide variety of functions is difficult to 
interpret. Efferocytosis commonly alters the immunological activity of phagocytes (328), so it 
would be intuitive that a transcriptional alteration also occurs in hepatocytes. However, due 
to the speed and frequency at which hepatocytes clear dying cells, particularly necrotic cells, 
it is unlikely that such a drastic phenotypic change would occur within hepatocytes. 
Otherwise, in the presence of large sheets of necrosis (329) which are associated with liver 
disease (1), many proximal live hepatocytes would be unable to function. In support of this, I 
showed that hepatocytes became multinucleate by clearing dead cells originating from both 
chemical and physical injury (APAP and ex vivo cauterisation respectively) (Fig. 4D+4G). It is 
thus unlikely that the capacity of hepatocytes to clear dead cells is affected by their zonation 
within the liver. Overall, besides providing nutrients to the hepatocyte, efferocytosis is 
unlikely to drastically alter hepatocyte biology to the same extent as in other cells.  
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6.1.2 Live CD4+ T cell capture and hepatocyte function 
Although efferocytosis is unlikely to alter hepatocyte biology, the same may not be true for 
live CD4+ T cell capture. It was observed that not all internalised cells enter acidic 
compartments within the hepatocyte (Fig. 5I). Moreover, these cells do not exhibit other 
signs of stress once they’re captured and do not appear to die through other means. This 
would imply that internalised T cells are not always ‘starved’. Related to this, our lab has 
observed, through membrane labelling, that small, non-acidic vesicles derived from the 
hepatocyte were trafficked to the internalised T cell. This implies that the hepatocytes invest 
internal resources to either communicate with the internalised T cell or promote its survival. 
This may detract from the other functions of hepatocyte if much of its cytoskeletal 
trafficking network is directed towards internalised T cells. Comparable mechanisms of 
molecular parasitism have been reported by the invading bacterial species, Chlamydia 
Trachomatis, which usurps the endosomal trafficking proteins of a host macrophage (330).  
Changes caused to hepatocyte activity by internalising T cells are likely to be reciprocated 
with alterations to T cell behaviour. It is still not clear as to whether T cells remain active 
from within hepatocytes. This entails whether a T cells’ receptors are available to possible 
agonists from within their vesicular enclosure. As such, it is not certain as to whether T cells 
could be activated from with a hepatocyte. Furthermore, it would be of interest to observed 
whether T cells can secrete cytokines into the hepatocyte cytoplasm. Would this propagate 
immune signalling within the hepatocyte, or would be they continue to be secreted by the 
hepatocyte itself? Time-lapse imaging of T cell-specific, fluorescently tagged cytokines may 
be required to investigate this notion, by tracking cytokines in internalised CD4+ T cells.  
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Furthermore, it would be of interest to assess how zonation alters hepatocyte capacity for 
live CD4+ T cell internalisation. It is likely that periportal hepatocytes are more likely to 
capture T cells, as these hepatocytes make first contact with infiltrating lymphocytes. 
Hepatocytes in this zone also possess a higher metabolic rate (3, 40), which would be likely 
to facilitate the cytoskeletal rearrangements for capturing a live cell. In support of this, 
cancer cells generally exhibit higher metabolic rates then their normal counterparts, which 
facilitates their ability to capture their neighbours by Entosis (201, 203, 331). As such, more 
metabolically active hepatocytes may be more successful in capturing CD4+ T cells.  
Specific activities may be directly altered by accommodating an internalised cell. 
Hepatocytes are the major stores of lipids within the liver. These are stored in relatively 
large droplets that are often enlarged in patients with fatty diets, which is known as 
steatosis (332). Hepatocytes containing internalised cells may not be able to store large 
quantities of lipids. In relation, T cells may be altered if internalised by hepatocytes which 
already possess reasonable lipid stores. Such lipids may incorporate into the T cells 
membrane and alter their behaviour, as lipid content has been linked to alterations in Teff 
activity (319, 320). However, it is unlikely that hepatocytes which possess giant lipid droplets 
associated with steatosis will have cytoplasmic space to house live CD4+ T cells. This would 
likely increase T cell population in the parenchyma which may contribute to the associated 
increased inflammation.  
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6.2. Mechanisms of cell-in-cell structures in the liver 
6.2.1 How do hepatocytes know what they’re eating? – Treg vs Non-Treg 
6.2.1.1 Possible role of autophagy in captured live cell processing 
The mechanisms which underlie the recognition and capture of CD4+ T cells by hepatocytes 
are lacking. Equally, it is uncertain as to how these cells are trafficking within the hepatocyte 
on their capture. Results described in this thesis showed that not all engulfed T cells entered 
acidic compartments within the hepatocyte (Fig. 5I). Treg cells, however, were more likely to 
acidify than non-Tregs. It is likely that there is some form of checkpoint present within the 
hepatocyte which prevents certain internalised live cells from fusing with lysosomes. A 
candidate for this checkpoint is when a live cell-containing vesicle converges on the 
autophagy pathway. This was described in breast cancer cell entosis, whereby internalised 
cells were transiently labelled with LC3-II (111). This recruitment required the presence of 
Phosphatidylinositol 3-phosphate (Pi3P) for the recruitment of downstream autophagy 
proteins possessing FYVE domains and was subsequently followed by lysosomal fusion. PI3P 
formed at phagosomes was reported as a requirement for autolysosome formation (333).  
Of note, PI3P has been shown to promote the activity of the K+ channel, KCa3.1, which has 
been linked to T naïve cell proliferation (334, 335). Such systems may therefore be employed 
by hepatocytes to specifically target overly proliferating T cells for LC3-II-mediated lysosomal 
degradation. Further understanding into the differences in signalling lipids between Tregs 
and non-Tregs, during different stages of activation, will be required to potentially confirm 
this role of PI3P and hepatocyte-derived LC3-II.  
Autophagy is frequently active within hepatocytes and is required for the mobilised lipid 
droplets stored within them (336). Such lipid droplets were also shown to co-localise with 
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LC3 and lysosomal protein, LAMP1, in the same investigation. Notably, acute increases in 
hepatocyte lipid-content were shown to activate autophagy-related lipid depletion, or 
lipophagy, whereas chronic exposure associated with a high-fat diet was inhibitory. The 
entry of T cells into hepatocytes may therefore trigger autophagy through similar 
mechanisms, derived from increases in cytosolic lipid content. Were this to be accurate, 
hepatocytes may be less likely to deploy lysosomes to internalised T cells in fatty livers. 
Observations of lipid-rich hepatocytes containing T cells may prove useful in proving this 
concept.  
6.2.1.2 Mimicry of intracellular parasitism 
Another possibility for the observed differences in the treatment of Tregs by hepatocytes is 
that Teffs possess some sort of ‘don’t kill me’ signal which is inefficiently expressed by Tregs. 
This is not likely to be related to the don’t-eat me signal, CD47, which prevents the 
engulfment of cells (176). As both Tregs and non-Tregs can be engulfed, it more likely to be a 
protein which prevents lysosomal fusion. Many intracellular pathogens, such as Chlamydia 
or Listeria, achieve this through manipulation of the actin cytoskeleton through which the 
lysosomes are trafficked upon (337). Perhaps T cells can manipulate the hepatocyte 
cytoskeletal network, with non-Tregs being more adept at this process. This is dependent on 
whether hepatocyte or T cell is in control of the captured cells fate. Real-time imaging of 
hepatocyte cell lines with fluorescently-labelled actin may provide insights into the 
spatiotemporal organisation of cytoskeletal rearrangements induced by T cell capture.   
6.2.1.3 Survivability of CD4+ T cell subsets 
The differences in survival between Tregs and Teffs may not be due to their internal 
recognition by hepatocytes whatsoever. Perhaps Treg themselves possess deficits in 
autophagy and are simply not well accustomed to situations of starvation. Related to this, 
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internalised breast cancer cells were shown to upregulate autophagy up entry into 
neighbouring cells (111). Inhibition of autophagy resulted in the starvation of the captured 
cell and death through apoptosis. Although captured T cells may obtain resources from their 
hosts, they would still be required to recycle internal structures to promote their survival 
once they were separated from the extracellular environment. Tregs may be unable to do 
this as efficiently as non-Tregs, which may predispose them more to apoptosis and 
subsequent degradation by the hepatocyte. Importantly, it was reported that Tregs require 
autophagy more than other CD4+ lineages to promote their survival, but also to maintain 
FOXP3 expression (338). Treg-specific deletions of Atg7 were associated with reduced 
viability of these cells, as well as an expansion of Teffs (338, 339). This implies that Treg cells 
may be addicted to autophagy pathways and drain internal resources faster than they can 
replenished by the hepatocyte. Tregs may therefore be less-well prepared for separation 
from the extracellular environment that non-Tregs. It was not clear from the experiments 
described in this thesis as to the processes through with captured CD4+ T cells died. Analysis 
of changes in phenotype and caspase activation will be needed to confirm this possibility.  
Overall, further research into the role of autophagy in T cell capture by hepatocytes is likely 
to elucidate numerous molecular aspects of this process. This may provide further insight 
into the possible molecular explanations for why Tregs are more likely to acidify than non-
Tregs.   
6.2.2 Differences and similarities between live and dead cell capture 
The observations made in this project have provided some insight into separating 
efferocytosis from live cell capture in hepatocytes (Fig. 6A). The processes are phenotypically 
different, using different membranal structures with which to internalise their cargo (Fig. 
5B). Efferocytosis was also shown to occur more frequently and at a faster rate than CD4+ T 
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cell capture (Fig. 5C). It was also observed that hepatocyte efferosomes were enriched with 
SCARF2, a phenomenon which was absent from vesicles containing live cells. Although the 
exact involvement of SCARF2 in hepatocyte efferocytosis if not clear, its absence from 
vesicles containing live T cells implies that hepatocytes can distinguish dead cells from live 
cells. Together, with the use of alternative membrane structures and differences in capture 
rates, it is clear that these processes are distinct and separate. What’s more, the presence of 
SCARF2 at intracellular structures within hepatocytes could be used to specifically identify 
efferosomes in vivo. Conversely, I showed that increased expression of β-catenin at similar 
structures can denote internalised CD4+ T cells. Although these molecular differences are 
currently only superficial, they are sufficient to deviate them as separate processes.  
These mechanistic and spatiotemporal differences between live and dead cell capture are 
likely related to their purposes within the liver. I observed that efferocytosis was a rapid 
process, especially with the clearance of necrotic cells, where Huh-7 cells were saturated 
within 1.5 hr co-culture (Fig. 5C). This rapid onset of efferocytosis would be necessary in 
preventing the accumulation of dying cells, both in homeostasis and disease. Further, 
although the distribution of SCARF2 was altered under inflammatory circumstances, its 







Figure 6A: The differences between live CD4+ T cell capture and efferocytosis by hepatocytes 
uncovered from this project. Hepatocytes (brown) form blebs when live CD4+ T cells (dark blue) 
are internalised. The vesicle containing the fully internalised T cell associated with β-catenin. In 
contrast, the capture of both apoptotic (red) and necrotic (green) cells was concurrent with the 
formation of membrane ruffles on the hepatocyte membrane. Both types of dead cells associate 
with hepatocyte scavenger receptor family f, class 2 (SCARF2) when fully internalised. Adhered 
apoptotic cells were also shown to associate with SCARF2 prior to their internalisation. Details 




As several different ligands have been reported for the related receptor, SCARF1 (130, 145), 
it is likely that SCARF2 may contribute to hepatocyte uptake of several molecules, given its 
constitutive expression. This system would allow hepatocytes to be primed for dead cell 
clearance without the continuous expression of a specialised receptor. Hepatocytes can 
therefore respond swiftly upon encountering dead cells as they do not require 
transcriptional alterations. Whether this situation is the same for CD4+ T cell capture is 
uncertain. Although β-catenin is also constitutively expressed in the liver, it does not possess 
the same diversity of binding partners as SCARF2 has, in the way of potential ligands, and is 
mostly required for adhesion junctions. From these potential binding partners, I showed that 
E-cadherin is not involved in this process. Moreover, although its involvement in CD4+ 
capture is not known, its activity is heavily influenced by Wnt signalling (340). It is thus likely 
that signalling events will be required for changing the distribution of β-catenin prior to T cell 
capture. Requiring such fulfilment would limit the number of T cells which can be captured 
by hepatocytes at any given time, allowing some to patrol the parenchyma. Alternatively, 
requiring alterations in signal transduction may also limit the number of hepatocytes which 
are capable of T cell capture. Hepatoma cultures with limited differentiation are 
heterogeneous and not all cells internalised T cells during time-lapse experiments. In relation 
to this, hepatocyte zonal distribution in the liver is dictating by Wnt signalling (36, 40). 
Perhaps periportal hepatocytes are more efficient hunters of CD4+ T cells than pericentral 
hepatocytes and are tasked with controlling the traffic of these cells as they drain through 
the parenchyma. Analysing the frequency of CICSs across these zones may provide insight to 
this notion.   
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Of note, the staining procedures used in this investigation do not distinguish the cellular 
ownership of β-catenin. As such, it is unknown as to whether T cell or hepatocyte-derived β-
catenin is associated with the capture process. Cell-specific labelling may be required to 
determine the specific interactions. The requirement for these interactions and the time 
taken to establish them are likely what dictate the lower frequency of live cell capture, 
compared to efferocytosis.  
6.3 Cell-in-cell structures and drug discovery 
6.3.1 Manipulating T cell capture in chronic liver disease 
It is likely that CD4+ capture by T cells contributes to immune regulation of the liver. As such, 
it may be possible to manipulate this process for therapeutic benefit (Fig. 6B). It is not 
certain however as to how preventing or encouraging this process would affect liver. The 
most beneficial application of manipulating this process would most likely be aimed at 
manipulating the availability of Tregs in the liver. It was shown that this subtype was more 
frequently acidified by hepatocytes (Fig. 5I). Preventing this acidification or their initial 
capture could increase their viability in liver and consequently promote resolution of 
inflammatory responses. This presumes that they are unchanged following their 
internalisation by hepatocytes. However, if using global inhibitors of CD4+ T cell capture 
(such as EIPA), pro-inflammatory non-Tregs would also be less likely to be captured by 
hepatocytes. Their persistence in the parenchyma would increase the likelihood of 
developing inflammatory responses. Although this may be beneficial at early stages of 
disease pathogenesis, it would counteract the concurrent increased viability of Tregs. 
Further understanding into how hepatocytes distinguish Tregs from Teffs may provide 
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Figure 6B: The consequences of manipulating Treg and non-Treg capture by hepatocytes. 
Hepatocytes can engulf live CD4+ T cells. This work has shown that a specific anti-inflammatory 
subset of these cells, T regulatory cells (Tregs) are more likely to enter acidic compartments of the 
hepatocyte and be killed compared to non-Tregs. As reported for other types of cell-in-cell 
structure, unacidified non-Tregs may be released from there host cells, allowing them to contribute 
to inflammatory responses. Inhibiting the formation of these cell-in-cell structures could have 
profound consequences for liver immune response. Inhibiting the capture or acidification of Tregs 
could promote their survival in the liver and promote resolution of inflammatory response. 
Conversely, inhibiting non-Treg capture by hepatocytes may have the opposite effect and increase 
the likelihood of developing inflammation. Further understanding into the molecular processes 
which dictate the capture of CD4+ T cells and the selective acidification of Tregs is required to the 
validate these possibilities.  
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6.3.2 Cell-in-cell structures – a new therapeutic target for hepatocellular carcinoma 
One of the major findings of this project was the consistent and reproducible increase in 
multinucleation in hepatocytes caused by efferocytosis (Chapter 4). This provides a further 
source for the frequent binucleate hepatocytes witnessed within the liver besides seemingly-
random cytokinesis failure (275, 341). Exactly what this means for the liver is still not entirely 
certain. Some have stated that increased ploidy can be beneficial for the liver by providing 
residence from tumorigenesis and the potential for genetic diversity amongst hepatocytes 
(298, 299).  However, increased ploidy could also provide an advantage for tumour cells. 
Gaining further mutations increases the likelihood of further dysregulation of proliferation 
pathways, and of metastasis. This outcome has been described for other cancers which 
gained increases in ploidy (265, 270, 272). In the liver, the risk of developing HCC is increased 
throughout end-stage, regardless of aetiology (342, 343). Besides the genetically instability 
from certain viral infections (344), the reason for this is not certain. Chronic liver disease 
(CLD) is also synonymous with wide-spread cell dead throughout the liver (1). As such, 
continuous efferocytosis by hepatocytes may be a risk factor for oncogenesis associated with 
CLD. Reducing hepatocyte efferocytosis may therefore be of therapeutic benefit for 
managing the risk of developing HCC. Although this could increase the risk of apoptotic cells 
progressing to secondary necrosis, many other cells in the liver are capable of efferocytosis 
and could compensate, including Kupffer cells, BEC and infiltrating macrophages (1). Once 
these mechanisms of how hepatocytes recognise dead cells are better understood, they 
could be therapeutically targeted specifically, sparing the activity of other phagocytes, and 
removing the requirement for broader inhibitors like EIPA.  
It is also likely that increased efferocytosis would not be the only contributor for increased 
multinucleation in tumours.  It is likely that the CD4+ T cells would also be engulfed by 
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hepatomas. Some of these cells were shown not to be digested by Huh-7 hepatomas (Fig. 
5C). As such, they might persist longer within hepatocytes in vivo and also prevent 
cytokinesis and induce multinucleation. This would also have the added benefit of 
preventing the liver from mounting an immune response against the tumour. As cancer cells 
often acquire the ability to engulf their neighbours upon transformation due to increased 
cytoskeletal malleability (185), it is also likely that hepatomas could engulf live cells more 
readily than normal cells. Taken together, reducing the number of T cell capture by both 
hepatocytes and hepatomas may be efficacious for controlling tumour growth both by 
limited their level of genetic instability and increasing the number of available effector CD4+ 
T cells to mount immune responses against the tumour. Overall, limiting the creation of 
CICSs in the liver could be beneficial both in reducing the risk of oncogenesis, and managing 
the growth of already established tumours.  
6.3.3 How hepatocyte efferocytosis contributes to disease 
This project has the revealed the adeptness of hepatocytes to engulf dying cells. Although 
their capacity for this was described a long time ago, little work has been conducted in its 
contribution to liver disease pathogenesis. The inability of phagocytes to clear dying cells has 
been described in a multitude of other diseases (125, 128, 152, 345). It is thus likely that 
defects in hepatocyte efferocytosis may be related to forms of chronic liver disease. This is 
likely the case for many diseases whose initiating events are not well understood, 
particularly for autoimmune diseases. These largely include primary biliary cholangitis (PBC), 
primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH), whose molecular 
causalities are unknown. As a result, there are currently no mouse models for these 
diseases. Many autoimmune diseases are caused through the production of self-recognising 
antibodies, which can develop upon immune recognition of dead cell components, 
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particularly from apoptotic blebs (78, 156). It is difficult to fathom diminished efferocytosis 
within the liver, as almost all tissue-forming cells have been reported to clear dead cells (1, 
143, 346-348). It is more likely that certain diseases may be associated with defects in 
efferocytosis at a cell-specific level. Defects in BEC efferocytosis by contribute to the 
pathogenesis of PBC, for example (156). Further understanding into the markers of 
hepatocyte efferocytosis, as well as its effects on hepatocyte biology may therefore prove 
useful in understanding the pathogenesis of these diseases.  
In other liver diseases whose pathogeneses are better understood, the contribution of 
efferocytosis is easier to observe and comprehend. Both acute and chronic forms of diseases 
are commonly associated with necrotic lesions (1). Furthermore, lymphocytes recruited to 
the liver during inflammation are more prone to apoptosis in the liver (24). As such, there is 
a high burden of dead cell clearance in the diseased liver. Hepatocyte efferocytosis is likely 
to be increased in diseased livers, on the verge of exasperation. This was exemplified by the 
upregulation and translocation of SCARF2 that was observed both in diseased livers and 
cytokine-treated hepatomas (Fig 3K+3L). As SCARF2 associated with vesicles containing both 
apoptotic and necrotic cells (Fig. 3I), it would thus seem that efferocytosis is increased in the 
hepatocytes under inflammatory conditions to promote resolution and repair.  Manipulation 
and prolongation of efferocytosis may therefore be of therapeutic benefit. Investigations 
into the effects of SCARF2 knockout on liver disease pathogenesis would aid to understand 
its role in the liver and potentially measure the necessity of hepatocyte efferocytosis in 
controlling disease pathogenesis.  
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6.3.4 Cell-in-cell structures and liver regeneration 
The liver is unique amongst other internal organs with its ability to regenerate following 
injury. However, this ability is often compromised in patients with chronic liver disease and 
is difficult to induce experimentally. Furthermore, the exact signals which switch off the 
hepatocytes capacity to regenerate are not fully understood. It was recently reported that 
efferocytosis by macrophages caused increased liver regeneration in mice, through the 
STAT3-IL10 signalling pathway (45). In relation to this, IHC staining suggested that 
efferocytosis increased the frequency of Ki67 on hepatocytes in APAP-treated mice and 
injured ex vivo human tissue (Fig 4I). Moreover, efferocytosis also caused a reduction in 
hepatocyte p21 expression in cauterised ex vivo human liver tissues (Fig. 4K). This suggests 
that efferocytosis could promote liver regeneration. This must also be an efferocytosis-
specific event, as EIPA-treated tissues failed to show the same alterations in p21 and Ki67 in 
human tissues. Dying cells therefore may be an important factor in promoting liver 
regeneration.  
This is a cogent observation, with the liver promoting its own repair in response to injury. It 
is likely that regeneration is not limited to hepatocytes which have captured dying cells. 
Otherwise the hepatocytes lost during injury would not be replenished if all proliferating 
cells failed cytokinesis. Of interest, it appears that hepatocytes can promote their own 
genetic diversity with this system; efferocytosis induces the hepatocyte to enter the cell 
cycle but also prevents it from dividing, promoting multinucleation. Other hepatocytes not 
conducting efferocytosis are likely the cells to be charged with regeneration. It is likely that 
soluble factors are also involved in this promote of hepatocyte proliferation in response to 
dying cells. Efferocytosis has been reported to invoke transcriptional alterations in 
macrophages, and subsequently promote the secretion of anti-inflammatory cytokines 
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(155). It is thus more likely that dead cell capture alters the hepatocyte secretome which 
ultimately induces neighbouring hepatocytes to divide. Cytokine and growth factor profiling 
of efferocytosing hepatocytes will prove useful in understanding this in the future.  
6.4 Conclusions and prospects 
This project has unearthed a novel and likely important aspect of hepatocyte biology in the 
form of cell-in-cell structures (CICSs). Here, I have described and contrasted the mechanism 
of efferocytosis by a hepatocyte, to their unique ability to specifically capture live CD4+ T 
cells (Fig 6B). Both processes share phenotypic aspects of macropinocytosis, although 
utilising distinct cytoskeletal structures. Each occur at different rates and subsequently 
formed vesicles associate with different membranal proteins; efferosomes with SCARF2 and 
live CD4+ T cell-containing vesicles with β-catenin. Efferocytosis can be both beneficial and 
detrimental to liver biology; frequent efferocytosis represents another form of immune 
regulation within the liver and may be necessary for promoting regeneration. It represents a 
mechanism by which the liver can alter its own genetic diversity through hepatocyte 
multinucleation. Uncontrolled efferocytosis and increased multinucleation, however, may be 
associated with the development of HCC. In contrast, the novel action of CD4+ T cell capture 
is infrequent and mechanistically different to a major process of CICS formation, entosis. 
Hepatocytes can also distinguish between CD4+ T cell subsets, as shown by the preferential 
acidification of Tregs in vitro. Such a process is likely to contribute to the immune regulation 
in the liver. Mechanistic details for both for both CICS-forming processes are still lacking, 
including methods of recognition, the sequential events involved in internal processing and 
the transcriptional consequences for the hepatocyte. Both events are likely to be prominent 
events occurring throughout liver disease. As such, a greater understanding of both 
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processes will likely improve our knowledge of pathogenesis across all liver diseases and 





A.1 Isotyped- matched control (IMC) stains 
The following figures display immunofluorescence or immunohistochemistry stains using 
IMC controls corresponding to specific stains used within this thesis that were not present 
within the main figures.  
A.1.1 Chapter 3 IMCs 
This section contains all IMCs for immunofluorescence stains performed in Chapter 3 that 




Figure A1: Isotyped matched control (IMC) immunofluorescence staining of efferocytosing 
Huh-7 cells for ICAM-1. Huh-7 seeded in 24-well plates on glass coverslips were fluorescently 
labelled with Cell Tracker Green (CTG)/ Chloromethylfluorescein diacetate (CMFDA). Huh-7s 
were then co-cultured with primary human CD4+ T cells, labelled with Cell Tracker Violet 
(CTV)/ bromomethyl derivative of coumarin (BMQC) for 3 hr. Cells were then fixed with 
MeOH formaldehyde and stained by immunofluorescence using an anti-intercellular 
adhesion moledule 1 (ICAM-1) antibody, or a mouse IgG1 IMC (shown here) via 
immunofluorescence (shown in red). Cells were then imaged by confocal microscopy using a 
Zeiss LSM 880, in which Z-stacks were acquired. Scale bars represent 10 µm. Corresponding 
stain: Figure. 3E. 
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A.1.2 Chapter 5 IMCs 
This section contains all IMCs for immunofluorescence and immunohistochemistry stains 




Figure A2: Vesicles containing captured live CD4+ T cells did not associate with E-cadherin 
within Huh-7 hepatomas. Huh-7 seeded in 24-well plates on glass coverslips were 
fluorescently labelled with Cell Tracker Green (CTG)/ Chloromethylfluorescein diacetate 
(CMFDA). Huh-7s were then co-cultured with primary human CD4+ T cells, labelled with Cell 
Tracker Violet (CTV)/ bromomethyl derivative of coumarin (BMQC) for 3 hr. Cells were then 
fixed with 3.7% formaldehyde and stained for E-cadherin, β-catenin or corresponding IMCs 
(shown here) via immunofluorescence (shown in red). Cells were then imaged by confocal 
microscopy using a Zeiss LSM 880, in which Z-stacks were acquired. Scale bars represent 10 
µm (i) IMC staining for β-catenin using a mouse IgG1 antibody. Corresponding stain: Figure 





Figure A3: Isotyped matched control (IMC) immunohistochemistry staining of donor human 
liver for β-catenin. Immunohistochemistry (IHC) staining of paraffin-embedded normal donor 
liver tissue for β-catenin IMC (Mouse IgG1 - brown). Tissues were counterstained with Mayers 
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